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ABSTRACT 
YANG ZHOU: Mechanisms of Antibody Mediated Neutralization of Dengue Virus  
(Under the direction of Aravinda de Silva) 
 
Dengue virus (DENV) is the most significant arthropod-borne virus in this world, 
affecting 2.5 billion people. Pre-existing sub-neutralizing antibodies (Abs) can enhance 
virus infection, leading to severe disease. Thus a better understanding of the interaction 
between humoral immunity and dengue virus is imperative. In this thesis I characterized 
37 human monoclonal Abs (hMAbs) cloned from human PBMC. The majority of these 
MAbs were broadly cross-reactive and capable of enhancement of infection in vitro; few 
exhibited serotype-specific neutralizing activity. I next studied the mechanism and 
stoichiometry of Ab mediated neutralization of DENV and found that MAbs displaying 
threshold stoichiometry all neutralize post-attachment steps while MAbs neutralizing pre-
attachment step display linear stoichiometry, indicating that different neutralization 
mechanisms are associated with different stoichiometric models respectively. I also 
studied the neutralization using multiple MAbs mixed together and demonstrated that the 
neutralization two MAbs are independent of each other in the mixture.   
It was previously found that MAb 8A1 displays variable neutralizing activity 
against different DENV-3 genotypes. My results demonstrated that EDIII mutations at 
301 and 383 alter the ability of 8A1 to bind and neutralize different genotypes of DENV-3. 
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Besides genetic mutation, non-genetic variation such as maturation state of the dengue 
virion can also modulate neutralization.  I found that monocytic cell derived dengue 
virions were more mature than mosquito cell derived virions.  Using a panel of MAbs and 
sera, I demonstrated that maturation reduces virus sensitivity to neutralization mediated 
by weakly neutralizing cross-reactive MAbs or sera but it does not affect sensitivity to 
type-specific and strongly neutralizing MAbs or sera. Most interestingly, maturation 
enhanced virus sensitivity to neutralization of certain MAbs and sera. Further study 
indicated that preferential binding of immature virions by weakly neutralizing MAbs and 
furin cleavage of partially mature virions inside endosome are responsible for the 
maturation dependent differential neutralization. These results offer new insight into how 
humoral immunity neutralizes dengue viruses and how viruses evade the immunity. 
These discoveries may also shed light on rational design of dengue vaccine and 
antibody therapy.   
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CHAPTER 1 
 BACKGROUND AND SIGNIFICANCE 
 
1.1 General Introduction  
1.1.1 Emerging virus: Dengue virus (DENV) is a re-emerging arth2ropod-borne virus. In 
the last 50 years, dengue incidences increased 30 fold and its geographical distribution 
expanded to most tropical and subtropical areas. As a result, dengue is becoming 
increasingly recognized as one of the world's most threatening infectious diseases. 
However, despite decades of research, we still do not have a vaccine to prevent its 
transmission or feasible post-exposure therapy to treat the disease.  
1.1.2 Dengue epidemiology: Dengue is endemic in more than 110 countries in tropical 
and subtropical areas such as Southeast Asian, Latin America, and Sub-Sahara Africa. 
These areas are all heavily populated and every year 50 - 100 million people are 
infected with Dengue, leading to half a million hospitalization and 12,500 - 25,000 deaths 
(WHO 2009; Whitehorn and Farrar 2010). Most people can recover from dengue 
infection without any adverse consequences. Overall, the mortality rate is very low, but in 
cases of severe disease, the mortality rate roars up to 26% without supportive therapy 
(WHO 2009; Ranjit and Kissoon 2011). 
Dengue is transmitted by mosquitoes through a human-mosquito-human cycle. 
Mosquitoes of species A. aegypti and A. albopictus, infect humans by injecting virus 
containing saliva while taking a blood meal. An infected patient will have viremia lasting 
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for about 4 days and mosquitoes taking blood meal from this patient will get infected and 
transmit the virus to other humans living in the neighborhood, leading to localized 
outbreak. In the last 50 years, due to a combination of urbanization, population growth 
and increasing international travel, dengue became a global epidemic, putting 2.5 billion 
people worldwide in risk (WHO 2009). 
1.1.3 Dengue virology: Dengue is a single-stranded, positive sense RNA virus of the 
family Flaviviridae, genus flavivirus.  It is closely related to several other important 
human pathogens such as Japanese encephalitis virus (JEV), West Nile virus (WNV), 
Yellow fever virus (YFV) and Tick-borne encephalitis virus (TBEV).  The DENV genome 
encodes 10 genes and is translated into a single polyprotein and then cleaved into 
structural proteins (C-prM-E) and non-structural proteins (NS1-NS2A-NS2B-NS3-NS4A-
NS4B-NS5) (Figure 1.1). The C (capsid) protein forms a virion scaffold that encapsidates 
the RNA genome. The prM (membrane) protein is important in the assembly of virion 
and subsequent maturation. The E protein (envelope) is the major surface exposed 
antigen and the principal target of host antibody response.  The 7 NS proteins have 
diverse roles such as protease, RNA-dependent RNA polymerase or immune regulation 
proteins participating in evading immune response.   
Serology and phylogenetic evidences indicated that there are four serotypes of 
Dengue: DENV1, DENV2, DENV3 and DENV4, sharing about 70% sequence homology 
between different serotypes (Fields Virology).  The remaining 30% sequences variation 
results in antigenic, transmission and virulence variation between different serotypes. 
Each serotype can be further divided into genotypes by phylogeny and geographic 
distribution, for example, DENV3 consists of four genotypes (I, II, III, IV) (Villabona-
Arenas, Miranda-Esquivel et al. 2009); DENV2 consists of 4 genotypes too and among 
them two genotypes are associated with very different virulence: the Southeast Asian 
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genotype causes severe disease epidemics whereas the American genotype has only 
been linked to mild or subclinical epidemics (Rico-Hesse 2003). 
The E glycoprotein has been crystallized and the structure has been solved 
(Modis, Ogata et al. 2004; Nayak, Dessau et al. 2009). E protein forms a homodimer on 
the mature DENV virion. The virus envelope consists of 90 E glycoprotein homodimers. 
Three dimers are arranged in a herringbone pattern to form a raft-like structure on the 
virion surface (Figure 1.2).  The ectodomain of E protein has three domains:  domain I, II 
and III (EDI-EDIII). Specifically, EDII contains fusion loop, which mediates membrane 
fusion and EDIII belongs to IgG superfamily and is believed to participate in cell receptor 
binding (Crill and Roehrig 2001).  
The Envelope protein is involved in critical steps of virus infection such as 
attachment and endocytosis. E protein mediates virus attachment to cells through DC-
SIGN molecule, heparan sulfate or mannose (Kroschewski, Allison et al. 2003; Navarro-
Sanchez, Altmeyer et al. 2003).  After entry into cells of mononuclear phagocyte lineage 
through unknown cell receptors via endocytosis, the low pH in the endosome triggers 
dissociation of the E homodimers and exposes the hydrophobic fusion peptide to the 
target membrane (Stiasny, Allison et al. 2002) (Figure 1.3). Subsequently insertion of the 
fusion peptide into the endosome membrane induces assembly of E trimers and finally 
leads to fusion of the endosome membrane and virus membrane, resulting in the entry of 
virus nucleocapsid into cell cytoplasm. After uncoating of nucleocapsid, the viral RNA 
genome is released to cytoplasm, where it functions as an mRNA to direct the translation 
of the viral polyprotein. The translated polyprotein is further cleaved into three structural 
proteins (C, prM, E) and 7 non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, 
NS4B and NS5). The E glycoprotein is glycosylated at amino acid residue Asn67 and 
Asn153 to assure proper folding of the protein (Modis, Ogata et al. 2003; Bryant, Calvert 
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et al. 2007). Then the NS proteins initiate replication of viral genomes and subsequently 
the newly synthesized RNA is packaged by C protein to form a nucleocapsid (Figure 1.3). 
Through unknown mechanisms, the nucleocapsid is encapsulated by ER membrane 
rafts covered with prM/E trimers and buds into the ER to form immature virion. The 
immature virion contains 180 prM/E dimers that project vertically outward from viral 
surface as 60 trimeric spikes (Zhang, Chipman et al. 2003; Zhang, Corver et al. 2003) 
(Figure 1.4). The immature virions are transported through trans-Golgi network, in which 
the low pH environment triggers structural reorganization of glycoproteins (Figure 1.3). 
The prM/E heterodimers dissociate and form 90 E dimers lying flat on the surface of the 
particle, with prM capping the fusion peptide of the E protein. This exposes the cleavage 
site for cellular endoprotease furin to cleave "pr" peptide that covers the fusion peptide 
(Stadler, Allison et al. 1997; Yu, Zhang et al. 2008; Zybert, van der Ende-Metselaar et al. 
2008). This process is called maturation. It has been shown that the maturation process 
is not efficient in certain cell lines, resulting in the production of partially mature or totally 
immature virions (Lok, Kostyuchenko et al. 2008; Dejnirattisai, Jumnainsong et al. 2010; 
Junjhon, Edwards et al. 2010).  
1.1.4 Pathogenesis: Dengue infection with any serotype results in long term protection 
against the same serotype but not the other serotypes. Majority of all dengue infections 
are asymptomatic.  The symptomatic cases include mild dengue fever, or severe 
disease like dengue hemorrhagic fever or dengue shock syndrome (DHF/DSS) (WHO 
2009). The symptoms of DHF/DSS include rash, internal bleeding, thrombocytopenia, 
plasma leakage and collapse of the circulation system which is fatal. Majority of 
DHF/DSS cases occurred in secondary infection by dengue serotype that is different 
from the primary infection (Halstead, Nimmannitya et al. 1970; Kliks, Nimmannitya et al. 
1988). For infants with waning maternal dengue immunity, their chances of developing 
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DHF/DSS are much higher than infants born to mothers who are naïve to dengue 
infection (Halstead, Nimmannitya et al. 1970). These evidences strongly suggested that 
pre-existing heterotypic immunity is critical for development of DHF/DSS. Halstead 
proposed Antibody Dependent Enhancement (ADE) as an underlying mechanism of 
DHF/DSS (Halstead 1970). The ADE hypothesis stated that during secondary infection, 
the pre-existing antibodies from a primary infection fails to neutralize heterotypic virus 
but forms infectious immune complex with the virus, and the immune complexes bind to 
and infect monocytic cells expressing Fc-ɣ receptors via the Fc portion of the antibody. 
This leads to increased total infected cell mass and enhanced virus replication and is 
hypothesized to be responsible for the severe disease outcome. Other competing 
hypothesis such as dengue strain-dependent virulence or host factors had been 
proposed but none of them have been extensively studied like the ADE hypothesis 
(Halstead, Rojanasuphot et al. 1983; Mongkolsapaya, Dejnirattisai et al. 2003). 
Numerous studies have confirmed the ADE phenomenon in vitro or in vivo with animal 
models but the detailed mechanisms of how ADE leads to DHF/DSS are still unknown.  
1.1.5 Vaccine development: Despite numerous approaches that have been tried in the 
last sixty years, an effective dengue vaccine remains elusive. The ideal dengue vaccine 
must be protective against all four serotypes and cost-effective. Various groups have 
tried many vaccine development strategies, including live attenuated tetravalent 
vaccines ( Guirakhoo, Pugachev et al. 2001; Sun, Edelman et al. 2003), chimeric 
tetravalent vaccines based on attenuated dengue virus or Yellow Fever 17D ( Durbin, 
Kirkpatrick et al. 2011;Guy, Barrere et al. 2011; Osorio, Huang et al. 2011), recombinant 
DNA vaccines based on flavivirus and non-flavivirus vectors or VEE Replicon Particles 
( White, Sariol et al. 2013) and Recombinant protein vaccines (Putnak, Coller et al. 
2005). Among these efforts, alphavirus vector based tetravalent dengue vaccine shows 
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promising potential compared to other vaccine candidates. The major concern with any 
dengue vaccine is to avoid eliciting cross-reactive and non-neutralizing antibodies which 
may enhance subsequent virus infection instead of preventing it. To address this 
problem, the goal of vaccines in development is to elicit robust and simultaneous 
protective immunity to all 4 serotypes. In addition, we need to know exactly which virus 
epitopes induce type-specific/neutralizing or cross-reactive/non-neutralizing antibodies. 
My work will help to shed some light on this question.  
1.2 Antibody Neutralization of Dengue Virus 
1.2.1 Neutralizing antibody: Most of my work in this dissertation is about antibody 
neutralization of dengue virus. The study of dengue neutralization is critical for 
understanding dengue virology and pathogenesis and advancing vaccine development. 
Type-specific antibodies are believed to be the major neutralizing component in dengue 
polyclonal serum and depletion study by de Alwis et al. demonstrated this hypothesis (de 
Alwis, Smith et al. 2012). So the questions are where do these type-specific antibodies 
bind and where do most human dengue-reactive antibodies bind? Studies using mouse 
MAbs indicated that most neutralizing antibody epitopes are on EDIII (Cockburn, 
Navarro Sanchez et al. 2012) but Wahala and colleagues noted that EDIII is not the 
main target of human neutralizing Abs (Wahala, Kraus et al. 2009). The generation of 
large cohorts of human anti-dengue MAbs from PBMC revealed the existence of cross-
reactive Ab response decades after infection (Smith, Zhou et al. 2012). Other reports 
also found that the cross-reactive MAbs make majority of the cloned MAbs and type-
specific and strongly neutralizing MAbs are rare (Beltramello, Williams et al. 2010; de 
Alwis, Beltramello et al. 2011). Recent reports further suggested that most of these 
cross-reactive E antibodies target fusion loop (Lai, Tsai et al. 2008; Costin, Zaitseva et al. 
2013). Further characterization of the few strongly neutralizing MAbs revealed one 
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particular group of antibodies binding to conformational epitopes on virion surface which 
appear to be the major neutralizing epitopes targeted by Abs in polyclonal sera (de Alwis, 
Smith et al. 2012). These Abs bind to whole virus but do not bind to soluble E 
glycoprotein which suggests that the epitope exists only on virus surface but not E 
protein monomer. Whether these Abs bind to tertiary structure of E trimers on the 
immature virion surface or E dimmers of the mature virion surface is still unknown.  
1.2.2 Mechanisms of neutralization: Many DENV neutralizing MAbs had been 
characterized up to today but the mechanisms and stoichiometry of neutralization are 
still largely elusive. Pierson and colleagues suggested that antibody neutralization of 
flavivirus is a multiple hit phenomenon in which the number of antibodies binding to the 
virion must exceed certain threshold for neutralization to happen (Pierson, Xu et al. 
2007). This model has been demonstrated in West Nile virus and the threshold is 
estimated to be around 30 antibodies. This stoichiometry model explains the MAb’s 
neutralization potency as occupancy of accessible epitopes: for strongly neutralizing 
MAb, its accessible epitopes are much more than 30, so it takes small occupancy of 
binding (percentage of the total available epitopes that are bound by antibodies) to 
exceed the threshold; otherwise for weakly neutralizing MAb, its total available epitopes 
are less than 30, then even maximum occupancy (at highest concentration) are still 
below threshold. However, this model has several flaws as it ignores the possibility that 
location and function of epitope itself may affect the threshold requirement as binding to 
different epitopes may exert different effect on virus entry, fusion, replication steps and 
thus the stoichiometry of neutralization may vary. Secondly, it does not take into 
consideration the cases of different MAbs binding to the same virion and composition of 
these bound antibodies may alter the threshold requirement of neutralization.  In this 
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work, I tried different experimental design and proposed additional stoichiometry model 
to address these flaws.  
 
1.3 Methods to study dengue Virus   
1.3.1 Generation of Infectious Viruses: Most previous DENV neutralization and ADE 
studies have used virus derived from mosquito cell line C6/36. The C6/36 cell monolayer 
is infected at low MOI and kept in 28 ºC incubator for 6 days before the supernatants are 
harvested as infectious virus stocks. Occasionally, people may use Vero cell derived 
viruses for their work, but seldom did anyone uses human monocytic cells derived 
viruses as infectious virus. As mentioned above, viruses derived from different cells lines 
may vary in glycosylation and maturation. It has been shown that mosquito cells and 
mammalian cells have variation in processing prM Cleavage (Dejnirattisai, Jumnainsong 
et al. 2010). Our experience suggested even using the same method of virus production 
such as C6/36 methods mentioned above, the virus stocks produced at different batches 
still vary in neutralization assays, not only the titer varies in logs magnitude but also the 
sensitivity to neutralization. In this thesis, the mechanisms of this variation will be 
illustrated. But it is important for the field to recognize the existence of this pitfall and 
take serious effort to standardize infectious virus stock between different labs.  
More attention should be paid to human monocytic cell derived virus in the future. 
After mosquito biting and injecting the virus to human blood, the viruses in the primary 
infection site are mosquito cell derived but after one replication cycle, the progeny 
viruses now turn into be human monocytic cell line derived for the rest of the viremia. So 
in general, it is the human cell derived viruses that challenged and shaped our immune 
response to dengue infection. Therefore the human cell derived viruses are more 
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relevant in pathogenesis than the mosquito cell derived viruses. However, so far there 
were not any reports using human monocytic cell derived viruses for dengue 
neutralization or ADE study. Considering the lack of knowledge about these viruses, it is 
imperative and indispensable for us to study human monocytic cell line derived viruses 
and its neutralization.  
1.3.2 Neutralization Assays: Focus Reduction Neutralization Assays (FRNT) is 
currently the most widely used assay for dengue neutralization study. It is derived from 
the focus assay, which is also the standard method for titration of virus (Okuno, Igarashi 
et al. 1978). Compared to traditional Plaque Reduction Neutralization Assay (PRNT), 
FRNT uses Vero cell monolayer and antibody staining to detect the virus infection focus 
instead of plaque formation and this improvement provides better accuracy, higher out-
put and the ability to use virus strains that do not plaque well. Based on this assay, a 
more sophisticated high-throughput assay called micro-neutralization test (MNT) has 
been developed. This assay utilizes 96 well plates and automated counting of focus 
using ELISpot reader (Taketa-Graham, Powell Pereira et al. 2010).  
However, since dengue virus infects monocytic cell in vivo, the Vero cell based 
neutralization has limitations in representing biologically relevant neutralization. Our 
collaborator Mark Heise developed a human monocytic cell line U937 expressing DC-
SIGN molecule and created dengue permissive cell line U937-DC-SIGN. Using this cell 
line, a FACS based neutralization assay was developed in our lab (Lambeth, White et al. 
2005). Instead of counting focus formations, this method counts single cell infection 
(stained with Alexa-488 conjugated Dengue specific antibodies) using flow-cytometry. It 
is a high volume automated method and the results are more relevant in estimating the 
neutralization potency of antibodies or sera in vivo.   
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Both FRNT and FACS based neutralization assay were employed in this 
research. For most of the neutralization assay, FACS based assay using U937-DC-SIGN 
is preferred for its efficiency and relevance, especially in experiment when only C6/36 
derived viruses are used. But when U937-DC-SIGN derived viruses are used as 
infection agents, the traditional FRNT is preferred because monocytic cell line derived 
viruses show a very low efficiency in infecting other monocytic cell lines such as U937-
DC-SIGN (data not shown), a phenomenon already reported by Dejnirattisai 
(Dejnirattisai, Webb et al. 2011).  
1.3.3 Factors Modulating in vitro Neutralization: DENV neutralization by antibodies in 
vivo is critical for host to clear virus infection. While using animal models for dengue 
neutralization study is expensive and time-consuming, researchers are forced to rely on 
in vitro neutralization assays that can mimic in vivo neutralization. Dengue infection of 
cell in vitro is a complicate process involving viruses, cells, temperatures, pH, incubation 
time, antibodies and other serum components such as complement. Any variation in 
these factors can alter virus infection and affect antibody mediated virus neutralization. 
However, most of these factors are understudied. But they must be taken into 
consideration when interpreting neutralization data.   
Many cell lines have been found permissive to dengue viruses and several of 
them (Vero, U937-DC-SIGN, Raji-DC-SIGN and BHK) have been used in neutralization 
assay. These cell lines are known to use different surface molecule as attachment 
molecule for dengue virus (Kroschewski, Allison et al. 2003; Navarro-Sanchez, Altmeyer 
et al. 2003). The different usage of attachment molecule is a factor that must be 
considered when comparing neutralization data among assays using different cell lines. 
Besides, the endosome furin level may also vary between cell lines, and this will affect 
virus maturation both during virus secretion out of cell and virus entry to the cell.  Apart 
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from cellular factors, viral factors such genetic mutation and non-genetic variation (such 
as maturation or glycosylation) affect neutralization even more. A lot has been studied 
about virus genetics and indicated how mutations increase or decrease neutralization 
sensitivity. This part is well elucidated and explained in this dissertation. There are also 
some non-genetic factors may affect neutralization, including maturation and 
glycosylation.  
 
1.4 Objectives of Study 
One important question in DENV studies is that the humoral immunity fails to 
protect heterologous secondary infection.  In order to elucidate this question, we aim to 
investigate the long term antibody response in vivo and characterize the neutralizing and 
enhancing monoclonal antibodies. Strongly neutralizing MAbs have the potential of 
treating DENV infection as therapeutic antibodies. To promote development of DENV 
antibody therapy, we aim to study mechanisms and stoichiometry of dengue-antibody 
interaction and to illustrate the mechanisms of virus escaping neutralization through 
natural genetic mutations. The monocytes are major targets of DENV infection in vivo 
but monocytic cell derived virus was seriously understudied in previous neutralization 
and ADE studies. To fill in this gap, we aim to determine the maturation of viruses 
derived from monocytes, and study how this may affect virus sensitivity to antibody 
mediated neutralization. In general, the objective of this study is to get better 
understanding of interaction between antibody and virus, and provide clues for DENV 
antibody therapy and vaccine development.   
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Figures and Legends 
 
Figure 1.1 
 
Figures 1.1: Genome structure of dengue virus and the 11 virus proteins (adapted from 
Exp Biol Med April 2008 vol. 233 no. 4 401-408) 
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Figure 1.2 
 
Figure 1.2: Top and side view of the Dengue virus envelope protein dimer structure with 
domain III hi-lighted in magenta and cyan (Adapted from Volk based coordinates from 
Harrison et al, RSCB protein data bank)  
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Figure 1.3  
 
 
Figure 1.3: The flavivirus life cycle. A - G represents each step of flavivirus life cycle 
(adapted from Perera et al, Antiviral Res. 2008 Oct; 80(1):11-22. doi: 
10.1016/j.antiviral.2008.05.004.) 
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Figure 1.4  
 
Figure 1.4: Structure of mature virion and immature virion. A. A surface shaded view of 
the cryo-EM reconstruction of immature DENV-2.  B. A surface shaded view of the cryo-
EM reconstruction of mature DENV-2. C. Arrangement of the E proteins on the surface 
after fitting of the atomic coordinates of the E protein Cα residues into the immature virus 
and D. mature virus. The 3 vertices of the triangle and number 3, 3, 5 represent different 
symmetry points in an icosahedral unit (adapted from Izabela A. Rodenhuis-Zybert, 
trends in microbiology, Volume 19, Issue 5, May 2011, Pages 248–254).  
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CHAPTER 2 
CHARACTERIZATION OF MONOCLONAL ANTIBODIES ISOLATED FROM 
PBMC OF DENGUE IMMUNE PATIENTS 
 
2.1 Introduction 
Dengue viruses (DENV) are expanding globally with an estimated 50-100 million 
cases of dengue infection worldwide annually, and more than 20,000 deaths. It is now 
estimated that approximately one fifth of the world population is at risk of infection by 
DENV (Guzman, Halstead et al. ; Gibbons and Vaughn 2002; Gubler 2002). Dengue is 
also threatening the continental US. More than 25 cases of locally acquired infection 
were reported in Key West, Florida in 2009 and 2010 . Symptomatic dengue disease 
ranges in severity from an influenza-like illness to life threatening hemorrhagic fever or 
shock. Understanding the pathogenesis of dengue hemorrhagic fever/dengue shock 
syndrome (DHF/DSS) is of central importance in the rationale development of antiviral 
for treatment and vaccines to prevent dengue disease (Green and Rothman 2006; 
Whitehead, Blaney et al. 2007).  
The DENV complex consists of 4 serotypes. Infection with a single serotype 
leads to antibody responses that cross-react with all serotypes (Halstead 2002). Despite 
the cross-reactivity, individuals only develop protective immunity against the serotype 
responsible for infection (Halstead 2002; Rothman 2004). Human studies have 
established clearly that the risk of progressing to DHF is greater during secondary than 
during primary infection (Halstead 2003). A prevailing theory that explains severe 
dengue during secondary infection is that pre-existing, non-neutralizing dengue-specific 
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antibodies bind to virions and enhance entry and replication in Fc-receptor-bearing cells, 
which leads to a higher viremia and release of cytokines and vasoactive mediators that 
increase vascular permeability (Halstead 2003). The molecular process of antibody-
dependent enhancement (ADE) of infection has been demonstrated to occur with DENV 
and antibodies using cells in culture and animal models (Halstead and O'Rourke 1977). 
A better understanding of the molecular, genetic, and structural basis for recognition of 
dengue viruses by human antibodies is greatly needed, and could lead to the rational 
design of vaccines that enhance the induction of neutralizing antibodies while lowering 
the risk of DHF/DSS.  
Dengue viruses are enveloped viruses of the Flaviviridae family that display 
pseudo-icosahedral symmetry, with 180 copies of the envelope (E) glycoprotein and 180 
copies of the membrane (M) protein in the lipid bilayer membrane. Previous structural 
studies have shown that the dengue virus E protein is arranged into 30 rafts of three 
parallel dimers in mature virion particles (Kuhn, Zhang et al. 2002). Envelope 
glycoproteins form dimers, and crystal structures of the dimeric E protein have been 
determined for three DENV serotypes (DENV1, DENV2 and DENV3) (Modis, Ogata et al. 
2003; Zhang, Zhang et al. 2004; Modis, Ogata et al. 2005; Nayak, Dessau et al. 2009).  
The E glycoprotein monomer possesses three principal domains, designated domains I, 
II, and III (DI, DII, DIII). DIII is likely the recognition domain for the principal cell receptor 
(Rey, Heinz et al. 1995; Bhardwaj, Holbrook et al. 2001; Crill and Roehrig 2001; Hung, 
Hsieh et al. 2004). DII possesses the fusion loop (Modis, Ogata et al. 2004) and an N-
linked glycan, which can contribute to cell binding by interaction with DC-SIGN, a 
dendritic cell-specific adhesion receptor that is a C-type lectin (Pokidysheva, Zhang et al. 
2006).  Extensive characterization of neutralizing epitopes on dengue virus E protein has 
occurred over the past 10 years, using monoclonal antibodies (MAbs) generated in mice 
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inoculated multiple times with dengue viruses (Brien, Austin et al. ; Shrestha, Brien et al. ; 
Roehrig, Bolin et al. 1998; Chen, Huang et al. 2007). Mapping of epitopes recognized by 
strongly neutralizing mouse MAbs has identified several major antigenic sites on the E 
protein (Pierson, Fremont et al. 2008). Studies have shown that sites in the region of the 
fusion peptide, located at the tip of E protein DII (Rey, Heinz et al. 1995; Oliphant, 
Nybakken et al. 2006) and near the E protein hinge and linker regions between DI and 
DII, are recognized by cross-reactive, moderately neutralizing mouse MAbs. The most 
potent neutralizing antibodies are serotype-specific, however, and bind epitopes on the 
lateral surface of DIII of the E protein (Modis, Ogata et al. 2005; Oliphant, Engle et al. 
2005). Investigators also have started to uncover specific mechanisms of antibody 
neutralization of flaviviruses.  Some flavivirus antibodies that neutralize probably do so 
by sterically blocking attachment of the virus to the cell receptor. Other neutralizing 
antibodies block a step after cell attachment and such antibodies possibly neutralize by 
preventing protein conformational changes required for viral fusion in endosomes 
(Nybakken, Oliphant et al. 2005; Kaufmann, Nybakken et al. 2006). Some antibodies (for 
example the DENV MAb1A1D-2) appear to bind to hidden epitopes that are transiently 
exposed on the particle and promote a cascade of E protein rearrangements on the 
particle (Lok, Kostyuchenko et al. 2008). These studies have been instrumental in 
understanding mechanisms for flavivirus neutralization, however, since the antibodies 
were generated artificially in mice, the ability to translate this information to humans is 
limited. 
The ability of flavivirus MAbs to enhance dengue virus infection in cell culture and 
animal models has been studied extensively (Balsitis, Williams et al. ; Dejnirattisai, 
Jumnainsong et al. ; Halstead and O'Rourke 1977; Goncalvez, Engle et al. 2007). ADE 
of infection has been shown to occur with antibodies binding to E or prM proteins 
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(Dejnirattisai, Jumnainsong et al. ; Kou, Lim et al. ; Huang, Yang et al. 2006). This 
phenomenon results in as much as a 1,000-fold increase in infectivity and is Fc-
mediated (Balsitis, Williams et al. ; Littaua, Kurane et al. 1990). Recent work by Pierson 
et al., using mouse MAbs against WNV, has shed light on the stoichiometry of this 
process (Pierson ; Pierson, Xu et al. 2007). For each antibody studied, a threshold 
number of MAbs docked to the virion dictated whether neutralization or enhancement 
took place. The type of functional activity was determined not only by the location of the 
epitope, but also by the antibody affinity and epitope accessibility. An additional related 
ADE mechanism has been demonstrated to occur with anti-prM antibodies. Using either 
mouse or human MAbs, investigators have shown that the presence of anti-prM 
antibodies causes immature viral particles that have prM on the surface, which are 
normally noninfectious, to acquire the ability to infect cells efficiently through Fc-
mediated pathways (Dejnirattisai, Jumnainsong et al. ; Rodenhuis-Zybert, van der 
Schaar et al. ; Rodenhuis-Zybert, Wilschut et al.). The role that ADE and anti-prM 
antibody-mediated enhanced infectivity of immature virus particles play in the 
pathogenesis of dengue infection is of significant interest. Characterization of antibodies 
obtained from humans following natural infection could prove to be an important tool for 
further investigation. 
Until very recently, the isolation of naturally occurring human MAbs has been 
challenging. Most of our knowledge of the human antibody response to dengue has 
come from studies using polyclonal sera of naturally infected patients. Using antibody 
depletion experiments, we have previously demonstrated that E protein DIII binding 
antibodies make up a small fraction of the anti-dengue binding and neutralization activity 
in immune sera (Wahala, Kraus et al. 2009). Crill et al. confirmed that serotype-specific 
DIII antibodies formed a very small proportion of the polyclonal response, however, 
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these investigators showed a significant correlation between the presence of such 
antibodies and dengue virus neutralizing activity (Crill, Hughes et al. 2009). Taken 
together, these studies suggest that very rare serotype-specific potent neutralizing 
antibodies may be the primary determinants of protection against severe disease in 
humans.  
Recently, several groups have generated panels of human dengue-specific MAbs 
using B cells from people exposed to natural DENV infection, to investigate the humoral 
response to dengue infection. Schieffelin et al. generated three E protein reactive human 
MAbs and showed that all three where at least partially cross-reactive and two lacked 
neutralizing activity (Schieffelin, Costin et al.). A panel of six human anti-preM 
monoclonal antibodies was developed and shown to be entirely cross-reactive and 
devoid of significant neutralization activity (Dejnirattisai, Jumnainsong et al.). Other 
investigators have isolated larger panels of human MAbs to dengue (Beltramello, 
Williams et al. ; de Alwis, Beltramello et al.). These studies indicate that most antibodies 
are serotype cross reactive and weakly to non-neutralizing.  Fewer than 5% of the 
antibodies displayed moderate to strong neutralization of one or more serotypes.  
In the study presented here, we use a high efficiency optimized method to 
generate human hybridomas to make a large panel of MAbs to dengue viruses derived 
from peripheral blood cells of travelers following natural primary or secondary infections.  
2.2 Materials and Methods 
Viruses and recombinant proteins used in study. DENV1 WestPac-74, DENV2 S-
16803, DENV3 CH-53489, and DENV4 TVP-360, provided by Dr. Robert Putnak (Walter 
Reed Army Institute of Research, Silver Spring, MD) were used in the present study. 
These viruses were used to prepare infectious stocks and purified DENV antigens as 
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previously described (Wahala, Kraus et al. 2009). A pure virus antigen mixture 
containing equal quantities of each of the 4 serotypes were used to screen and 
characterize human hybridomas. Recombinant proteins containing fragments of E or prM 
were used to determine antigens and domains recognized by human antibodies. 
Recombinant envelope (rE) proteins (80% of E protein) from the 4 DENV serotypes were 
purchased from Hawaii Biotech, Inc (Modis, Ogata et al. 2003). This antigen binds to 
conformational MAbs and X-ray crystallography studies have demonstrated that these 
proteins retained a native-like structure (Modis, Ogata et al. 2003; Modis, Ogata et al. 
2005).  DIII of envelope from each of the 4 serotypes was expressed as fusion protein 
with maltose binding protein (MBP) in E. coli and purified as previously described (Modis, 
Ogata et al. 2003).  These proteins also bind to conformational MAbs and retain native-
like structure (Modis, Ogata et al. 2003).  Purified DENV2 proteins containing DI and II of 
envelope and pr peptide of prM were kindly provded by Margaret Kielian and A. Zheng 
from Albert Einstein College of Medicine, New York (Liao, Sanchez-San Martin et al. ; 
Zheng, Umashankar et al.). 
Human subjects and peripheral blood cell isolation.  We identified a panel of 12 
dengue immune subjects in North Carolina by screening volunteers who suspected 
exposure during past travel to dengue endemic regions.  In most cases we were able to 
pinpoint the year and country of infection by taking a detailed travel and clinical history.  
From dengue immune subjects approximately 100 mL of blood was collected by 
veinpuncture and immediately processed to isolate peripheral blood mononuclear cells 
(PBMCs) by density gradient separation on Ficoll.  The cells were immediately 
cryopreserved and stored in liquid nitrogen. The protocol for recruiting and collecting 
blood samples from people was approved by the Institutional Review Board of the 
University of North Carolina at Chapel Hill.  
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 Generation of human hybridomas. Previously cryopreserved samples were thawed 
rapidly in a 37 ºC water bath and washed once in 10 mL pre-fusion medium (Stemcell 
Technologies, ClonaCell®-HY 03801). Cells were counted and viability assessed with 
trypan blue staining (Gibco 15250-061). For every 4 million viable cells, the following 
then was added: 13 mL warmed pre-fusion medium, 20 L CpG stock (2.5 mg/mL)(ODN 
2006; Invivogen #tlrl-hodnb-5), 20 L cyclosporin A stock (1 mg/mL in ethanol; Sigma 
C1832), 20 L Chk2i stock (10 mM; Sigma #C3742), 4.5 mL clarified supernatant from 
cultures of B95.8 cells (ATCC VR-1492) containing Epstein-Barr virus. The mixture then 
was plated into 384-well plates (NUNC 164688) at 50 L/well, and plates were incubated 
at 37 ºC with 5% CO2 for 10 days, prior to screening for antigen specific cell lines with 
ELISA. Cells from wells with supernatants reacting in dengue virus-specific ELISA then 
were expanded by collecting all cells in the well and transferring them to a 96 well flat 
bottom plate (Falcon 353072) in 200 L pre-fusion medium containing irradiated human 
PBMCs, as follows: 20 mL pre-fusion media, 20 L CpG stock, 20 L Chk2i stock, and 8 
million heterologous healthy donor PBMCs that had been gamma-irradiated with 3,000 
rad. Plates were incubated at 37 ºC for 4 days before exchanging 100 L of medium with 
fresh pre-fusion medium. Plates then were incubated for an additional 3-4 days prior to 
fusion with HMMA2.5 non-secreting myeloma cells (kindly provided by Dr. Marshall 
Posner). 
Screening ELISA. Gradient-purified DENV prepared in carbonate binding buffer was 
used to coat ELISA plates (Nunc 242757), then UV-inactivated using a calibrated UV 
light source (Stratalinker; Stratagene) for 10 min, prior to incubation at 4 °C overnight. 
Plates then were blocked with 50 L/well blocking solution and incubated at room 
temperature for 1 hr in block, consisting of 10 g powdered milk, 20 mL goat serum, 100 
mL of 10X PBS, 0.5 mL Tween (Sigma 7949), mixed to 1L final volume with dH2O. 
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Plates were washed x 4 with PBS, and 5 L of supernatant was transferred from one 
well of a 384-well plate containing EBV-transformed B cell lines, using a pin-tool device 
(V&P Scientific), into 25 l/well of block. Plates were incubated at room temperature for 
1 hr prior to washing x 4 with PBS. Secondary antibody (goat anti-human Fc; Meridian 
Life Science, W99008A) was applied at a 1:5,000 dilution in blocking solution using 25 
l/well, and plates again were incubated at room temperature for 1 hr. Following repeat 
PBS washing x 4, phosphatase substrate solution (1 mg/mL phosphatase substrate in 1 
M Tris aminomethane) (Sigma, S0942) was added at 25 L/well and plates were 
incubated at room temperature for 3 hr before reading the optical density at 405 nm on a 
Molecular Devices plate reader. 
Electrofusion of EBV-transformed B cells with myeloma fusion partner. HMMA2.5 
cells were counted and suspended as 10 million cells/mL in a microcentrifuge tube in 1 
mL warmed cytofusion media prepared as follows: 300 mM sorbitol (Fisher, BP439-500), 
0.1 mM calcium acetate (Fisher, AC21105-2500), 0.5 mM magnesium acetate (Fisher, 
AC42387-0050), 1.0 mg/mL BSA (Sigma, A2153). Following 7 days of expansion in 96-
well plates, cells from EBV-transformed B cell wells were pipetted gently into 
microcentrifuge tubes containing 1 mL of warmed cytofusion medium. Transformed B 
cells and HMMA2.5 cells were centrifuged at 900 x g for 4 min, supernatants were 
decanted and the pellets resuspended in 1 mL of cytofusion medium. This process was 
repeated three times to ensure equilibration to cytofusion medium. Cytofusion medium 
then was decanted gently from each sample tube such that approximately 100 L 
remained, and the pellet was retained. HMMA2.5 cells then were resuspended in 
cytofusion medium to achieve a 10 million cells/mL concentration. One hundred µL of 
HMMA cell suspension then was mixed with each sample tube and the mixture of HMMA 
and EBV transformed B cells was pipetted into cytofusion cuvettes (BTX, 450125). The 
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cuvette then was placed in a modified cytofusion device, using a BTX cuvette holder 
(BTX Safety stand, Model 630B) and Cyto-Pulse Sciences generator (Cyto-Pulse 
Sciences, PA-4000/PA-101) and the electrical discharge program run with following 
settings: pre-fusion AC current of 70 volts for 40 sec, followed by a DC current pulse of 
300 volts for 0.04 msec, then post-fusion AC current of 20 volts for 30 sec. Following 
fusion, cuvettes were incubated at 37 °C for 30 min. The content of each cuvette then 
was added to 20 mL of HAT medium containing ouabain, composed of the following: 500 
mL post-fusion medium (Stemcell Technologies, 03805), one vial 50X HAT (Sigma, 
H0262), and 150 L of a 1 mg/mL stock of ouabain (Sigma, 013K0750). Fusion products 
then were plated at 50 L/well into 384-well plates and incubated at 37 °C for 21 days 
before screening hybridomas for antibody production by ELISA. 
MAb production and purification. Wells containing hybridomas producing dengue 
virus-specific antibodies were cloned biologically by two rounds of limited dilution plating. 
Once clonality was achieved, each hybridoma was expanded in post-fusion medium 
(Stemcell Technologies, 03805) until 50% confluent in 75 cm2 flasks (Corning, 430641). 
For antibody expression, the cells in 75 cm2 flasks were collected with a cell scraper; the 
hybridomas were washed in serum free media (GIBCO Hybridoma-SFM from Invitrogen, 
12045084), and split equally amongst four 225 cm2 flasks (Corning, 431082) containing 
250 mL serum free media. Flasks were incubated for 21 days before medium was 
clarified by centrifugation and 0.2 m sterile filtered. Antibodies were purified from 
clarified medium by protein G chromatography (GE Life Sciences, Protein G HP 
Columns, 17-0404-03). 
Neutralization assay.  The neutralizing potency of antibodies was measured using a 
flow cytometry-based neutralization assay with the U937 human monocytic cell line 
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stably transfected with DC-SIGN, as previously described (Kraus, Messer et al. 2007).  
ADE assays. The ability of antibodies to enhance DENV was measured using U937 
cells that had not been engineered to express DC-SIGN in the absence of the virus 
attachment factor; these Fc receptor bearing cells are only susceptible to infection in the 
presence of dengue-specific antibodies. Test antibodies were diluted to different 
concentrations and mixed with viruses containing 104 FFU in 96-well round bottom plates, 
and incubated at 37°C for 45 minutes.  Then 2 x 104 U937 cells were added to the 
mixture and incubated for 2 hrs at 37°C.  The cells were washed to remove unbound 
virus/ antibody mixtures and incubated with fresh medium at 37°C.  The cells were 
harvested 24 hrs later, fixed and processed for flow cytometric analysis to determine the 
percent of infected cells.  ADE activity was expressed as the percent increase of infected 
cells in the dengue-specific antibody treated sample compared to the sample treated 
with a control antibody. 
2.3 Results 
Electrofusion technique for generation of human hybridomas. For generation of 
human hybridomas using PBMCs from individuals who had recovered from natural 
infection, we used an established electrofusion method, but made several alterations to 
the previously published protocol (Yu, McGraw et al. 2008). First, we found that the 
kinetics and efficiency of transformation of human B cells using EBV with CpG 
stimulation was improved inhibiting EBV-associtated apoptosis with the addition of a 
pharmacologic inhibitor of CHK2, a protein kinase that is activated in response to DNA 
damage and is involved in cell cycle arrest (Nikitin, Yan et al.). Also, following EBV 
transformation of PBMCs and identification of a well producing a dengue antibody of 
interest, expansion of EBV transformed B cells in the presence of irradiated PBMCs, 
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CpG, and CHK2 inhibitor greatly increased transformed B cell numbers, resulting in the 
greater likelihood of generating the hybridoma of interest by electrofusion. This added 
step improved the overall efficiency of isolation of hybridomas by at least two-fold (data 
not shown). Additional improvements in throughput and efficiency were achieved by 
adapting a different electroporation cuvette system (BTX cat no. 45-0207, Model 630B) 
from that previously described for use with a PA-4000/PA-101 electrofusion device (Cyto-
Pulse Sciences). This cuvette system allows for the use of standard disposable 
electroporation cuvettes, permitting cytofusion of two samples at one time. In addition to 
the convenience of the disposable cuvette, a moderate improvement in the efficiency of 
hybridoma generation was observed when compared to the Cytopulse cuvette system 
(data not shown). Finally, improvement in consistency was seen with the use of a 
commercial hybridoma cell culture medium, typically used for generation and growth of 
mouse hybridomas (ClonaCell-HY Medium, STEMCELL Technologies). Together these 
modifications resulted overall in a greater than ten-fold increase in the number of human 
hybridomas that could be generated using PBMCs from immune individuals, compared to 
historical data in our laboratory. 
Demographics and screening of traveler subjects. To better our understanding of the 
human antibody response to DENV following infection, we initiated a study to identify and 
obtain blood from people living in North Carolina who had been exposed to DENV during 
travel or previous residence in endemic regions.  Subjects with a past clinical history 
compatible with DENV infection were invited to volunteer.  We confirmed a past DENV 
infection by identifying the presence of dengue virus neutralizing antibodies in donor 
serum, testing against each of the 4 serotypes of DENV (Table 2.1).  An individual whose 
serum mainly neutralized a single serotype was classified as having a past history of 
infection with a single serotype (“primary”) (Table 2.1).  Individuals whose serum 
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contained antibodies that broadly neutralized two or more serotypes were considered to 
have had two or more previous infections (“secondary”) (Table 2.1).  For secondary 
cases, it was not possible to use the neutralization titers to identify the specific serotypes 
causing infection or the sequences of the infecting viruses, since these sera typically 
recognized all four serotypes. All DENV immune subjects filled out a detailed 
questionnaire about previous travel and clinical history, and this information was used to 
determine the year and location of likely infection, as well as the interval between 
infection and sample collection for the current study (Table 2.1). 
To produce dengue specific human hybridomas, cryopreserved PBMC samples 
from each subject were thawed and inoculated with EBV in the presence of CpG, CHK2 
inhibitor, and cyclosporine A, as described in the Materials and Methods section. As 
shown in Table 2.1, between 744 and 2,976 EBV transformed B cell cultures were 
generated from samples from each of the twelve subjects, who had suffered primary 
DENV 2 (2 subjects) or DENV 3 (4 subjects) infection, or secondary infection (6 subjects). 
Screening for the presence of antibodies to dengue virus in the supernatant of 
transformed B cell cultures showed that between 0.4 and 5% of wells in the 384-well 
transformations were positive. Based on the number of positive wells and the number of 
lymphocytes tested, the frequency of DENV-specific B cells in circulation was estimated 
for each subject (Table 2.1). Frequency was based on the total number of B cells plated 
(estimated as 5% of total PBMCs) with an estimated 10% EBV transformation efficiency 
(based on average colony counts in transformed wells). A total of thirty-seven human 
anti-dengue virus hybridomas was generated from twelve different subjects, with a yield 
ranging from 1 to 10 hybridomas per subject. Twenty-eight hybridomas were derived 
from individuals who had primary infection and nine from secondary infection. 
Remarkably, five hybridomas were derived from cells of subjects who had been infected 
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with dengue 20 years or more prior to PBMC collection. Antibodies secreted by each of 
the thirty-seven human hybridoma cell clones were purified and characterized to 
determine their dengue virus protein specificity. Twenty-nine MAbs bound the E protein, 
while eight bound the M protein. 
Characteristics of E protein binding human MAbs. Results of the characterization of 
29 purified human anti-E MAbs from anti-dengue hybridomas are shown in Table 2.2 
Hybridomas derived from subjects 3, 19, 103 and 105 comprise the majority (23 of the 29 
anti-E MAbs generated). Cells were obtained from these subjects following a primary 
infection. The remaining six anti-E antibodies were derived from six individuals following 
either primary or secondary infection. Three anti-E MAbs (designated 4G9, 2C2, and 3H4) 
were IgG2 molecules, while the rest were of the IgG1 isotype. Of the anti-E MAbs 
generated, 12 used kappa and 17 used lambda light chains. 
As can be seen in Table 2, 29 of the 37 human anti-dengue MAbs bound to E 
protein in either ELISA or western blot assay. Of the 29 anti-E antibodies characterized, 
all but 3 were fully cross-reactive, binding all four dengue serotypes in ELISA at the 
lowest concentration tested (1 ng/ml). Two antibodies, MAbs 2J20 and 2D7, were 
considered partially cross-reactive, as they bound to more than one but less than four 
serotypes. The DENV 2 serotype-specific MAb 2D22 bound only to purified DENV 2 virus 
in ELISA. Next, we determined the binding of these MAbs to recombinant E protein in 
ELISA. All but 5 MAbs bound recombinant E protein in ELISA. E protein-specific MAbs 
that did not bind recombinant E protein were shown to bind E protein using western 
blotting, with the exception of 2D22. DENV 2 serotype-specific antibody 2D22 did not 
bind to structural proteins in western blot or to recombinant E protein constructs in ELISA. 
Finally, we evaluated the ability of the twenty-nine anti-E MAbs to bind domain I/II or 
domain III fragments of E protein. Five antibodies bound the domain III portion of E 
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protein – 1C17, 1M23, 2J20, 1B23 and 1M19. Antibodies that did not bind recombinant 
domain III of E protein were tested in ELISA for binding to domain I/II of E. All of the anti-
E protein antibodies that did not bind domain III (except for 2D22; i.e., 23 out of 29 anti-
envelope antibodies) bound DI/II. 
The ability of these 29 human anti-E protein MAbs to neutralize representative 
viruses of the four dengue serotypes is shown in Table 2.2. Interestingly, six antibodies 
exhibited little or no neutralizing activity (neut50 > 10μg/ml) against any of the four dengue 
serotypes. Most MAbs, 13 out of 29, were found to neutralize viruses weakly from three 
or four serotypes, with equivalent potency against those viruses. Seven antibodies were 
found to neutralize only one or two serotypes weakly. Of the 29 antibodies determined to 
bind E protein, only three MAbs, 2D22, 5J7, and 2J20, were determined to have 
moderate to strong (neut50 < 1μg/ml) neutralizing activity against at least one serotype. 
In Figure 2.1, the concentration-dependent neutralization activity of two strongly 
neutralizing human anti-E protein MAbs is shown. The percent neutralization for the four 
dengue serotypes is shown in panel A for MAb 5J7. This MAb, which was isolated from 
an individual who recovered from a primary DENV 3 infection, cross reacted with all 4 
serotypes and bound to an epitope on DI/II of E protein (Table 2.1). Despite the serotype 
cross reactivity in binding assays, MAb 5J7 neutralized only serotype 3 virus. In panel C, 
the concentration-dependent neutralization activity of MAb 5J7 is shown in more detail, 
using a broader range of halving dilutions. MAb 5J7 neutralized 50% of serotype 3 virus 
at a concentration of 0.1μg/ml. The percent neutralization for MAb 2D22 against viruses 
from the four dengue serotypes is shown in Figure 2.1 panel B and D. This antibody, 
which was isolated from a subject exposed to a primary DENV2 infection, bound to DI/II 
of envelope protein of DENV2 only (Table 2.1).  In panel B, MAb 2D22 is shown to have 
neutralizing activity only to serotype 2. MAb 2D22 exhibited 50% neutralization of DENV 
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2 at a concentration of 0.08 μg/ml (panel D). Interestingly, as can be seen in Figure 2.1, 
the maximum percentages of virus neutralization for MAbs 5J7 and 2D22 were very 
different. The maximum percentage of neutralization for MAb 5J7 was nearly 100%, 
whereas MAb 2D22 could neutralize only about 60% of virus in the assay at the highest 
concentration of antibody tested. 
The ability of the 29 human anti-E MAbs to enhance infection in vitro is shown in 
Table 2. ADE assays were performed at a concentration of 1 μg/ml against a virus from 
each dengue serotype. Four antibodies did not exhibit enhancing activity (i.e., caused < 5 
fold enhancement) to three or even four dengue serotypes. Most MAbs, 15 out of 29, 
were found to enhance infection moderately (5–25 fold) for viruses from two to four 
dengue serotypes. Of the 29 antibodies tested, 17 had strong (> 25 fold) enhancing 
activity against virus from at least one serotype. Interestingly, MAb 2J20 strongly 
neutralized DENV 3 virus but strongly enhanced DENV 2 infection.  
In Figure 2.2, neutralization or enhancement activity against a heterologous 
DENV 4 virus is shown for several representative human anti-E protein MAbs. Flow 
cytometric neutralization assays were performed using U937-DCSIGN cells and 
enhancement assays were performed using U937 cells lacking DCSIGN, as described in 
the Materials and Methods section. In Figure 2.2 panel A, data for fully cross-reactive, 
weakly neutralizing and moderately enhancing MAbs 2A15, 1L5, and 2A10 are shown. 
All three MAbs neutralized 50% of DENV 4 at a concentration of approximately 10μg/ml. 
These antibodies enhanced dengue infection moderately, resulting in a 5-25 fold peak 
increase in titer of DENV 4. In Figure 2.2 panel B, fully cross-reactive, non-neutralizing 
and non-enhancing MAbs 3F13, 1A15, and 3H9 are shown. All three antibodies bound 
DENV 4 but they did not neutralize or enhance virus infection effectively. Together, these 
two principal categories of anti-E protein antibodies represented the majority of the 
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human MAbs we isolated from donors with history of previous primary or secondary 
dengue infection. 
Characteristics of membrane (M) protein binding human MAbs. A significant number 
of the MAbs we isolated were specific for M protein. Results of the characterization of 
purified M protein-specific human MAbs from anti-dengue hybridomas are shown in 
Table 2.3. Hybridomas derived from subjects 27 and 105 comprise 4 of the 8 anti-M 
MAbs generated. The remaining 4 antibodies were derived from cells from subjects 3, 5, 
15, and 110. In contrast to the findings with anti-E protein MAbs, an equal number of anti-
M protein MAbs was generated from subjects following primary or secondary infection. 
All of the anti-M protein MAbs were of the γ1 isotype. Of the anti-M protein MAbs 
generated, 4 had kappa light chains and 4 had lambda light chains. 
As can be seen in Table 2.3, eight of the 37 human anti-dengue MAbs did not 
bind E protein in initial analysis, but instead bound to M protein in western blot. Of the 
eight anti-M protein antibodies characterized, all were fully cross-reactive, binding all four 
dengue serotypes in ELISA at the lowest concentration tested, 1μg/ml. To further 
characterize these human anti-M protein antibodies, we tested their ability to bind the 
recombinant “pr” portion of the membrane protein of DENV2 in ELISA. All eight MAbs 
bound recombinant “pr” in ELISA (Table 2.3). We tested these 8 human anti-M protein 
MAbs for ability to neutralize viruses from each of the four dengue serotypes (Table 2.3). 
Interestingly, each exhibited some weak neutralizing activity against virus from at least 
one of the four dengue serotypes. Surprisingly, MAbs 2M2 and 2H12 showed moderate 
to strong neutralization activity against virus of a single serotype.  
The ability of the eight human anti-M protein MAbs to enhance infection in vitro is 
shown in Table 2.3. ADE assays were performed at a concentration of 1μg/ml against 
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representative viruses from each dengue serotype. All but one of the eight MAbs had 
strong (> 25-fold) enhancing activity for virus from at least one serotype. Interestingly, 
anti-M protein MAb 5L20 was nearly devoid of enhancing activity for viruses of any of the 
dengue serotypes in this assay. 
Concentration-dependent neutralization and ADE assays were performed for 
each of the human anti-M protein MAbs against viruses from each of the four dengue 
serotypes. Results for several representative MAbs are shown in Figure 2.3. The ability 
of each anti-M protein antibody to neutralize and/or enhance infection with DENV 1 
(panel A), DENV 2 (panel B), DENV 3 (panel C), or DENV 4 (panel D) is shown. MAbs 
4F8, 1G6, and 4E9, each exhibited similar concentration-dependent neutralization curves, 
with neut50 concentrations of > 10μg/ml against viruses from each dengue serotype. The 
concentration-dependent neutralization of MAb 5L20, however, differed, exhibiting almost 
no neutralizing activity. ADE occurred with MAbs 4F8, 1G6, and 4E9 (as well as 5E6, 
2M2, 2H12, and 5G22 - data not shown). Overall, all but one anti-M protein MAb 
exhibited enhancing activity. The degree of enhancement varied between 2- and 126-fold, 
depending on the MAb and the serotype of the virus tested. Interestingly, anti-M protein 
MAb 5L20 did not enhance infection in this assay at any concentration tested. 
 
2.4 Discussion 
These studies reveal that the human B cell response to DENV infection is 
dominated by cross-reactive antibodies with low or no neutralizing potency and 
significant potential to enhance infectivity by Fc-mediated mechanisms. Antibodies with 
enhancing activity were isolated that were directed to both E and M proteins, thus 
conferring the ability to enhance infectivity not only with mature infectious particles but 
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also with partially or fully immature particles displaying prM protein that otherwise would 
be poorly infectious or non-infectious. Remarkably, B cells encoding these types of 
antibodies persisted in the circulation for decades after infection. 
Interestingly however, a few rare, potently neutralizing antibodies that are nearly 
devoid of enhancing activity were produced naturally by humans in response to infection. 
Mapping of the epitopes recognized by naturally-occurring human dengue virus specific 
antibodies is essential in determining whether these enhancing and neutralizing activities 
can be separated. Understanding the epitopes and activity of these neutralizing 
antibodies will be critical for vaccine development, as vaccines that induce high potency 
neutralizing antibodies that lack enhancing activity are desirable. Ideally, the reactivity of 
epitopes bound by enhancing antibodies should be reduced or eliminated in candidate 
antigens during the rational development of a dengue vaccine, so as to discourage such 
dominant recognition of these antigenic features by the humoral immune response. The 
goal is that such molecular information could be used in the rational design of dengue 
vaccines that enhance the induction of protective neutralizing antibodies and reduce the 
risk of development of severe disease. 
DENV E protein was the most common protein target of circulating human 
memory B cells in this study. Over three-quarters (29 of 37) of the human anti-dengue 
antibodies identified in this study bound to E protein. We screened for virus-specific 
antibodies using purified whole virus preparations that contained both immature and 
mature virus particles and all of the virus structural proteins [including a complete (non-
truncated) E protein]. Therefore, these results confirm that the bulk of the human B cell 
response to exposed structural antigens is directed toward the E protein. The majority of 
the anti-E protein antibodies, 23 of 29, was obtained from subjects following primary 
infection. The E protein has been thought to be the dominant antigen following primary 
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and secondary dengue infection, when evaluated by western blotting studies using 
soluble antibodies in polyclonal sera from immune subjects (Lai, Tsai et al. 2008). Our 
studies show that the pattern of specificity of circulating B cells also reflects this 
predominance. Characterization of the E protein-specific antibodies showed that most 
were of the IgG isotype. This distribution is typical of the profile of most virus-specific 
responses in humans and also reflects the predominance of the IgG1 isotype in the 
circulating human memory B cell population. Light chain usage was split almost evenly at 
12 kappa light chains and 17 lambda light chains. Both isotype and light chain usage 
suggest that isolation of clones using the hybridoma method is unbiased, as expected. 
Thus, the panel of human antibodies presented here likely reflects the frequency and 
specificity of the anti-dengue B memory cell pool present in circulation following recovery 
from primary or secondary infection.  
The most striking feature of the anti-E protein antibodies was the predominance 
of cross-reactivity. Of the 29 anti-E protein antibodies characterized, all but three were 
fully cross-reactive, binding all four dengue serotypes. Considerable attention has been 
place on the DIII portion of the E protein for dengue and other flaviviruses (Beasley and 
Barrett 2002; Oliphant, Engle et al. 2005; Sanchez, Pierson et al. 2005; Sukupolvi-Petty, 
Austin et al. 2007). The importance of the human antibody response to DIII has been 
studied extensively, originally using polyclonal sera and more recently using human 
MAbs (Beltramello, Williams et al. ; Wahala, Kraus et al. 2009). However, it is clear that 
epitopes across other regions of the E protein contribute significantly to human protection 
(Oliphant, Nybakken et al. 2006; Wahala, Kraus et al. 2009). The data here provides 
additional information, specifically a better understanding of the frequency of these 
antibodies in circulation. Only 5 of the 29 E protein reactive antibodies bound the DIII 
portion of E protein. All the DIII antibodies were cross-reactive, and only one (2J20) had 
38 
neutralizing activity. Characterization of the 26 fully cross-reactive anti-E protein MAbs 
showed that most, but not all, were directed toward the DI/II region.  
E protein specific human B cells specifying strongly neutralizing antibodies are 
rare. Of the 29 human anti-envelope antibodies generated, only three (MAbs 5J7, 2J20 
and 2D22) met our definition of moderate to strongly neutralizing (neut50 < 1.0μg/ml) – 
two following primary and one following secondary infection. Two of the three antibodies, 
MAbs 5J7 and 2J20 exhibited cross-reactive binding to all four dengue viruses in ELISA, 
yet strongly neutralized virus of only one serotype. 2D22 was DENV2 type-specific both 
for binding and neutralization. MAb 2J20 bound to DIII and 5J7 to DI/II of E protein. 2D22 
was particularly interesting because it bound to the virus particle but not to any of the 
recombinant protein constructs used in the current study. There are several plausible 
explanations for these observations. The 2D22 epitope may be located on a region of the 
E that is not included in the recombinant constructs, given that the membrane proximal 
regions were removed in the design of these constructs in order to make them soluble. 
Additionally, the conformation of the epitope may be altered during preparation for ELISA 
or western blot. Alternatively, the epitope recognized by this very interesting human 
antibody might be very complex, involving the interface of neighboring E proteins.  
Indeed human MAbs that only bind a West Nile virus E protein epitope that is preserved 
on the intact virion but not recombinant protein have recently been described (Vogt, 
Moesker et al. 2009).  The maximum percentage of virus neutralization for MAbs 5J7 and 
2D22 differed greatly. The maximum percentage of neutralization for MAb 5J7 was nearly 
100%, whereas MAb 2D22 could neutralize only about 60% at the highest concentration 
of antibody tested. This finding not only suggests that the MAbs recognize different 
epitopes, but also probably means that they use different mechanisms of neutralization. 
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ADE activity, not neutralization, was the dominant functional activity noted for the 
E-protein specific antibodies in this study. All but two anti-E protein antibodies enhanced 
infection of at least one serotype at the concentration tested (1μg/ml). Strongly 
neutralizing serotype-specific MAb 2D22 and fully cross-reactive weakly neutralizing MAb 
3H4 were the only MAbs that had no detectable ability to enhance dengue infection at 
this initial concentration. Interestingly, further dilution of 2D22, well below the 
concentration where enhancement occurred with all of the other MAbs, demonstrated 
enhancement of infection (data not shown).  Maximum ADE activity (25-fold) was seen at 
a concentration of 0.025μg/ml, as compared to between 0.1 and 1.0μg/ml, seen for other 
MAbs in our panel. Sixteen antibodies met our definition for mediating strong (> 25-fold) 
enhancement of at least one serotype, including the DIII-binding strongly neutralizing 
antibody 2J20. Taken together, these data show that potency of neutralization does not 
always inversely correlate with the strength of enhancement, as strongly neutralizing 
antibodies also were strongly enhancing at lower concentrations, while MAb 3H4 that 
was weakly neutralizing did not display enhancing activity. It is important to note that the 
human antibody response to dengue infection seems to rarely include antibodies that are 
able to separate neutralization from enhancement, as exemplified by MAb 2D22. This 
MAb possesses potent serotype-specific neutralization activity without the ability to 
enhance infection at the typical concentration range seen with weakly neutralizing cross-
reactive MAbs. Understanding the specificity of these rare but very important antibodies 
is critical for the rational design of a dengue vaccine. 
Nearly one-quarter, eight of 37, of the human anti-dengue antibodies identified in 
this study were M protein-specific. When compared to the number of anti-E protein 
antibodies obtained following primary versus secondary infection (24 following primary, 5 
following secondary), there appeared to be a greater percentage of anti-M protein MAbs 
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generated from subjects following secondary infection (17 % anti-E, 50 % anti-M). This 
finding suggests that the human antibody response to M protein may be increased 
relative to the response to E protein following a secondary infection. This observation has 
been suggested previously by others using western blotting methods and dengue 
immune sera (Lai, Tsai et al. 2008). The most prominent characteristic noted in the panel 
of human anti-M MAbs here was the degree of cross-reactivity. All eight MAbs were fully 
cross-reactive, binding all four dengue serotypes in ELISA at the lowest concentration 
tested (1μg/ml) using whole virus as antigen. All but one M protein-specific MAb met our 
definition for strong (> 25-fold) enhancement of infection. Further characterization of 
these eight MAbs showed that all were directed toward the “pr” portion of the M protein, 
as they bound to recombinant “pr” fragment protein in ELISA. Interestingly, however, two 
anti-M protein MAbs met our definition for moderate to strongly neutralizing activity 
(neut50 < 1.0μg/ml) – MAbs 2H12 and 2M2. These two pr-specific MAbs demonstrated 
serotype-specific neutralizing activity despite being fully cross-reactive. The physiologic 
significance of potent neutralization of dengue by pr-specific antibodies that should 
recognize only immature particles is uncertain, but bears further exploration. 
In summary, the human B cell response encoding dengue-specific antibodies is 
complex. Human antibody-mediated neutralizing activity is directed to several proteins 
and diverse epitopes in those proteins. Most of the E protein specific antibodies exhibit 
ADE activity, while only rare clones possess potent neutralizing activity. The antibodies 
that do neutralize exhibit features that suggest differing mechanisms of neutralization. 
Most intriguingly, the most potent E protein specific neutralizing antibodies recognize 
occult epitopes that are present in virus particles, but not represented in recombinant 
antigens. Discovery of the structure and nature of the epitopes for these unique MAbs 
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could point the way toward better rational design of dengue vaccine antigens. 
Unexpectedly, some pr-specific antibodies exhibit relatively potent neutralizing activity.  
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Figures and Legends  
 
Figure 2.1.  
 
Figure 2.1: Serotype-specific strongly neutralizing E protein binding human MAbs  
A. The ability of purified human MAb 5J7 to neutralize the four serotypes of dengue virus 
is shown over a concentration range. B. The ability of purified human MAb 2D22 to 
neutralize the four serotypes of dengue virus is shown over a concentration range. C. 
Purified human MAb 5J7 neutralization of serotype 3 virus over a detailed, broader 
range of halving dilutions. D. Purified human MAb 2D22 neutralization of serotype 2 virus 
over a detailed range of halving dilutions. Flow cytometric neutralization assays were 
performed using U937-DCSIGN cells.  
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Figure 2.2  
 
Figure 2.2: Cross-reactive poorly neutralizing E protein binding human MAbs 
A. The ability of purified human MAb 2A15, 2A10, or 1L5 to neutralize or enhance DENV 
4 is shown over a concentration range. These MAbs represent a class of fully cross-
reactive, weakly neutralizing and moderately enhancing antibodies. B. The ability of 
purified human MAb 3F13, 1A15, or 3H9 to neutralize or enhance DENV 4 is shown over 
a concentration range. These MAbs represent a class of fully cross-reactive, non-
neutralizing and non-enhancing antibodies. Flow cytometric neutralization assays were 
performed using U937-DCSIGN cells. ADE assays were performed using U937 Fc 
receptor expressing cells.  
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Figure 2.3 
 
Figure 2.3: Cross-reactive poorly neutralizing PrM protein binding human MAbs 
The ability of purified human MAb 1G6, 4E9, 4F8, or 5L20 to neutralize or enhance 
DENV 1 (panel A), DENV 2 (panel B), DENV 3 (panel C), or DENV 4 (panel D) is shown 
over a concentration range. Flow cytometric neutralization assays were performed using 
U937-DCSIGN cells. ADE assays were performed using U937 Fc receptor expressing 
cells.  
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CHAPTER 3 
THE STOICHIOMETRY MODELS AND MECHANISMS OF ANTIBODY 
MEDIATED VIRUS NEUTRALIZATION  
 
3.1 Introduction  
Dengue is an emerging flavivirus and it is endemic in tropical and subtropical 
areas putting 2.5 billion people in risk of infection every year (WHO 2009). Dengue 
infection can cause either mild flu like disease called dengue fever (DF) or a severe life 
threatening disease called Dengue Hemoharrgic Fever or Dengue Shock Syndrome 
(DHF/DSS). Four serotypes of dengue viruses co-circulate world-widely and immunity 
against one serotype is unable to protect virus against re-infection from another serotype 
(WHO 2009). Epidemiological evidence further suggests that the sub-neutralizing 
heterotypic immunity in secondary infections can lead to enhancement of the infection, 
which is called Antibody Dependent Enhancement (ADE) (Halstead and Simasthien 
1970). ADE occurs when Fc-γ receptors of monocytic cells serve as additional 
attachment molecules, helping antibody-coated dengue viruses to infect cells (Halstead 
and O'Rourke 1977). ADE poses the greatest obstacle to the development of a safe 
dengue vaccine. Therefore understanding the mechanisms of dengue neutralization is 
critical for preventing ADE and the subsequent severe disease.  
The dengue virus genome is a positive-sense RNA of 11kb, encoding 3 structure 
proteins (C-prM-E) and 7 non-structure proteins. The mature DENV particle is composed 
of 90 E glycoprotein dimers in an icosahedra scaffold. The E glycoprotein is the primary 
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surface antigen inducing protective immunity. It is essential for membrane fusion and 
binding to cellular receptors. The E protein ecto-domain consists of three domains: EDI, 
EDII and EDIII, each connected by flexible hinge regions. EDIII belongs to the IgG 
superfamily and it binds to viral receptors, and many strongly neutralizing MAbs were 
found to bind to EDIII (Roehrig 2003; Brien, Austin et al. 2010; Shrestha, Brien et al. 
2010; Sukupolvi-Petty, Austin et al. 2010). However, later research suggests that EDIII 
plays a minor role in dengue neutralization by polyclonal sera (Wahala, Kraus et al. 
2009). EDI/II contains the fusion peptide and recent studies have suggested that fusion 
loop is the major target of neutralizing antibodies (Lai, Tsai et al. 2008; Lin, Tsai et al. 
2012; Costin, Zaitseva et al. 2013). As shown in Figure 1.3, to infect a cell, the virus will 
go through attachment, internalization, transformation and membrane fusion before it 
can release the RNA genome into the cell cytoplasm. Specifically, attachment to a cell 
involves E glycoprotein binding to the DC-SIGN molecule (or heperan sulfate) or through 
antibody bridged binding of the Fc- γ receptors. Then, the putative dengue cellular 
receptor will bind to E and mediate the uptake and internalization of virus into the 
endosome, where the low PH environment activates the virus envelope to go through a 
conformational change (transformation), during which the 90 glycoprotein E dimers 
dissociate, and re-associate to form 60 trimers (Yu, Zhang et al. 2008).  The 
transformation exposes the fusion peptide for subsequent fusion.  The hydrophobic force 
between the fusion loop and cellular membrane enables insertion of the fusion loop into 
the membrane, starts structure rearrangement of the envelope and drives the virus 
membrane to fuse with the cellular membrane, resulting in the release of virus genome 
RNA into the cell cytoplasm (Kuhn, Zhang et al. 2002; Modis, Ogata et al. 2004). 
Antibodies neutralize dengue viruses through binding E protein and blocking the 
steps mentioned above. In the last decade, cloning and characterization of both murine 
54 
MAbs and human MAbs have enabled detailed study of antibody neutralization 
mechanisms. Particularly, a function assay has been developed to differentiate 
neutralization at the attachment step and post-attachment step. At 37°C, endocytosis of 
viruses follows spontaneously and immediately after virus attachment. The function 
assay utilizes cold temperatures to enable virus attachment without subsequent 
endocytosis and thus allows us to separate the attachment step out. Apart from 
attachment, all the following virus infection steps, such as receptor-mediated 
internalization, transformation and membrane fusion, are labeled as post-attachment 
steps in the function assay. So far, less than 50 DENV MAbs have been studied using 
this function assay and these MAbs were found to block mostly post-attachment steps 
(Rajamanonmani, Nkenfou et al. 2009; Teoh, Kukkaro et al. 2012; Costin, Zaitseva et al. 
2013). Other complicated assays, such as the liposome coflotation assay, have been 
adapted to identify the MAbs’ capability to block membrane fusion (Yu, Holdaway et al. 
2009).  
The multi-hit model of virus neutralization argues that neutralization is the 
cumulative effect of multiple antibodies binding to a virion simultaneously (Della-Porta 
and Westaway 1978). Recent advances in West Nile virus neutralization research 
secured the multi-hit model as a dominant model in flavivirus neutralization. Pierson and 
colleagues examined the stoichiometry of antibody-mediated neutralization of WNV and 
demonstrated that a threshold of antibody binding is required for neutralization to occur 
(Pierson, Xu et al. 2007). This model is named as the Threshold Model and it implies 
that antibody neutralization potency is determined by interplay between antibody affinity 
and epitope accessibility. As of the present day, the threshold model has not been tested 
with DENV. Gromowski and colleagues studied the stoichiometry of several mouse 
MAbs and did find evidence supporting the threshold model, though they also reported a 
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linear correlation between antibody binding of EDIII and the neutralization of infectivity 
(Gromowski and Barrett 2007).  
It is unknown whether antibodies that neutralize through different mechanisms 
vary in binding/neutralization stoichiometry, but such knowledge is invaluable for both 
understanding dengue neutralization and antibody therapy or vaccine design. To fill in 
this gap, I collected a panel of well characterized MAbs and determined their 
binding/neutralization stoichiometry using the FACS-based neutralization assay and 
ELISA. The neutralization mechanism of each MAb is determined through FACS-based 
function assay. Our results demonstrated that there is an association between the 
stoichiometry model and neutralization mechanisms.  
 
3.2 Materials and Methods  
Cells. Mosquito Aedes albopictus C6/36 cells were maintained in MEM (Gibco) media at 
28°C. Human monocyte lymphoma cell line U937cells expressing DC-SIGN (U937 DC-
SIGN) were maintained in RPMI-1640 (Gibco) at 37°C supplemented with 50mM beta 
mercaptoethanol. Vero-81 cells were maintained in DMEM at 37°C. All media used were 
also supplemented with 5% FBS, 100U/mL penicillin, 100mg/mL streptomycin, 0.1mM 
non-essential amino acids (Gibco) and 2mM glutamine and all cells were incubated in 
the presence of 5% CO2. The 5% FBS was reduced to 2% to make infection media for 
each cell line.  
Antibodies, Infectious Viruses and Antigens. A total of 10 monoclonal antibodies 
were obtained from multiple sources and stored in -20°C (Table 3.1).   80% confluent 
C6/36 cells were infected with viruses at an MOI of 0.05 and incubated at 29°C 5% CO2 
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for 6 days. Supernatants were harvested, clarified of cell debris, aliquoted and stored at -
80°C for future use as infectious virus stocks. 80% confluent vero-81 cells were infected 
with viruses at an MOI of 0.05 and incubated at 37°C for 6 days. Supernatants were 
harvested, cleared of cell debris, and ultra-centrifuged at 80,000 x g for 4 hrs with a 20% 
sucrose cushion to pellet down virions (Beckman Countler ultracentrifuge, OptimaTM L-
90K). Virion pellets were resuspended in PBS and further purified by density gradient 
ultracentrifugation at 100,000 x g for 2 hrs (OptiPrep® Density Gradient Medium, Sigma). 
The gradient was fractioned immediately after ultracentrifugation and each fraction was 
measured for virus content using reducing protein gel. Pure antigen containing fractions 
were pooled, diluted in PBS and ultra-centrifuged again. The final pellets were 
resuspended in PBS, titrated for concentration using Bradford assay and stored at -80oC 
for future use as virus antigen.  
ELISA. high binding ELISA plates (Corning Life Sciences) were coated with 50 ng of 
purified virus antigen per well in 0.1 M carbonate buffer. Plates were incubated at 4˚C 
overnight, washed three times (all washes were performed three times with tris-buffered 
saline containing 0.2% Tween-20), then blocked with dilution buffer on a shaker at 37˚C 
for 1hr. 50 µL of antibodies prepared in Tris-buffered saline containing 0.05% Tween-20 
and 3% Normal Goat Serum were added to the wells and incubated on a shaker at 37˚C 
for 1 hr. Unbound primary antibodies were washed off and 1:1000 alkaline phosphatase 
conjugated diluted goat anti-mouse or anti-human secondary antibody added; the plate 
was then incubated on a shaker at 37˚C for 1 hr. Unbound secondary antibodies were 
washed off, pNPP substrate added, and absorbance readings were taken at 405 nm in 
an Epoch Microplate Spectrophotometer (Biotek Instruments Inc. Winooski, VT).   
FACS Based Neutralization Assay. Antibodies were diluted in RPMI 1640 media with 2% 
FBS buffered with 20mM HEPES (infection media).  Infectious virus stocks were diluted 
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in infection media to make 20, 000 PFU/mL. 40 µl of diluted antibodies and 40 µL of 
diluted viruses were added to a 96 well round bottom plate (Corning Life Science, Lowell, 
MA) and incubated in a 37˚C incubator for 45 minutes.  20 µL of U937-DC-SIGN cells at 
a density of 106 cells/mL were added to each well and incubated for 2 hrs. Unbound 
viruses and antibodies were washed off by pelleting cells at 1500 rpm for 5 minutes and 
the cells were resuspended in 200 µL infection media. After 24 hrs of incubation, the 
cells were pelleted, washed with PBS and fixed with Cytofix/Cytoperm solution (BD 
Biosciences, San Jose, CA) at room temperature for 10 minutes. After washing twice 
with permeablization buffer (BD Biosciences, San Jose, CA), cells were stained with 
Flexor-488 conjugated 2H2 antibody for 1 hr at 37oC. The unbound conjugated 
antibodies were washed off and the plates were read using Guava system flow 
cytometry (Millipore Inc. Billerica, MA).   
FACS-based Function Assay. The Function Assay is modified from the FACS-based 
Neutralization Assay described above. Specifically, for the pre-attachment assay, U937-
DC-SIGN cells were pre-chilled at 4°C. Viruses were incubated with serial diluted MAbs 
at 4°C for 1 hr and then the cells were added and kept in 4°C incubation for another 1 hr. 
Unbound antibodies and viruses were washed off with 4°C washing media and then 
moved to a 37°C incubator for 24 hrs. For the post-attachment assay, the viruses were 
added to pre-chilled cells and incubated at 4°C for 1 hr. Unbound viruses were washed 
off using chilled media. Then diluted MAbs were added to the cells and incubated at 4°C 
for 1 hr. After washing off unbound antibodies, the plate was moved to 37°C and 
incubated for 24 hrs. All operations were done on ice surface.  
 
 
58 
3.3 Results  
Variation in antibody binding affinity and neutralization potency  
The 10 MAbs studied here vary in neutralization potency, isotype, subclass and 
specificity (Table 3.1). Most of the MAbs (4G2, 9F16, 2Q1899, 5C36, DVC 3.7, DVC25.5, 
1A1D-2, 8A1 and 14A4) had been characterized in previous studies while 9D1 was 
characterized for the first time (Littaua, Kurane et al. 1990; Gromowski and Barrett 2007; 
Lok, Kostyuchenko et al. 2008; Wahala, Donaldson et al. 2010; de Alwis, Beltramello et 
al. 2011). Among these MAbs, 8A1, 14A4 and 9D1 were DENV3 type-specific; all others 
were either DENV2 type-specific or cross-reactive (in this study they were tested against 
DENV2 viruses). To study the stoichiometry between binding and neutralization, MAbs 
were tested for binding affinity using ELISA and for neutralization potency using FACS-
based Neutralization Assay. Each MAb was tested at 12 concentrations (2-fold dilutions) 
for a complete sigmoidal shape dose response curve (Figure 3.2). The EC50 of a MAb 
represents a concentration at which the virus is half occupied by this MAb and it 
indicates the MAb’s binding affinity to the virus. Neut50 represents a concentration at 
which half of the virus’ infectivity is inhibited by the MAb and it indicates the 
neutralization potency of the MAb. Both EC50 and Neut50 were calculated based on the 
sigma-dose response curve fitting (Table 3.1). Comparison of the two values of each 
MAb indicated that for some MAbs (4G2, 9F16, 5C36, 2Q1899, 9D1 and DVC 3.7), the 
two values are very close (Figure 3.2A, 3.2B and Table 3.1) while for some other MAbs 
(1A1D-2, DVC 25.5, 8A1, 14A4 and 9D1) the two values have 10 fold differences (Figure 
3.2C, 3.2D, and Table 3.1). This discrepancy suggests that the stoichiometry of 
binding/neutralization may be different between the two groups of MAbs.  
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Two Stoichiometry Models of Binding/Neutralization 
To better contrast the stoichiometry difference between the two groups of MAbs, I 
plotted each MAb’s percentage neutralization against its corresponding ELISA OD value 
at each concentration. This plot is adapted from a similar plot drawn by Growmoski but is 
improved here by replacing rEDIII protein with purified virus antigen (Gromowski and 
Barrett 2007; Gromowski, Barrett et al. 2008). The results indicated that the MAbs with 
small Neut50/EC50 ratio (4G2, 9F16, 5C36, 2Q1899 and DVC3.7) show a good linear 
correlation between antibody binding and neutralization, as shown by representative 
MAb 4G2 in Figure 3.2A. On the other hand, the MAbs showing large Neut50/EC50 ratio 
(8A1, 14A4, 1A1D-2 and DVC 25.5) indicated a threshold pattern of neutralization 
(Figure 3B). The hallmark of the threshold model is that there is no significant 
neutralization until the ELISA binding exceeds a certain threshold, however, once 
binding reaches the threshold, incremental binding will enable the neutralization jump to 
100% (Figure 3.2B). However, MAb 9D1 is an exception as it indicated a decent linear 
stoichiometry (Figure 3.2A) with an R2 value of 0.9 while its Neut50/EC50 ratio is close 10. 
For this MAb, the plot is more convincing as it is based on the whole sigma dose curve 
rather than its middle point (Neut50/EC50). Generally stoichiometry model results are 
consistent with the Neut50/EC50 results, as for MAbs with the linear model, half of total 
occupancy means half of total neutralization, but for MAbs with the threshold model, half 
of total occupancy did not enable neutralization until it reaches the threshold, which is 
close to saturation.  
The neutralization mechanisms: pre-attachment or post-attachment 
To demonstrate that the distinct stoichiometry models of binding/neutralization 
are associated with different neutralization mechanisms, the function assay was 
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employed to identify the neutralization mechanisms of each MAb. Though this assay can 
only differentiate blocking attachment from blocking post-attachment steps, it can still 
provide evidence supporting or disproving my hypothesis. For pre-attachment 
neutralization, antibodies were added before viruses’ absorption to cells at cold 
temperature (4°C) and this exposed viruses to antibody-mediated neutralization before 
and after attachment. For post-attachment neutralization, the antibody was added to 
viruses that were already absorbed to cells, which allowed antibody neutralization at the 
post-attachment steps only. Pre-attachment neutralization and post-attachment 
neutralization of each MAb were measured at serial MAb dilutions, allowing the 
neutralization mechanism to be identified by comparing the pre-attachment and post-
attachment neutralization curves (Figure 3.3A and 3.3B).  For MAbs 9D1, 9F16, 5C36 
and 2Q1899, the function assay results indicated that these MAbs block the attachment 
step and exert little inhibition on post-attachment steps (Figure 3.3C). MAbs added at 
pre-attachment step induced neutralization while antibodies added post-attachment 
induced insignificant neutralization. For MAbs 4G2, DVC3.7, 8A1, 14A4, 1A1D-2 and 
DVC25.5, the majority of neutralization is contributed by inhibition of the post-attachment 
steps, as the antibodies added post-attachment induced neutralization almost equal to 
the neutralization resulting from adding the antibody at pre-attachment step (Figure 
3.3C).  
 
3.4 Discussion  
In this study I systematically investigated the stoichiometric relationship between 
antibody binding and virus neutralization. Comparison of MAb EC50 and Neut50 clearly 
suggested that there might be two different stoichiometric models among the studied 
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MAbs. Plotting the percentage neutralization against ELISA OD value further confirmed 
the two distinct stoichiometric models. Simply put, 6 MAbs displayed a linear model, as 
their neutralization was proportional to antibody binding, while 4 MAbs revealed a 
threshold model as only antibody binding exceeding a threshold can lead to 
neutralization. None of the MAb characteristics such as isotype, type specificity, binding 
epitope or neutralization potency were found to be correlated with the stoichiometry 
model (Table 1).  Therefore I hypothesized that different neutralization mechanisms are 
associated with the two distinct stoichiometric models respectively. Function assay was 
employed to identify the neutralization mechanism of MAbs and the results suggested a 
correlation between stoichiometry models and neutralization mechanisms.   
As shown in Figure 3.3, the 4 MAbs 9F16, 5C36, 9D1 and 2Q1899 all indicate 
neutralization at the attachment step but not at the post-attachment steps, and most 
intriguingly, all four MAbs display linear stoichiometry of binding/neutralization. This 
suggests that MAb neutralization by blocking the attachment step is associated with 
linear stoichiometry of binding/neutralization (Figure 3.4).  
It is commonly believed that only total abolishing of virus infectivity via antibody 
binding can lead to neutralization of virus. But flavivirus has a limited life-span in vivo or 
in vitro and for DENV, the half-life is about 2 hr to 3 hrs in vitro in neutral pH at 37 ºC 
(unpublished data). When only a few antibodies bind to the functional E protein of the 
virus and block these E proteins from “attaching” to the cell (but leave all other E proteins 
intact and fully functional), it will not result in total loss of virus infectivity, but will 
definitely lead to a decrease of chances of infection within the virus’ limited life-span, and 
ultimately resulted in the decrease of total infection. Obviously a 50% decrease of 
chances of infection by antibody binding within the life-span will lead to a 50% decrease 
of infection of the total virus population, which is 50% neutralization by definition. The 
62 
feature of this neutralization mechanism is that with more E proteins blocked, there is 
less chance of attachment (and less infection). Put simply, the more antibody binding, 
the more E proteins blocked from attachment function, and the more neutralization. 
Statistically, neutralization is linearly correlated to antibody binding (the linear model of 
stoichiometry). Since in this scenario, neutralization occurs without the requirement of 
total abolishing of the virus’ infectivity, there is no “threshold” requirement. The evidence 
of 9F16, 5C36, 9D1, and 2Q1899 supports this hypothesis and indicates that the 
neutralization mechanism of blocking attachment is associated with linear stoichiometry 
of binding/neutralization (Figure 3.4).  
On the other hand, the 6 MAbs identified as neutralizing post-attachment steps 
do not all display the threshold model: MAb 4G2 and DVC3.7 displayed the linear model 
of stoichiometry. Specifically, MAb 4G2 is identified as blocking membrane fusion (Crill 
and Chang 2004). The membrane fusion mediated by fusion peptide is subject to 
antibody blocking and the fusion event itself is similar to attachment, depending on the 
function of individual fusion peptides. In other words, the chance of successful fusion is 
determined by the quantity of available functional fusion peptides (free from antibody 
occupation). This explains why MAb blocking the fusion step also displays linear 
stoichiometry of binding/neutralization (Figure 3.4). Similar to blocking attachment and 
fusion, blocking the cellular receptor also depends on the quantity of occupied individual 
E proteins, so it is very likely that MAbs with this neutralization mechanism also follow a 
linear stoichiometry model (Figure 3.4). I speculate that EDIII-binding MAb DVC 3.7 may 
be candidate MAb for blocking receptor binding and it may prove useful in future 
research involving identification of the dengue cellular receptor.   
Besides receptor binding and fusion, another post-attachment step prone to 
antibody mediated neutralization is the pH-triggered conformational change of envelope 
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(E dimers transform to trimers). During this transformation, an obvious fact is that at least 
3 dimers co-dissociated all together can make 2 integrate trimers. Considering the 
compact organization of 90 E dimers of the virion and the close inter-connection 
between adjacent E proteins (Figure 1.4), the 3 dimers do not act alone but mobilize 
transformation of neighboring dimers, initiating a chain reaction and finally a global 
transformation. Therefore I speculate that the envelope transformation is a “global” 
conformational change that involves all 180 E proteins simultaneously. If this is the case, 
it is either a “global” transformation or no transformation and no “partial” transformation. 
Therefore only occupation of enough number of E simultaneously is able to inhibit this 
“global” transformation, which suggests that antibody binding needs to pass a threshold 
quantity to be effective. Put in other words, this implies that neutralization by blocking 
transformation is associated with a threshold stoichiometry. Interestingly, in this dimer to 
trimer transformation,  6 neighboring E proteins are one minimal unit for this kind of 
change and since there are 30 such units in one virus, theoretically, to inhibit all 30 units 
simultaneously, a minimum number of 30 MAbs are required, which is exactly what 
Pierson estimated the threshold number to be (Pierson, Xu et al. 2007). According to this 
hypothesis, the 4 MAbs (8A1, DVC 25.5, 1A1D-2 and 14A4) showing the threshold 
stoichiometry model should all neutralize DENV by blocking transformation. Though it is 
beyond this thesis scope to prove, the function assay results indicated that they all block 
the post-attachment step and this is consistent with my hypothesis (Figure 3.4).  
In general, I hypothesized that the neutralization mechanisms of blocking 
attachment (A), blocking cellular receptor binding (B), and blocking fusion peptide (C) 
are associated with linear stoichiometry model; blocking conformational change (D) 
should follow a threshold stoichiometric model (Figure 3.4). The limited evidence from 
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the function assay supported hypotheses A and C, and is consistent with hypothesis D 
while hypothesis B cannot be proved or disproved with current knowledge.  
This is the first systematic study to explore the relationship between binding-
neutralization stoichiometry and mechanisms of neutralization. Though due to the 
limitation of experiment techniques, the results could not provide complete and 
conclusive evidence for the hypothesis, it nevertheless provides new insights into our 
understanding of how antibodies neutralize viruses. A statistical perspective of 
"neutralization" is introduced and discussed here. It suggests that neutralization of the 
virus does not necessarily means the virus is completely deprived of any chance of 
infecting a target cell. For example, if we observe a 50% reduction of neutralization, it 
may suggest half of the virus population is completely sterilized while the other half is 
unhampered in infectivity, or it could be that on average, each virus’s chance to infect a 
cell is decreased by half (due to antibody binding). In other words, 50% neutralization is 
a statistical average of all viruses as a whole and there is no clear demarcation of "dead" 
and "live" virus at all.  In this scenario, no threshold of neutralization is needed and 
neutralization increases proportionally to antibody binding. Experiments shall be 
designed to demonstrate this concept of neutralization in future. Though methods are 
limited to directly differentiate blocking receptor binding, blocking fusion, or blocking 
conformational change, by plotting post-attachment neutralization only against ELISA 
binding, we may be able to differentiate these post-attachment steps of neutralization 
and test if blocking fusion and blocking receptor binding follows linear model while 
blocking conformational change follows threshold model of stoichiometry.  
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Tables:  
Table 3.1: MAbs and their EC50 of binding and Neutralization 
name subclass specificity Source Epitope EC50 Neut50 
Neut50/EC50 
Ratio  
4G2* mIgG2a Flavivus-group ATCC EDI/II 2.07 1.51 0.75 
9D1 mIgG1 DV3 type-specific 
Dr. Mary Ann 
Accavitti-Loper 
 Unknown
#
 0.0539 0.732 13.6 
14A4 mIgG1 DV1and DV3 Dr. Putnak EDIII 0.027 2.79 10 
8A1 mIgG1 DV3 type-specific Dr. Putnak EDIII 0.045 0.61 14 
9F16 mIgG1 DV2 type-specific U.S. Biological EDIII 3.9 6.31 1.6 
2Q1899 mIgG1 DV2 type-specific U.S. Biological EDIII  1.5 3.20 2.1 
5C36 mIgG1 DV2 type-specific U.S. Biological EDIII 1.47 3.15 2.1 
1A1D-2 mIgG1 Dengue group Dr. Look EDIII 0.0099 0.26 26 
DVC3.7 hIgG1 DV2 type-specific 
Dr. 
Lanzavecchia 
EDIII 0.0232 0.0133  0.6 
DVC25.
5 
hIgG1 DV2 type-specific 
Dr. 
Lanzavecchia 
EDIII 0.0084 3.17 377 
 
*: Except the DENV3 type-specific MAbs, all other MAbs were tested against DENV2 
virus for ELISA and Neutralization. 
#: ELISA results indicated 9D1 have high binding affinity to DENV3 viruses but it showed 
negative binding to either EDIII or E protein or EDI/II protein. This is similar to the 
conformational epitope binding MAb 2D22 (Chapter 6) but this is not proved yet.   
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Figures and Legends  
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Figure 3.1: ELISA Binding Curve and Neutralization Curves of representative MAbs 
1A1D-2 (2A, 2B) and DVC3.7 (2C, 2D).  
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Figure 3.2  
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B) 
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Figure 3.2: Neutralization/Binding Plots of 6 MAbs showing A) linear stoichiometry and 4 
MAbs showing B) threshold stoichiometry.  
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Figure 3.3 
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Figure 3.3: Function assay results of all 10 MAbs.  A) MAb 9F16 represents MAbs 
neutralize at attachment step only; B) MAb 4G2 represents MAbs neutralize at post-
attachment only; C) Each MAb were tested at several different concentrations but to 
simplify the comparison among the 10 MAbs, a concentration at which neutralization 
ranged from 50% to 80% was chosen as representative to contrast the pre-attachment 
and post-attachment neutralization results. The pre-attachment neutralization in this Bar 
graph is calculated by deducting the post-attachment neutralization from the total 
neutralization (which is neutralization measured with MAb added at the pre-attachment 
step in the function assay). The concentration of each MAb at µg/ml was included in the 
MAb tag.  
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Figure 3.4 
 
 
Figure 3.4: Hypothetical relationship between neutralization mechanisms and 
stoichiometry models and the MAbs assumed to associate with each scenario.  
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CHAPTER 4 
MODELING COMBINED NEUTRALIZATION AND ENHANCEMENT OF 
DNEGUE VIRUS BY MULTIPLE MONOCLONAL ANTIBODIES  
 
4.1 Introduction  
Dengue (DENV) is a re-emerging flavivirus that affects 2.5 billion people 
worldwide (WHO 2009). The number of reported severe DENV cases has been 
increasing at an alarming rate in the past several decades, while an effective vaccine is 
still not available (WHO 2009). DENV is divided into four serotypes (DENV1-4) based on 
their antigenicity. Immunity to one serotype does not protect against re-infection with 
different serotypes (Guzman, Kouri et al., 2000). In most cases, dengue infection results 
in a mild flu-like disease called dengue fever (DF). However, secondary infection with a 
heterologous serotype can lead to life-threatening Dengue Hemoharrgic Fever or 
Dengue Shock Syndrome (DHF/DSS). It was found that pre-existing heterologous 
antibodies are sub-neutralizing and can bridge viruses with Fc-ɣ receptors of non-
permissive cells, assisting virus entry into these cells (Halstead et al., 1984). This was 
referred to as Antibody Dependent Enhancement (ADE) and evidences strongly 
suggested that ADE leads to DHF/DSS (Halstead 2003). ADE has seriously hindered the 
development of dengue vaccine. In the absence of effective dengue vaccine, therapeutic 
antibody is another option for treating dengue infection and many groups are working on 
screening candidate monoclonal antibodies (MAbs).  
74 
Both broadly cross-neutralizing and type-specific strongly neutralizing MAbs have 
been characterized as potential therapeutic antibodies (He, Innis et al. 1995; Lai, 
Goncalvez et al. 2007; Lok, Kostyuchenko et al. 2008; Cockburn, Navarro Sanchez et al. 
2012; de Alwis, Smith et al. 2012). Most of the type-specific MAbs are mapped to EDIII. 
Though it was found that unlike in mouse models, EDIII reactive antibodies constitute a 
small fraction in human immune polyclonal serum and play an insignificant role in 
neutralization (Batra, Raut et al. 2010; Wahala, Kraus et al. 2009). Nevertheless, EDIII 
recognizing type-specific MAbs are still the most promising candidate for therapeutic 
MAbs. However, single MAb is known for its potential to drive escaping mutation, 
especially for a RNA virus with high mutagenesis rate. The generation of escape mutant 
not only risks spreading treatment resistance virus but also inducing ADE. Therefore, a 
cocktail of MAbs is necessary to achieve maximum neutralization and minimal risk of 
escape mutation. 
It has been shown that the cross-reactive antibodies poses a risk of ADE during 
secondary infections though type-specific neutralizing MAbs can mediate ADE too when 
diluted to sub-neutralization level (Brandt, McCown et al. 1982). It has been reported 
that majority of anti-E antibody responses in vivo were cross-reactive against domain II 
(Lai, Tsai et al. 2008). PrM antibodies are also non-neutralizing, cross-reactive and 
enhancing (Huang, Yang et al. 2006). A recent report revealed that prM MAbs comprise 
a significant fraction in the MAbs cloned from human dengue convalescent PBMC 
(Dejnirattisai, Jumnainsong et al. 2010). Other reports revealed that cross-reactive E 
MAbs are the majority of cloned dengue reactive MAbs (Beltramello, Williams et al. 
2010;Smith, Zhou et al. 2012). These cross-reactive MAbs must be taken into 
consideration when therapeutic antibodies were to be used to treat patients with pre-
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existing immunity. Understanding their interaction with therapeutic MAbs is critical for 
designing safe and effective antibody therapy. 
Understanding how various antibodies in polyclonal serum interact with each 
other in neutralization and ADE is another important medical question. Both in vitro and 
in vivo experiments have shown that DENV neutralizing polyclonal serum, diluted to sub-
neutralizing concentration, can enhance dengue infection of monocytic origin cells 
(Cardosa 1987; Morens, Halstead et al. 1987; Morens, Larsen et al. 1987; Morier, Kouri 
et al. 1987; Littaua, Kurane et al. 1990; Morens and Halstead 1990; Burke and Kliks 
2006). Polyclonal serum is a complicated mixture of various fractions of antibodies, such 
as type-specific and cross-reactive, neutralizing and non-neutralizing, prM antibodies 
and E antibodies, EDIII and EDI/II reactive antibodies, and antibodies of different 
isotypes and subclasses. It was found that these antibodies vary in neutralization 
potency and ADE potential, and specifically, different isotype or subclass are associated 
with different neutralization and ADE potential (Littaua, Kurane et al. 1990; Thein, 
Aaskov et al. 1993; Schlesinger and Chapman 1999; Shu, Chen et al. 2000; Mehlhop, 
Ansarah-Sobrinho et al. 2007; Rodrigo, Block et al. 2009). It is unclear how different 
fractions of polyclonal antibodies interact with each other in neutralization or 
enhancement.  Studying the mixture of MAbs should be the first step to investigate the 
subtle interactions between different fractions of the polyclonal serum.  
In this project, we mixed well-characterized MAbs together and studied their 
neutralization potency and ADE potential using neutralization assay and ADE assay. We 
established a model of combined neutralization and ADE between two different MAbs 
and developed empirical mathematic equations to describe them.  These results offered 
insights into understanding how various antibody subsets in polyclonal serum interact 
with each other and provided guidelines for further therapeutic antibody formulation.  
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4.2 Materials and Methods  
Cells. Vero cells (American Type Culture Collection, CCL-81) were maintained in 
Dulbecco's Modified Eagle Medium (DMEM). A cell line designated U937-DC-SIGN was 
maintained in RPMI-1640 (Gibco) supplemented with 50 mM beta mercaptoethanol. This 
human monocyte lymphoma cell line was derived from U937 cells but also expresses 
Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin or DC-
SIGN, also known as CD209 (Cluster of Differentiation 209). Mosquito Aedes albopictus 
C6/36 cells were maintained in Minimum Essential Medium (MEM; Gibco) at 28°C. All 
media used also were supplemented with 5% FBS, 100 U/mL penicillin, 100 mg/mL 
streptomycin, 0.1 mM non-essential amino acids (Gibco) and 2 mM glutamine, and all 
cells were incubated in the presence of 5% CO2 at 37°C, unless otherwise specified. The 
5% FBS was reduced to 2% to make infection medium for each cell line.  
Serum and MAbs. Murine MAbs 2Q1899, 9F16 and 5C36 were purchased from US 
Biological (Swampscott, MA). MAbs 14A4, 2H2, 1A1D-2 and 8A1 were kindly provided 
by Dr. Robert Putnak (Walter Reed Army Research Institute, MD) (Table 4.1).  
Virus suspension and virus antigen. C6/36 cells at 80% confluency were infected at 
MOI of 0.05 for 2 hrs followed by addition of 25 mL of infection medium. After 6 days of 
incubation, the supernatants were harvested, clarified by 30 minutes ultracentrifugation 
at 18,000 x g, aliquoted into cryovials and frozen at -80°C as working virus stock. Vero 
cells were inoculated and its supernatants were harvested in the same way as C6/36 
cells. Viruses from the supernatants were pelleted at 70,000 x g through 20% sucrose 
cushion. The pelleted viruses were further purified using OptiPrep™ Density Gradient 
Medium (Sigma-Aldrich) and the virus containing fractions were collected, pelleted, 
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resuspended and frozen at -80°C for further use as purified virus antigens. All the 
viruses used were WHO reference strains of each serotype. 
ELISA. high binding ELISA plates (Corning Life Sciences) were coated with 50 ng of 
purified virus antigen per well in 0.1 M carbonate buffer. Plates were incubated at 4˚C 
overnight, washed three times (all washes were performed three times with tris-buffered 
saline containing 0.2% Tween-20), then blocked with dilution buffer on a shaker at 37˚C 
for 1hr. 50 µL of antibodies prepared in Tris-buffered saline containing 0.05% Tween-20 
and 3% Normal Goat Serum were added to the wells and incubated on a shaker at 37˚C 
for 1 hr. Unbound primary antibodies were washed off and 1:1000 alkaline phosphatase 
conjugated diluted goat anti-mouse secondary antibodies added; the plate was then 
incubated on a shaker at 37˚C for 1 hr. Unbound secondary antibodies were washed off, 
pNPP substrate added, and absorbance readings were taken at 405 nm in an Epoch 
Microplate Spectrophotometer (Biotek Instruments Inc. Winooski, VT).     
FACS Based Neutralization Assay. Antibodies were diluted in RPMI 1640 media with 2% 
FBS buffered with 20mM HEPES (infection media). Infectious virus stocks were diluted 
in infection media to 20, 000 PFU/mL. Then 40 µL of the MAb dilutions or MAb mixtures 
and 40 µL of the diluted viruses were added together into each well in a 96-well round 
bottom plate (Corning Life Science, Lowell, MA) according to experiment design and 
incubated in 37˚C incubator for 45 minutes for antibody-virus binding. U937-DC-SIGN 
cells were concentrated to 1,500,000 cells/mL density and 20 µL of the cells were added 
to each well and incubated for 2 hrs for infection. The cells were washed twice with 
infection media and incubated for 24 hrs. The rest of the experiment is the same as 
described in previous literatures (Lambeth, White et al., 2005)   
FACS Based ADE Assay. The FACS Based ADE assay protocol is same as the FACS 
Based Neutralization assay except that 1) infectious virus stock is diluted to 500,000 
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PFU/mL in infection media and 2) the U937-DC-SIGN cell line is replaced with U937 
cells.  
  
4.3 Results  
Independent neutralization of two MAbs in mixture 
Study of neutralization by a homogeneous population of MAbs has been well 
described in many previous reports and was further explored in Chapter 3. However, it is 
still unclear how neutralization by heterogeneous antibody binding of DENV using a 
mixture of MAbs might work. To study this question, the combined neutralization of two 
MAbs was assayed by mixing MAbs together in the FACS-based neutralization test. We 
first studied two DENV2-neutralizing EDIII-binding MAbs, 1A1D-2 and 2Q1899 (Table 
4.1). As shown in figure 4.1A, the neutralization curve of serially diluted MAb 1A1D-2 is a 
typical sigma dose response curve. When MAb 2Q1899 at a 1.6ng/μL concentration 
(neutralizing 40% of the DENV2 infection) was added to each dilution of 1A1D-2, the 
combined neutralization increased, but the increment varied over different 
concentrations of 1A1D-2. After fitting the data, we found a simple equation to describe 
the numerical relationship between neutralization of the mixture and that of the single 
MAb: 
1899221118992211 QDAQDAcombined NeutNeutNeutNeutNeut    
Based on this equation, we predicted combined neutralization and found it fitting 
well with the measured value (Figure 4.1A). We further tested two MAbs bound to 
different E domains: 4G2 (EDII) and 1A1D-2 (EDIII). Their combined neutralization is 
also a close approximation to what was predicted by the equation. Other combinations of 
MAbs such as mouse MAbs (5C36 or 1A1D-2) and human MAb (1E4), or MAbs with 
overlapping binding epitopes (5C36 and 9F16) were also tested (Figure 4.1A). Besides 
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DENV2, we also tried combinations of DENV3 neutralizing MAbs: type-specific 9D1 and 
8A1, and cross-neutralizing MAb 1A1D-2 in various dilution schemes (Figure 4.1B). All of 
these combinations demonstrated the accuracy and robustness of this equation.   
Additive ADE of two MAbs in mixture  
Sub-neutralizing antibodies can enhance dengue virus infection by bridging the 
virus to the Fc-γ receptors of monocytic cells. To assess how different antibodies interact 
during this process, MAbs of different subclasses or binding epitopes were mixed 
together and tested in ADE assay. Previous reports suggested that high antibody 
concentrations inhibit ADE through neutralization, as indicated by the bell-shaped ADE 
curve (Morens, Halstead et al. 1987). To avoid such complication, the MAbs were used 
at sub-neutralizing concentrations.   
Both 4G2 and 2H2 belong to the mouse IgG2a subclass, but they recognize E 
and prM protein respectively. MAbs 4G2, 2H2 and their mixture were assayed to 
evaluate the potential synergistic enhancement effect. Our results indicated that their 
combined ADE is precisely the addition of each MAb ADE alone (Figure 4.2A). This 
suggests that ADE mediated by the prM antibodies and E antibodies are additive to each 
other in antibody cocktail and there is no detectable synergistic effect. Next we tested if 
MAbs belonging to different subclasses may have a synergistic effect. It was shown that 
different subclasses of IgG bind to different Fc-ɣ receptors, RI and RII, which regulate 
different cell functions and modulate neutralization and ADE (Indik, Park et al. 1995). So 
two E MAbs: 4G2 (IgG2a) and 2Q1899 (IgG1), were mixed and tested in ADE assay. 
The results suggested that their combined enhancement is also the addition of that of 
each MAb ADE and no synergistic effect was detected (Figure 4.2B). In summary, 
combination experiments of various MAbs mixtures demonstrated that ADE is additive at 
sub-neutralizing concentrations. 
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Neutralizing MAb inhibits ADE mediated by Enhancing MAb 
Numerous works have revealed how neutralizing antibodies inhibit direct infection 
of cells (via DC-SIGN molecule or heperan sulfate) using various neutralization assays. 
But little has been done to study how neutralizing antibodies inhibit ADE infection of cells 
(via Fc-ɣ receptor). To fill in this gap, we mixed one enhancing MAb with one neutralizing 
MAb and assessed their combined ADE. MAb 2H2 represents the cross-reactive prM 
antibodies that play a major role in promoting ADE in secondary infections (Beltramello, 
Williams et al. 2010; Dejnirattisai, Jumnainsong et al. 2010).  As shown in Figure 4.3A, 
2H2 at a 0.0125 µg/mL concentration mediated 11 fold enhancement of infection. After 
the strongly neutralizing MAb 1A1D-2 was added, the 2H2 mediated ADE infection was 
reduced to base level. Moderately neutralizing MAb 9F16 (Table 3.1) can also inhibit 
most of the ADE infection (Figure 4.3B). We further found that even the weakly 
neutralizing MAb 4G2, at neutralizing concentrations, can inhibit 2H2 mediated 
enhancement (Figure 4.3C). In general, our data indicated that neutralizing MAbs can 
inhibit Fc-ɣ receptor mediated ADE infection as well as they inhibit direct infection of 
cells.  
Non-neutralizing Non-enhancing MAbs Modulate ADE infection 
EDIII binding MAbs 12C1 and 13A5 are cross-reactive with all four serotypes but 
do not neutralize any serotype, nor do they contribute to neutralization when mixed with 
neutralizing MAbs (Figure 4.4A – B and unpublished data). Surprisingly, they lack the 
capability to mediate ADE infection as well (Figure 4.4C – D). To test whether they 
contribute to ADE when mixed with other enhancing MAbs, each of them was mixed with 
MAb 4G2 in ADE assay. Interestingly, when MAb 12C1 was mixed with 4G2, the 
combined ADE increased significantly compared to that of 4G2 alone. The increase 
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becomes larger as the concentration of 12C1 goes up (Figure 4.4C).  Even more 
interestingly, MAb 13A5 displays just the contrary effect: It inhibits the ADE when mixed 
together with 4G2 and the ADE is totally abolished as 13A5 concentration increases to 
2µg/mL(Figure 4.4D). Although MAbs like 12C1 and 13A5 does not neutralize or 
enhancement infection by themselves, our data suggests that they do play a role in 
regulating the ADE mediated by other enhancing antibodies. 
  
4.4 Discussion  
Significant progress has been made in searching for candidate MAbs for dengue 
post-exposure therapy (He, Innis et al. 1995; Lai, Goncalvez et al. 2007; Lok, 
Kostyuchenko et al. 2008; Sukupolvi-Petty, Austin et al. 2010; Cockburn, Navarro 
Sanchez et al. 2012; de Alwis, Smith et al. 2012). However, using a single MAb for 
therapy could be problematic due to two reasons: 1) a single MAb, especially a type-
specific MAb, may not be broadly neutralizing against diverse dengue strains (Wahala, 
Donaldson et al. 2010; Zhou, Austin et al. 2013); and 2) a single MAb may drive dengue 
evolution to generate neutralization-escaping mutations, leading to ADE. Using a 
cocktail of different MAbs would be ideal to avoid these problems, with potential 
synergistic effect as a bonus. Therefore, knowledge about how the neutralization of 
cocktail MAbs work will be critical for the development of dengue antibody therapy. The 
synergistic effect in neutralization has been observed in HIV and Adenovirus antibody 
neutralization experiments (Tilley, Honnen et al. 1992; Potts, Field et al. 1993; Mascola, 
Louder et al. 1997; Gahery-Segard, Farace et al. 1998; Verrier, Nadas et al. 2001), but 
unfortunately for the dengue MAbs tested here, there is no evidence of such synergistic 
neutralization. Instead, our results suggested that for dengue, MAb neutralizations are 
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independent of each other and the combined neutralization follows this equation: 
BABABA NeutNeutNeutNeutNeut &  
This equation may be of interests to the medicine industry. Considering the dose 
response of antibody neutralization, this equation provides a guideline for the formulation 
of therapeutic MAbs to get maximum neutralization at the lowest possible cost. This 
equation also holds interesting implications for neutralization mechanisms. The above 
equation can be transformed to the following equation:  
)1()1()1( & BABA NeutNeutNeut   
If we define  as the percentage of non-neutralized infectivity, or rate of 
survival, the above equation can be further transformed to:
BABA SurvivalSurvivalSurvival & . This simple equation directly implies that the 
viruses have to survive the neutralization of MAb A and MAb B independently in the 
MAbs cocktail. It implies that each antibody neutralizes viruses independently and there 
is no synergistic neutralization. One explanation for this independence is that the two 
MAbs tested here are neutralizing the viruses through different mechanisms. Take the 
pair 5C36 and 4G2 as an example, 5C36 neutralizes viruses at the attachment step 
while 4G2 neutralizes viruses at the post-attachment step (Chapter 3), and the two MAbs 
work at different “time points” of the virus infection sequence.  
Pierson and colleagues proposed that flavivirus neutralization follows the 
“threshold model”, which states that viruses bound with MAbs exceeding the threshold 
will get neutralized. This model implies a synergistic neutralization of the virus. For 
example, a virus was bound by MAb A and MAb B simultaneously and each MAb alone 
is below the neutralization threshold, but together they are above the threshold 
Neut1
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requirement. Based on the threshold model, the virus should now be neutralized, which 
is known as synergistic neutralization (two MAbs at non-neutralizing concentrations are 
mixed together and become neutralizing). The threshold model predicted the existence 
of the synergistic effect, but our study failed to identify any. This result questions the 
threshold model as the universal model for flavivirus neutralization. Instead, the 
independent neutralization found here is compatible with the lack of synergistic effect 
and can also explain this equation. In other words, this result implies that the threshold 
model is not the universal model of flavivirus neutralization and there are other 
stoichiometry models.  
The results of the combined ADE of MAb mixtures also revealed no synergistic 
effect between MAbs of different subclasses, or MAbs recognizing different antigens 
(prM and E). The ADE of MAbs at sub-neutralizing concentrations are additive to each 
other when mixed together, implying that in the absence of neutralizing antibodies, ADE 
potential is proportional to the quantity of enhancing antibodies bound to viruses. By 
mixing neutralizing MAbs with enhancing MAbs, our results revealed that neutralizing 
MAbs can inhibit the ADE mediated by enhancing MAbs. The mechanism of inhibiting 
ADE is understudied, but it has been suggested that antibodies blocking the attachment 
step are not able to inhibit ADE infection because in ADE infection the virus-antibody 
complex does not utilize attachment molecules such as DC-SIGN but instead use of the 
Fc gamma receptors of the cell (Nybakken, Oliphant et al. 2005; Chan, Zhang et al. 
2011). 4G2 and 1A1D-2 were shown to block post-attachment steps (Chapter 3) and as 
expected they were able to block ADE infection (Figure 4.3A and 4.3C). However, MAb 
9F16 blocks mostly the attachment step (Chapter 3) and yet it was also able to block 
ADE infection efficiently (Figure 4.3B). This may suggest that 9F16 might utilize 
mechanisms other than blocking attachment to inhibit 2H2 mediated ADE infection. 
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Since circulation of enhancing antibodies is very common in dengue infected patients, 
the results presented here are critical to optimize usage of neutralizing MAbs to minimize 
ADE risk in therapy.  
Apart from these neutralizing or enhancing MAbs, the non-neutralizing non-
enhancing MAbs make up a significant fraction of cloned human MAbs yet they received 
little attention at all (Smith, Zhou et al. 2012). Usually, these MAbs are considered “idle”. 
However, our results indicated these “idle antibodies” are not really “idle” as we found 
the unexpected ADE modulation function of MAbs 12C1 and 13A5. The mechanisms of 
their inhibitory or synergistic effect in ADE is still unknown. Work should be done to 
investigate these mechanisms, as our recent human MAb cohort study also reveals quite 
abundant existence of this kind of “idle antibody” in human sera (Smith, Zhou et al. 2012) 
and their role in dengue pathogenesis may deserve more attention.  
By studying the neutralization and ADE of MAbs cocktail, we were able to reveal 
some medically important discoveries of dengue neutralization and ADE: neutralizations 
mediated by various antibodies are mostly independent from each other and ADE 
mediated by various sub-neutralizing antibodies are additive to each other. Both 
discoveries have important applications for medicine industry and academic field. 
Another important discovery is the ADE modulation by non-neutralizing non-enhancing 
antibodies.  
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Tables 
Table 4.1: Panel of mouse MAbs used in this project.  
Name Subclass Specificity Source Epitope 
4G2 IgG2a Flavivus-group ATCC EDII  
12C1 IgG1 Dengue group 
Dr. Accavitti-loper 
EDIII 
13A5 IgG1 Dengue group EDIII 
14A4 IgG1 
Dengue sub-complex (DV1and 
DV3) 
Dr. Putnak EDIII 
2H2 IgG2a Dengue group Dr. Putnak prM 
8A1 IgG1 DV3 type-specific Dr. Putnak EDIII 
9D1 IgG1 DV3 type-specific Dr. Accavitti-loper unknown 
9F16 IgG1 
DV2 type-specific U.S. Biological 
EDIII 
2Q1899 IgG1 EDIII  
5C36 IgG1 EDIII 
1A1D-2 IgG1 Dengue group Dr. Putnak EDIII 
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Figure and Legends  
Figure 4.1 
A) 
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B) 
 
Figure 4.1: Combined Neutralization of DENV by Two MAbs.  A) Combined 
neutralization of DENV2 virus by two MAbs. B) Combined neutralization of DENV3 virus 
by two MAbs. For each experiment, one MAb was serially diluted to different 
concentrations and mixed with another MAb at the Neut50 concentration. Dashed lines 
are predicted results. All the neutralization assays in the same figure were done side by 
side in one experiment. All the experiments were repeated 3 times and a representative 
result is presented here.  
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Figure 4.2  
 
 
Figure 4.2: Combined ADE of two MAbs at Non-neutralizing concentrations. A) E 
MAb 4G2 and prM MAb 2H2, each at non-neutralizing concentration of 0.0125µg/mL, 
were tested for ADE in U937 cells alone or mixed together. B) IgG2a subclass MAb 4G2 
and IgG1 subclass MAb 2Q1899, each at non-neutralizing concentration of 0.0125µg/mL, 
were tested for ADE in U937 cells alone or mixed together.  
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Figure 4.3  
 
Figure 4.3: Inhibition of ADE by Neutralizing MAbs. A) MAb 1A1D-2 (1.6 µg/mL, 95% 
neutralization potency in U937-DC-SIGN cells) was added to enhancing MAb 2H2 (0.2 
µg/mL) and totally inhibited the 11 fold enhancement mediated by 2H2. B) 9F16 (12.5 
µg/mL, 95% neutralization potency in U937-DC-SIGN cells) totally inhibited 2H2 
mediated ADE.  C) Adding 6.4µg/mL of 4G2 to 2H2 can inhibit the 2H2 mediated ADE at 
all concentrations.  
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Figure 4.4
  
Figure 4.4: Cross-reactive and non-neutralizing MAb 12C1 and 13A5 can modulate 
the ADE mediated by MAb 4G2. A) Both MAb 12C1 and 13A5 both are cross-reactive 
MAbs against four serotypes. B) 0.5 µg/mL of 12C1 or 13A5 was added to 1A1D-2 MAb 
and there was no increase of neutralization of DENV2 at any concentration of 1A1D-2. C) 
Increased concentrations of 12C1 were added to 4G2 (0.4µg/mL) and the DENV2 
infection enhancement mediated by 4G2 increased gradually. D) Increasing 
concentrations of 13A5 were added to 4G2 (0.4µg/mL) and the DENV2 infection 
enhancement mediated by 4G2 decreased gradually. 
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CHAPTER 5 
THE MECHANISM OF DIFFERENTIAL NEUTRALIZATION OF DENGUE 
SEROTYPE 3 STRAINS BY MONOCLONAL ANTIBODY 8A1 
 
5.1 Introduction  
Dengue virus (DENV) is a mosquito borne virus that is endemic in most of the 
tropical areas in the world, putting 2.5 billion people in risk (WHO 2009). Four serotypes 
of DENV co-circulate and infection with one serotype does not provide life-long immunity 
against other serotypes (Halstead 1988). Many DENV infections are asymptomatic, 
while symptomatic disease can manifest as classical Dengue Fever (DF), or can develop 
into more severe form of disease called Dengue Hemorrhagic Fever (DHF) or Dengue 
Shock Syndrome (DSS) (Shepard, Suaya et al. 2004). It is estimated that DHF/DSS 
leads to 10,000 – 15,000 deaths annually (WHO 2009). Epidemiologic data suggests 
that pre-existing antibodies, either from previous heterotypic DENV infection or, in the 
case of newborns and infants, maternally acquired anti-DENV antibodies, are associated 
with development of the more severe disease (Halstead and O'Rourke 1977). This 
phenomenon, known as Antibody-Dependent Enhancement (ADE), has been 
demonstrated in vitro using sub-neutralizing concentration of antibodies to facilitate 
infection of otherwise non-permissive cells such as monocytes via Fc-γ receptor 
mediated endocytosis (Halstead and O'Rourke 1977). This particular feature of DENV 
potentially confounds vaccine implementation and design strategies.   
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DENV is a single-stranded, positive-sense RNA virus in the family Flaviviridae, 
genus flavivirus.  It is closely related to several other important human pathogens such 
as Japanese encephalitis (JEV), West Nile (WNV), Yellow fever (YFV) and Tick-borne 
encephalitis (TBEV).  The DENV genome is translated into a single polyprotein and then 
cleaved into structural proteins (C-prM-E) and non-structural proteins (NS1-NS2A-NS2B-
NS3-NS4A-NS4B-NS5). The Envelope protein (E) is the major surface exposed antigen 
and the principal target of host antibody response. The envelope proteins of different 
DENV serotypes have been crystallized and their structures characterized (Rey, Heinz et 
al. 1995; Modis, Ogata et al. 2003; Zhang, Zhang et al. 2004; Modis, Ogata et al. 2005; 
Cockburn, Navarro Sanchez et al. 2012).   On the mature DENV virion, E forms a 
homodimer and is arranged on the virion surface in a herringbone pattern with dimers 
arranged in sets of three rafts.  The ectodomain of E protein has three domains:  domain 
I, II and III (EDI-EDIII). Importantly, EDIII is believed to be involved in cell receptor 
binding (Crill and Roehrig 2001).  EDIII belongs to the IgG superfamily and is composed 
of several beta-strands linked by loops (Figure 5.1A, 5.1B). A subset of these loops form 
a surface exposed structure called the lateral ridge, which is the target of many 
monoclonal antibodies that strongly neutralize DENV (Modis, Ogata et al. 2005; Pierson 
and Diamond 2008). 
EDIII is a potent immunogen that elicits type-specific antibodies in various animal 
models (Schmitz, Roehrig et al. 2011). Consequently, recombinant EDIII based vaccines 
have been under development with the hypothesis that EDIII type-specific antibodies will 
be protective but less likely to enhance dengue virus infection. Many type-specific 
monoclonal antibodies against EDIII target the most diversified/non-conserved region – 
the lateral ridge and hence mutations within this region may have important 
immunological consequences. 
96 
There are four distinct DENV-3 genotypes: I, II, III and IV (Lanciotti, Lewis et al. 
1994). Currently genotype I and II are circulating in Asia , genotype III is circulating in the 
Indian subcontinent, Africa and Latin America, while genotype IV appears to have been 
displaced but occurred throughout the Caribbean in the 1960s and 70s (Messer, Gubler 
et al. 2003; Araújo, Nogueira et al. 2009). Wahala et al. revealed difference of sensitivity 
between DENV-3 genotypes to certain type-specific neutralizing MAbs (Wahala, 
Donaldson et al. 2010). Other researchers have also shown that genotypes play a role in 
antibody neutralization and protection (Brien, Austin et al. 2010; Shrestha, Brien et al. 
2010; Sukupolvi-Petty, Austin et al. 2010; Pitcher, Gromowski et al. 2012), including the 
finding that intra-genotypic variations can elicit different immune response that fail to 
effectively neutralize virus of the same serotype (Wong, Abd-Jamil et al. 2007). Since 
multiple genotypes co-circulate worldwide (Nogueira, Stella et al. 2008; Jiang, Yu et al. 
2012), it becomes imperative to understand how viral genotypic variation affects 
neutralization and define its mechanism. The constant evolution of dengue viruses 
further justifies studying how mutations influence interactions with antibodies (de Mora, 
Andrea et al. 2009; Kukreti, Mirtal et al. 2010; Ramirez, Fajardo et al. 2010).  
To better understand the role of genotypic variation in DENV-3 neutralization, we 
tested the mouse monoclonal antibody 8A1 against a panel of recombinant DENV-3 
viruses that expressed complete envelope genes from each of the four genotypes.  We 
then constructed additional mutant recombinant viruses containing single or multiple 
amino acid mutations to identify the residues critical to 8A1 neutralization of DENV-3. 
We found that the sensitivity of genotype I and II, compared to resistant genotype III, are 
attributed to only two amino acid differences in EDIII region. Further study revealed that 
the amino acids work independently to confer the sensitivity to 8A1. Variation at two 
amino acid positions led to different on and off rates of epitope/antibody binding and thus 
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different affinity. Our studies provided insights into neutralization mechanism and how 
binding kinetics affect virus sensitivity to different antibodies. 
 
5.2 Methods and materials  
Cells. Mosquito Aedes albopictus C6/36 cells were maintained in MEM (Gibco) media at 
28°C. Human monocyte lymphoma cell line U937 expressing DC-SIGN (U937 DC-SIGN) 
were maintained in RPMI-1640 (Gibco) at 37°C supplemented with 50mM beta 
mercaptoethanol. Vero-81 cells were maintained in DMEM at 37°C. All media used were 
also supplemented with 5% FBS, 100U/ml penicillin, 100mg/ml streptomycin, 0.1mM 
non-essential amino acids (Gibco) and 2mM glutamine and all cells were incubated in 
the presence of 5% CO2. The 5% FBS was reduced to 2% to make infection media for 
each cell line.  
DENV-3 Molecular Clone Strategy.  The four fragment cloning strategy for the DENV-3 
clone was recently described (Messer, Yount et al. 2012). In brief, plasmids containing 
the four DENV fragments DNAs (A-D) were propagated in E. coli, purified, restriction 
enzyme digested and directionally ligated to create a full-length cDNA of the dengue 
viral genome.  The cDNAs were subsequently transcribed with T7 polymerase (Ambion).  
This RNA produced infectious dengue virus when electroporated into Vero E6 cells.  E 
variant clones have been previously characterized (Messer, Yount et al. 2012). Briefly, E 
genes from representative DENV-3 isolates (D3/InJ-16-82, D3/D95-0400, D3/Cuba21/02, 
UNC3001, D3/1339, each from genotype I, II, III, III, IV) were synthesized and introduced 
into the parent clone A and B fragments using unique Type IIS restriction enzymes. The 
resulted constructs were each named as Indonesia '82 (I), Thailand '95 (II), Cuba '02 (III), 
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Sri Lanka '89 (III), Puerto Rico '77 (IV), to indicate the isolates’ location, year of isolation 
and genotype.  
To generate A fragments with EDIII variants, synthesized EDIII constructs were 
amplified with the DenBglI #1+ (5’-gaagccaagagggcgcaatgcataccgcactg-3’) and the 
Den2kb- (nnnnncgtctcgcctcaatattgacaggctcc) primers.  These amplicons were digested 
with BglI and ligated to another amplicon which had been made using Den 985+ (5’-
nnnnnnacccagaaggtggtcattttcatactac-3’) and DenBglI#2- (5’-
gcgccctcttggcttccaaggacgactacttcttg-3’) and had been similarly digested. The ligated 
products were gel isolated and cloned into the pCR-XL TOPO cloning vector.  
Consensus clones were digested with BstEII and BsmBI and ligated into the parent A 
plasmid which had also been digested with BstEII and BsmBI.  Variants at position 383 
were generated either using parent B plasmid (N383) or Thailand ’95 B plasmid (K383).  
The B plasmid sequences were otherwise identical.  
Recombinant Virus Recovery. The virus clones were recovered following a protocol 
that was recently described by Messer et al. (Messer, Yount et al. 2012). Briefly, each 
plasmid was transformed, propagated, cloned to E. coli and expanded in LB media. 
Plasmid purified (Qiagen Mini-Spin Kit) and digested as follows according to 
manufacturer’s instructions.  Fragments were gel-isolated (Qiagen Gel Extraction Kit) on 
0.8% agarose gel, mixed in equivalent copy number and ligated with T4 ligase (NEB) 
overnight at 4°C. Full-length transcripts of DENV-3 cDNA constructs were generated in 
vitro and mixed with Vero cells trypsinized and resuspended in RNAse free PBS in an 
electroporation cuvette. After electroporation, the Vero cells were then incubated at 37°C 
for 4 days. Supernatant from transfected Vero cells were further passaged to Vero cells 
and these supernatants were harvested at day 7 as working virus stocks.   
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Virus Titration and Focus Reduction Neutralization Test (FRNT). The FRNT 
procedure is based on a method previously described (Durbin, Karron et al. 2001). 
Briefly, twenty-four well plates were seeded with Vero cells and grown to 80% 
confluence in incubator (37˚C, 5% CO2 unless otherwise specified). For virus titration, 
virus stocks were serially diluted, added to wells and after 1 hr incubation at 37˚C 
overlaid with 0.8% methylcellulose in Opti-MEM (Gibco) supplemented with 2% FBS, 
antibiotic mix (Gibco) and non-essential amino acids (Gibco).  Following incubation for 5 
days, the overlay was removed, the wells washed twice with PBS and cells fixed in 80% 
methanol/PBS.  Fixed monolayers were either stored at -80˚C or developed for foci 
visualization immediately.  Briefly, wells were blocked for 10 minutes with 5% non-fat 
milk in 1x PBS, followed by 1 hr incubation with anti-flavivirus MAb 4G2 diluted in 
blocking buffer at 37˚C, then washed, incubated with horseradish peroxidase (HRP) 
conjugated goat anti-mouse Ab (Sigma) dilutions, washed again and foci developed by 
the addition of TrueBlue HRP substrate (KPL).   Foci were counted on a light box and 
viral titers calculated by standard methods.  For FRNT, MAbs were serially diluted, 
mixed with approximately 600 focus forming units (ffu)/ml of virus to a final volume of 
400 ul, The virus-MAb mixes were incubated for 1 hr and added in triplicate (100 ul 
volumes) to 24-well plates and incubated and developed as described above.   
Monoclonal Abs. Purified MAbs 8A1 (IgG1), 7.5 mg/ml and 14A4 (IgG1), 9.6 mg/ml 
were kindly provided by Robert Putnak (Walter Reed Army Institute of Research, MD) 
(Matsui, Gromowski et al. 2010; Wahala, Donaldson et al. 2010). Hybridoma cells 
producing MAb 1H9 (IgM) were kindly provided by John Aaskov (Queensland University 
of Technology, Australia) (Serafin and Aaskov 2001).   
Software and statistics.  FRNT counts were entered into GraphPad Prism (Version 
5.00 for OSX, GraphPad Software, San Diego California USA, www.graphpad.com).  
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FRNT50 values were calculated by sigmoid dose-response curve fitting with upper and 
lower limits of 100 and 0 respectively.  All error bars show 95% confidence intervals 
unless otherwise specified.  Mean log values were compared by one-way ANOVA 
followed by Tukey HSD multiple comparison test with significance level alpha (P) set at 
<0.05. EDIII structure figure was made using The PyMOL Molecular Graphics System, 
Version 1.5.0.4 Schrödinger, LLC.(http://www.pymol.org). Alignment of the DENV-3 
genotype DIII sequences was prepared using ALINE (Bond and Schuttelkopf 2009). 
ELISA. High binding 96-well ELISA plates were coated with 300 ng human monoclonal 
antibody 3H4 (which binds E protein, but not EDIII) per well in 0.1 M carbonate buffer. 
Plates were incubated at 4˚C overnight, washed three times (All washes were performed 
three times with Tris-buffered saline containing 0.2% Tween-20), then blocked with 
dilution buffer on a shaker at 37˚C for 1hr.  Antigen was captured by adding virus in Tris-
buffered saline containing 0.05% Tween-20 and 3% Normal Goat Serum to wells and 
incubating on a shaker at 37˚C for 1 hr. Unbound antigen was washed off, primary 
mouse monoclonal antibody (either 8A1 or 1H9) was serially diluted and added to wells, 
and plates were incubated on a shaker at 37˚C for 1 hr. Unbound primary antibody was 
washed off and 1:1000 alkaline phosphatase conjugated diluted human sera-adsorbed, 
goat anti-mouse secondary antibody added; and plate was incubated on a shaker at 
37˚C for 1 hr. Unbound secondary antibody was washed off, pNPP substrate added, and 
absorbance readings were taken at 405 nm in Epoch Microplate Spectrophotometer 
(Biotek Instruments Inc. Winooski, VT).   
Mutagenesis and production of rEDIII. Recombinant EDIII constructs were created as 
described by Wahala et al. (Wahala, Donaldson et al. 2010). E gene fragments encoding 
EDIII each genotype of viruses were engineered into pMAL c2X vector to generate 
recombinant EDIII-MBP fusion protein construct. Individual or combinations of mutations 
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at E301 and E383 were further introduced to the rEDIII-MBP construct using 
QuikChange multi kit (Stratagene, LaJolla, CA) according to manufacturer's instructions 
and were confirmed by sequencing. The recombinant EDIII-MBP constructs, including 
the mutants, were expressed in E. coli DH5a (Invitrogen) and purified using amylose 
resin affinity chromatography (NEB) as instructed by manufacturer.  
Surface Plasmon Resonance (SPR). Kinetic information on the interaction between 
anti-dengue antibodies and DIII variants was obtained using a Biacore T100 instrument. 
Anti-mouse capture antibodies (GE Life Sciences) were immobilized at high density 
using amine coupling to a Series S CM5 chip. The anti-dengue antibodies or control 
(WNV E16) antibody were flowed over the surface of the chip and captured at 700 RUs 
(Response Units) or less. A two-fold dilution series of the DENV-DIII MBP fusion protein 
variants were injected over the chip at a flow rate of 65 ul/minute for 180 seconds and 
allowed to dissociate for 450 seconds. The flow cell was regenerated with 10 mM glycine 
pH 1.7 for 180 seconds, followed by a second pulse for 30 seconds, at 30ul/min.  Data 
was processed using the Biacore Evaluation Software (Version 1.1.1) by double 
referencing (control antibody and buffer alone subtraction) and a global 1:1 Langmuir fit 
of the curves.  Results were generated from at least three independent experiments. 
 
5.3 Results  
Mouse Monoclonal antibody (MAb) neutralization against four DENV-3 isogenic 
clones containing E protein from different genotypes  
It was commonly believed that only inter-serotype variation matters in virus-
antibody interactions. However, several recent studies challenged this assumption by 
showing that intra-serotype variation plays a role in this interaction too (Wong, Abd-Jamil 
et al. 2007; Brien, Austin et al. 2010; Wahala, Donaldson et al. 2010). To study this 
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problem we used a DENV-3 reverse genetic platform to capture naturally occurring 
variation in DENV-3 envelope glycoprotein. Because each variant E gene is expressed 
from an isogenic genome backbone, the recombinant viruses allow us to probe the 
impact of micro-variation on the antigenic properties of variant E glycoproteins.  Focus 
Reduction Neutralization Test (FRNT) for the parent and isogenic clones with variant E 
genes were performed against a panel of mouse monoclonal antibodies (14A4, 1H9 and 
8A1) and FRNT50 values were calculated for each of the MAbs against each of the 
clones. Mouse MAb 14A4 is a DENV-3 specific IgG1 MAb that has been mapped to the 
A-strand of DENV-3 E domain III (Matsui, Gromowski et al. 2010; Wahala, Donaldson et 
al. 2010). 14A4 is known to neutralize all four genotypes within DENV-3 and would be 
expected to neutralize all of the isogenic clones (Wahala, Donaldson et al. 2010).  As 
expected, 14A4 neutralized the entire recombinant DENV-3 panel at equivalent 
concentrations (Figure 5.2A).  Calculated FRNT50 values were not significantly different 
and ranged from 12 ug/ml for genotype I to 34 ug/ml for genotype III (Cuba ’02) (Figure 
5.2A).  
Mouse MAb 1H9 is an IgM antibody that is specific to DENV-3 and has been 
previously mapped to the lateral ridge of domain III of the E glycoprotein (Wahala, 
Donaldson et al. 2010). Serafin et al. demonstrated that mutation from lysine to 
asparagine in position E386 enabled DENV-3 prototype strain H87 to escape 
neutralization from 1H9 (Serafin and Aaskov 2001). Subsequently, Wahala et al. 
demonstrated by both binding and FRNT that clinical isolate genotype IV PR ’77, via a 
naturally occurring K to R mutation at 386, also allows for escape from neutralization by 
1H9 (Wahala, Donaldson et al. 2010).  1H9 was tested against the parent and isogenic 
clones using FRNT.  As expected, the genotype IV was not neutralized by 1H9 (Figure 
5.2B), consistent with the wild type PR ’77 phenotype.  In contrast, genotype I and 
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genotype II were neutralized at very low antibody concentrations - 0.046 ug/ml and 
0.061 ug/ml respectively (Figure 5.2B). Genotype III clones Cuba ’02 and SL ’89 were 
also effectively neutralized by 1H9, but at antibody concentrations significantly greater - 
1 log - than genotype I and II clones (P <0.01) (Figure 5.2B).  1H9 had essentially three 
neutralization phenotypes - an escape phenotype (IV), an intermediately sensitive 
phenotype (III), and a highly sensitive phenotype (I and II). 
Mouse MAb 8A1 is a DENV-3 specific IgG1 MAb that binds EDIII, via lateral ridge 
residues 301, 302, 380 and 386, similar to that observed for MAb 1H9 (Wahala, 
Donaldson et al. 2010).  The DENV-3 clones recapitulate genotypic variation at those 
residues. Purified 8A1 was tested for ability to neutralize parent and isogenic clones 
(Figure 5.2C and Table 5.1).  Previous studies have demonstrated that MAb 8A1 binds 
EDIII from DENV-3 genotypes I, II and III but not genotype IV (Wahala, Donaldson et al. 
2010). As predicted from these binding studies, the genotype IV clone was extremely 
resistant to neutralization, with a calculated FRNT50 of 413 ug/ml, which was 2-3 logs 
greater than values recorded for the other isogenic recombinant viruses (P <0.01).  
FRNT50s for genotype III recombinant viruses Cuba ’02 and SL ’89 were 13.5 ug/ml and 
9.9 ug/ml, respectively, virtually identical and forty-fold less than genotype IV (Table 5.1). 
The remaining genotype I and II clones were again significantly more sensitive to 
neutralization by 8A1, with calculated FRNT50s of 0.2 ug/ml and 0.37 ug/ml respectively, 
800-fold more sensitive to neutralization than genotype IV (P <0.01).   For MAb 8A1, as 
with MAb 1H9, a distinct pattern of neutralization was observed; genotype IV requires a 
high concentration of antibody for neutralization, genotype III requires intermediate 
concentration of antibody and finally genotype I and II are neutralized by low 
concentrations of antibody (Figure 5.2C).  
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Amino Acid Variations in EDIII lateral ridge  
Wahala et al. previously demonstrated that 8A1 bound to DENV-3 genotypes I, II 
and III but not to IV.  Moreover, Wahala et al. mapped loss of 8A1 binding to genotype IV 
to a K386R (lysine to arginine) mutation on the lateral ridge of DENV-3 genotype IV 
(Wahala, Donaldson et al. 2010). We analyzed EDIII sequence differences between 
DENV-3 genotypes I, II and III to explore why genotypes I and II were more sensitive to 
neutralization than genotype III, despite the antibody binding to all three genotypes. The 
EDIII sequence differences between the different DENV-3 genotypes are summarized in 
Figure 5.1B.  The more sensitive genotype I and genotype II clones have two common 
non-conservative variations compared to the less-sensitive genotype III clones: T301L 
and N383K. These two sites are located in adjacent loops of the lateral ridge, with 
position 301 at the apex of the N-terminal linker and position 383 in the FG loop. 
Genotype I and genotype III (Cuba ’02) viruses also each have variations at 303 and 329 
in the lateral ridge (Figure 5.1A), but as these variations are not conserved within 
sensitive genotypes (I and II) or within genotype III they are not considered critical to the 
phenotype. We hypothesized that variations at one or both sites (301, 383) are 
responsible for the sensitivity difference of MAb 8A1 and our reverse genetics system 
provided us a chance to test this hypothesis and further study the mechanism of this 
differential neutralization at molecular level. 
To test our hypothesis residues T301 and N383 were mutated from the parental 
DENV-3 genotype III background both individually and in combination to amino acids - 
T301L and N383R respectively, recapitulating the residues in the sensitive genotype I 
and II strains. FRNTs for the parent and mutant variants against 8A1 were done and 
FRNT50 values calculated.  We found that both mutations were required to increase 
sensitivity to neutralization (Figure 5.3). Single mutations led to partial increases in 
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neutralization sensitivity but only the double mutant was as sensitive to neutralization as 
the DENV-3 genotype I and II sensitive strains.  This suggests that the two amino acids 
at 301 and 383 both confer sensitivity to MAb 8A1, with double mutations at these two 
positions conferring the greatest effect. 
The Mutations Altered Binding Affinity 
To further explore the mechanism of neutralization sensitivity by the individual 
and combined effect of 301 and 383 site mutations, we studied the binding affinity 
difference of mutant viruses to MAb 8A1. ELISA plates were coated with equal quantities 
of purified antigen from DENV-3 genotype II and III for binding studies with MAb 8A1. 
The binding curve indicated that genotype II has higher binding affinity to 8A1 than 
genotype III. The EC50 concentration for DENV-3 genotype III virus and genotype II 
virus are 0.098 ug/ml, and 0.050 ug/ml respectively. This EC50 difference is consistent 
with the observed FRNT50 differences. We further studied the binding affinity of 8A1 to 
genotype II, genotype III and mutant virus variant using capture ELISA. After 
optimization, equal amount of virus was captured and 8A1 concentration at 0.2 ug/ml 
was chosen for comparison for its sensitivity of detecting affinity variation. As shown in 
Figure 5.4, the sensitive genotype II strain had 50% increase of OD value compared to 
non-sensitive genotype III in the capture ELISA and introduction of single mutation 
T301L can increase the OD value to the same level of genotype II, suggesting the 
mutation at position 301 fully restores binding affinity. Introducing N383K alone 
increased the OD value only slightly, indicating that N383K mutation failed to increase 
binding affinity. This is consistent with previous observation that mutation at this site did 
not cause change of 8A1 binding of EDIII recombinant protein (Wahala, Donaldson et al. 
2010). In other words, our ELISA data demonstrated that site 301 determines the 
differential binding affinity between genotype II and genotype III. 
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8A1 affinity is determined by off-rate  
We next employed surface plasmon resonance (SPR) to better understand how 
specific residues affect binding affinity and kinetics of 8A1 to the EDIII protein from each 
genotype. Recombinant EDIII proteins from genotypes I, II and III were engineered as 
fusion proteins with maltose binding protein (MBP), produced and purified as described 
and validated by Wahala et al. (Wahala, Donaldson et al. 2010). The recombinant EDIII 
proteins differ at two critical sites: position 301 and 383 (Table 5.1). The two EDIIIs from 
potently neutralized genotypes (I and II) display distinct binding curves relative to those 
of the poorly neutralized genotype III EDIII (Figure 5.5A-C). EDIII from genotype I and 
genotype II had a half-life of 60.5 seconds and 59.0 seconds respectively (Table 5.1). 
These values contrast with those of the genotype III EDIII-MBP, which had a half-life of 
16.6 seconds (Table 5.1). The association rate clearly cannot explain the half-life 
difference or neutralization sensitivity variation. The dissociation rate data are consistent 
with the neutralization data and half-life data as slower dissociation results in the longer 
half-life of binding, and subsequently a higher 8A1 occupancy of the virus at any given 
moment, which ultimately leads to neutralization (Pierson, Xu et al. 2007). Generally, our 
data suggests that the discrepancies of 8A1 binding affinity for DENVs EDIIIs are 
primarily due to distinct dissociation rates. 
EDIII Residues at Site 301 Alone Determines Dissociation Rate and Half-Life 
Expanding our kinetic data characterizing 8A1 binding to EDIII, we sought to 
determine the role of specific residues involved in this interaction. Our neutralization 
experiments suggested that sites 301 and 383 both contribute to neutralization 
sensitivity. To study how each site contributes to the kinetics of 8A1 binding, especially 
dissociation rate, EDIII-MBP from the genotype III background was mutated to the 
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corresponding residues found in the genotype II virus (L301 or K383) and tested by SPR 
as above. Mutation of position 301 from a threonine to a leucine resulted in a half-life of 
68.2 seconds (Figure 5.5D and Table 5.1), comparable to that of the wild-type genotype 
II EDIII. In contrast, mutation of position 383 from an asparagine to a lysine resulted in a 
decrease of only association rate and a half-life comparable to parental genotype III 
EDIII (11.9 seconds; Figure 5.5E and Table 5.1). These results suggest that the 
dissociation rate is determined by position 301 alone as T301 leads to short half-life (12-
16 seconds) while L301 leads to long half-life (50-68 seconds). 
 
5.4 Discussion 
How natural strain variation within each DENV serotype influences virus-antibody 
interactions has important implications for rational vaccine design and virus evolution 
(Wong, Abd-Jamil et al. 2007; Brien, Austin et al. 2010; Wahala, Donaldson et al. 2010). 
We and others have recently reported genotype dependent variable neutralization within 
serotypes using both MAbs and human DENV-3 sera (Wahala, Donaldson et al. 2010; 
Messer, Yount et al. 2012). Despite the accumulated evidence, the detailed mechanism 
of genotype dependent variable neutralization remains unknown. To better understand 
this mechanism, we employed a DENV-3 reverse genetic clone system to capture the 
amino acid variation in E glycoprotein of all the four genotypes into the otherwise 
isogenic background of genotype III. The resulting isogenic viruses recapitulated the 
previously reported sensitivity differences of the DENV-3 genotypes to these MAbs 
(Wahala, Donaldson et al. 2010).  Using these isogenic viruses, we mapped the 
mutations critical to MAb 8A1 neutralization to two sites - 301 and 383 - on the lateral 
ridge region of EDIII. We found that both mutations are needed to alter neutralization by 
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MAb 8A1. Study of antibody-antigen affinity of whole virus suggested the distinct 
neutralization sensitivity is mainly attributed to binding affinity differences between 
different residues at these two positions. Using SPR and recombinant EDIII protein, we 
further found that binding differences are determined mainly by the dissociation rate and 
mutation at site 301 alone affects the dissociation rate.  
Our finding that only two residues are responsible for differential neutralization 
between DENV-3 genotypes I, II, III and IV sheds light on our understanding of how 
neutralization is modulated by viral genetic variations. Consistent with previous research, 
our ELISA data suggests that binding affinity differences cause neutralization sensitivity 
variation (Gromowski and Barrett 2007; Lisova, Hardy et al. 2007; Gromowski, Barrett et 
al. 2008; Gromowski, Roehrig et al. 2010). However, mutant T301L restores fully binding 
affinity but it restores only partially the neutralization sensitivity. This suggests that site 
383 also contributes to 8A1 neutralization sensitivity via a mechanism other than binding 
affinity. The evidence is that mutant N383K increased neutralization sensitivity about 4 
times, without increasing binding affinity (Figure 5.4) or half-life of binding (Table 5.1). It 
is even more interesting to find that after introducing mutation N383K into the mutant 
virus T301L to make it double mutant/genotype I or II, the neutralization sensitivity 
increased about 3-5 times from mutant T301L, comparable to the effect of introducing 
N383K into the parental genotype III (Table 5.1). We can find a similar pattern for 
mutation T301L as introducing this mutation to genotype III increased sensitivity for 
about 10 times and introducing this mutation into mutant N383K also increased 
sensitivity for about the same extent. This pattern strongly argues that both sites 
contribute to 8A1 neutralization sensitivity through different and independent 
mechanisms. We speculate that N383K could alter neutralization by affecting virus 
structural dynamics so that each 8A1 antibody binding may exert more constraints on 
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virus post-attachment steps such as conformational change for fusion, as MAb 8A1 
neutralizes virus by blocking post-attachment steps (unpublished data). It has been 
shown that flavivirus dynamic equilibrium (breathing) can regulate antibody neutralization 
(Lok, Kostyuchenko et al. 2008; Dowd, Jost et al. 2011; Cockburn, Navarro Sanchez et 
al. 2012). It is also possible that the 383 mutation affects binding when the virion is in 
alternate conformation which can’t be detected with current ELISA methods.       
SPR has been proven a powerful tool in studying and viewing antigen-antibody 
interactions from a kinetic and structure perspective (Bedouelle, Belkadi et al. 2006). The 
correlation between the virus binding affinity data (Figure 5.4) and the half-life data 
(Table 5.1) suggests that 8A1 binding affinity is determined by off-rate. We further found 
that both residues 301 and 383 can affect association rate as mutation at either residue 
changed the association rate (Table 5.1).  However, only residue 301, not residue 383, 
affects dissociation rate, and also half-life (Table 5.1). These data are consistent with 
previous mapping data of 8A1 showing that mutation of residue 383 did not affect 8A1 
binding (Wahala, Donaldson et al. 2010).   
The association rate of genotype II is aberrant and extremely low, consequently 
the resulted unexpectedly high KD value contradicts with both genotype II EC50 and 
8A1 neutralization titer (Table 5.1). This anomaly could be either due to a) instability of 
this particular construct or b) non-specific interaction between the DIII and MBP fusion 
partner that occludes recognition of the 8A1 epitope. Another factor we must take into 
consideration is that there is essential difference between the affinity measured using 
EDIII-MBP fusion protein against immobilized 8A1 antibody (SPR) and the avidity 
measured using immobilized whole virus and 8A1 antibody (EC50). The two values may 
not necessarily corroborate each other.  Thus, caution must be taken when using the 
protein-antibody SPR results to interpret virus binding and neutralization.  
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In sum, these data established a causal relationship between binding kinetics, 
binding affinity and neutralization. Site 301 determines dissociation rate to 8A1 between 
the genotypes, which dominates binding kinetics difference, and subsequently 
determines binding affinity variation, and contributes 2/3 of neutralization differences. 
The other 1/3 is attributed to mutation at site 383, through a neutralization mechanism 
different and independent from binding affinity variation. Structural investigation is 
underway to resolve this problem.  
Our work demonstrates how two naturally occurring mutations altered binding 
kinetics, leading to change of affinity and then neutralization sensitivity. Understanding 
how single or multiple mutations alter the viral neutralization profile is critical for further 
understanding of how different virus strains elicit immunity after infection, and how 
potentially protective antibodies differentially interact with virus infection in a secondary 
infection with a homologous serotype. More importantly, for a vaccine to elicit immunity 
that fully neutralize all DENV-3 genotypes with minimal risk of ADE, studies like this one 
will help to understand which epitopes among the inter-genotype variable sites should be 
targeted. This knowledge is especially helpful considering the high diversity in the lateral 
ridge in DENV-3 and other serotypes. Our results identifying how mutations in this region 
lead to neutralization alteration through changing association and dissociation rates will 
help identify the most critical neutralization epitope of dengue virus. Future studies of 
antibodies with intra-serotype or intra-genotype neutralization variation employing this 
approach should define additional important neutralization epitopes and the mechanism 
of differential neutralization. 
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Table 5.1 : Kinetics of DENV-3 DIII-MPB variants with 8A1.  
DIII 
Variant 
301 383 ka 
(105M-1s-1) 
kd 
(10-3s-1) 
KD 
(nM) 
t ½ 
(sec) 
FRNT50 (ug/ml) 
III T N 2.176 43.51 200.9 16.6 13.5* 
I L K 1.124 11.51 103.2 60.5 0.20 
II L K 0.268 12.62 470.9 59.0 0.37 
T301L L N 0.6892 10.15 155.3 68.2 1.08 
N383K T K 0.823 59.8 718.2 11.9 3.50 
IV S K NA NA NA NA 413.1 
 
* There are two genotype III virus clones: SL ’89 and Cuba ’02. FRNT50 of SL ’89 (III) 
was indicated in this table and FRNT50 of Cuba ’02 (III) is 9.9 ug/ml. 8A1 binding was not 
detected for genotype IV DIII-MBP at concentrations of 5000 nM. 
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Figures and Legends  
Figure 5.1 
A) 
 
 
B) 
 
Figure 5.1: A) Cartoon of DENV3 EDIII. Lateral ridge EDIII variable sites for the 
recombinant clones are color labeled: 301 and 383 (red); 302, 303, 329, 380 and 386 
(green). Secondary structure features are labeled. PDB ID: 3VTT. B) Alignment of EDIII 
amino acid sequences. Beta-strands are labeled as arrows and genotypic variation is 
highlighted according to Fig 1A.   
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Figure 5.2 
A) 
 
B) 
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C) 
 
Figure 5.2: Calculated FRNT50 values for mouse MAbs against the recombinant 
virus clones. Error bars show 95% confidence intervals.  A) Calculated FRNT50 values 
for 14A4 did not differ (P >0.05 ANOVA). B) Calculated FRNT50 values for 1H9 against 
Indonesia ’82 (I) and Thailand ’95 (II) were significantly lower than SL ’89 (III) and 
Cuba ’02 (III) (P<0.05 ANOVA followed by Tukey’s HSD).  NN = not neutralized. C) 
Calculated FRNT50 values for 8A1 against Indonesia ’82 (I) and Thailand ‘95(II) were 
significantly lower than SL ’89 (III) and Cuba ’02 (III) and Puerto Rico 1977 FRNT50  was 
significantly greater than against the other clones (P <0.05, ANOVA followed by Tukey’s 
HSD). 
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Figure 5.3 
 
 
 
Figure 5.3: Calculated FRNT50 values for MAb 8A1 against the parent SL’89 clone, 
Thailand ’95 clone and point mutant clones T301L, N383K and the combined mutant 
T301L+N383K clone.  Error bars show 95% confidence intervals.  Calculated FRNT50 for 
8A1 against Thailand ’95 (II), mutant clones T301L, N383K and combined mutant 
T301L+N383K clone were significantly lower than parent SL ’89 clone (III) (P<0.05 
ANOVA followed by Tukey’s HSD).  Calculated FRNT50 against Thailand ’95 clone (II) do 
not differ significantly from combined mutant T301L + N383K clone (P>0.05 ANOVA 
followed by Tukey’s HSD). 
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Figure 5.4 
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Figure 5.4: Results of ELISA using mouse MAb 8A1 (0.2 ug/ml) against captured whole 
parent virus SL ’89, recombinant clone Thailand ’95, and mutant clones T301L, N383K 
and T301L+N383K.  Error bars show 95% confidence intervals.  Whole virus was 
captured with human MAb 1M19, a cross-reactive EDIII binding antibody. The virus 
captured were quantified to be equal amount using 12C1 (cross-reactive EDIII binding 
mouse MAb) as control.  
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Figure 5.5 
 
Figure 5.5: Kinetic analysis of 8A1 interaction with DENV-3 EDIII-MBP genotypes 
and mutants. MAb 8A1 was captured and recombinant EDIII-MBP proteins of genotype 
I, II, III or mutants were flowed over at two fold serial diluted concentrations to measure 
the kinetic parameters of the interaction. SPR sensorgrams and traces are presented as 
MAb 8A1 interacting with A) genotype III, B) genotype II, C) genotype I, D) mutant T301L, 
E) mutant N383K.   
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CHAPTER 6 
DENGUE VIRUS MATURATION MODULATES SENSITIVITY TO 
ANTIBODY MEDIATED NEUTRALIZATION  
 
6.1 Introduction 
Dengue is a mosquito borne re-emerging virus that affects 2.5 billion people 
worldwide (WHO 2009). There are four DENV serotypes (DENV1-4) co-circulating in 
tropical and subtropical areas (Guzman, Kouri et al. 2000). Most symptomatic dengue 
infections result in mild dengue fever (DF) with flu like symptoms. Some people exposed 
to DENVs develop a severe disease known as Dengue Hemoharrgic Fever or Dengue 
Shock Syndrome (DHF/DSS).  The risk of severe disease is greater in people exposed 
to a second infection with a different serotype from the original infection (Sangkawibha, 
Rojanasuphot et al. 1984). Severe plasma leakage and circulatory collapse are the 
hallmarks of DHF/DSS and these symptoms may put patients at risk of death without 
timely and proper supportive treatment. The number of reported severe DENV cases has 
been increasing at an alarming rate in the past several decades while an effective 
vaccine is still not available (WHO 2009). The goal of the current study is to explore how 
maturation state of DENVs influences the ability of antibodies (Abs) to neutralize the 
virus. 
DENV belongs to family Flaviviridae genus flavivirus. The virus has a single 
positive genome of 11kb encoding 3 structural proteins  [capsid (C), pre-Membrane (prM) 
and envelope (E)],  and 7 non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, 
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NS5). The mature DENV particle is about 50 nm in diameter, and its envelope is formed 
by an icosahedral scaffold of E protein and membrane (M) protein. A crystal structure of 
a soluble form of the extracellular region of E glycoprotein reveals that it is composed of 
three domains (I, II, and III) each connected by flexible hinges (Modis, Ogata et al. 2005).  
DENV assembles on the endoplasmic reticulum (ER) and buds into ER lumen as 
immature virions. Sixty trimeric spikes composed of prM and E heterodimers form the 
rough surface of the immature virion. During secretion of the virion from the cell, a furin-
like protease in the Golgi apparatus cleaves prM protein to separate the pr peptide from 
M protein. The cleavage of prM leads to dissociation of the trimeric spike to form an E 
protein dimer that lies flat on the viral surface of a smooth mature virion (Li, Lok et al. 
2008; Yu, Zhang et al. 2008). Incomplete cleavage may result in partially mature DENV 
particles being released from infected cells. DENVs grown in standard laboratory cell 
lines mainly consist of partially mature particles containing considerable proportion of 
uncleaved prM protein (Dejnirattisai, Jumnainsong et al. 2010; Junjhon, Edwards et al. 
2010). Consequently, most studies of antibody-mediated neutralization of DENVs have 
been conducted using virus stocks containing heterogeneous mixtures of immature and 
partially mature particles. 
Human monocyte-derived cells are the main target of DENV infection in people. 
The goal of this study was to compare the maturation state and neutralization 
phenotypes of DENV particles produced by human monocytic cells or other non-human 
cell lines commonly used to propagate DENVs in laboratories. We report here that the 
maturation state of DENVs varies depending on the cells used to grow the virus. We also 
report that the ability of some Abs to neutralize DENV was strongly influenced by 
maturation state, whereas other Abs neutralized DENVs irrespective of maturation state. 
124 
 
6.2 Methods and Materials 
Cells. Vero cells (American Type Culture Collection, CCL-81) were maintained in 
Dulbecco's Modified Eagle Medium (DMEM). A cell line designated U937 DC-SIGN (9) 
was maintained in RPMI-1640 (Gibco) supplemented with 50 mM beta mercaptoethanol. 
This human monocyte lymphoma cell line was derived from U937 cells but also 
expresses Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-
integrin or DC-SIGN, also known as CD209 (Cluster of Differentiation 209). Mosquito 
Aedes albopictus C6/36 cells were maintained in Minimum Essential Medium (MEM; 
Gibco) at 28°C. All media used also were supplemented with 5% FBS, 100 U/mL 
penicillin, 100 mg/mL streptomycin, 0.1 mM non-essential amino acids (Gibco) and 2 
mM glutamine, and all cells were incubated in the presence of 5% CO2 at 37°C, unless 
otherwise specified. The 5% FBS was reduced to 2% to make infection medium for each 
cell line.  
Serum and MAbs. Murine MAbs 9F16 and 5C36 were purchased from US Biological 
and MAB 8A1 was kindly provided by Dr. Robert Putnak, Walter Reed Army Research 
Institute, MD. The human MAbs used in the current study (DVC3.7, DVC25.5, DVC10.16, 
2D22, 2A10 and 1M19 have been described previously (de Alwis, Beltramello et al. 2011; 
de Alwis, Smith et al. 2012). Polyclonal DENV immune sera were collected from people 
living in North Carolina who had acquired DENV previously during foreign travel. The 
protocol for collecting blood was approved by the Institutional Review Board at the 
University of North Carolina at Chapel Hill. 
C6/36 cell derived virus. C6/36 cells at 80% confluency were inoculated at MOI of 0.05 
for 2 hrs followed by two washings and addition of 25 mL of infection medium. After 6 
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days of incubation, the supernatants were harvested, clarified by 30 minutes 
ultracentrifugation at 18,000 x g, aliquoted into cryovials and stored at -80°C as working 
virus stocks. Virus used were DENV2 (S16803) and DENV3 (CH 53498) low passage.  
U937-DC-SIGN cell derived virus. Monolayer cultures of U937-DC-SIGN cells were 
inoculated using C6/36 insect cell line derived virus at MOI of 0.1 in infection medium for 
two hrs, followed by washing to remove all unbound C6/36 cell line derived virus and 
replenishing with 25 mL fresh infection medium. After 36 hrs of incubation, the medium 
was harvested, and clarified by 30 minutes of ultracentrifugation at 10,000 x g. The virus-
containing medium was concentrated further ~10-fold using 100 kDa Amicon Ultra 
Centrifugal Filters (Millipore, Billerica, MA) and frozen at -80°C as working virus stock.  
Immature virus. C6/36 insect cell culture monolayers at 80% confluence were 
inoculated using C6/36 insect cell line derived virus at MOI of 0.2 for 2 hrs, followed by 
washing to remove all C6/36 cell line derived virus and replenishing with 25 mL fresh 
infection medium. Twelve hrs post infection, NH4Cl was added to the medium at a final 
concentration of 20mM.  The infected cell were incubated for a further 12 hrs before the 
supernatant was harvested and the virus concentrated by ultra-centrifugation at 100,000 
x g for 3 hrs. 
Virus titration and Focus Reduction Neutralization Test (FRNT). The FRNT 
procedure is based on a method previously described by Messer et al. (Messer, Yount et 
al. 2012). Briefly, twenty-four well plates were seeded with Vero cells to grow till 80% 
confluence in incubator (37°C, 5% CO2). For virus titration, virus stocks were diluted 
serially to 100 µL, added to wells and incubated for 1 hr before adding overlay. Plates 
were incubated for 3 days, washed with PBS, then fixed in 80% methanol, blocked for 10 
minutes with 5% instant milk in PBS for 1 hr. Anti-flavivirus MAb 4G2 (for DENV2) or 
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MAb 8A1 (for DENV3) diluted in blocking buffer at 37°C, was added to each well and 
incubated at 37°C for 1 hr. After washing, the plates were incubated with horseradish 
peroxidase (HRP) conjugated goat anti-mouse Ab (Sigma) dilutions, washed again, and 
foci developed by the addition of TrueBlue HRP substrate (Kirkegaard & Perry 
Laboratories). Foci were counted on a light box by visual inspection and viral titers 
calculated by standard methods. For FRNT, MAbs were diluted serially, mixed with 
approximately 30 focus forming units (ffu) of virus to a final volume of 200 µL, incubated 
for 1 hr and added to 24 wells plates and processed as above. FRNT ffu counts were 
entered into Graphpad Prism (Version 5.00 for OSX, GraphPad Software, San Diego 
California USA, www.graphpad.com). FRNT50 values were calculated by sigmoid dose-
response curve fitting with upper and lower limits of 100 and 0 respectively. All error bars 
show 95% confidence intervals unless otherwise specified. Mean FRNT50 values were 
compared by one-way ANOVA followed by the Tukey HSD multiple comparison test, 
with significance level alpha (P) set at <0.05.  
Function Assay. For pre-attachment neutralization, viruses were incubated with 
antibodies at 4˚C for 1 hr before being added to Vero cells and incubated at 4˚C for 1 hr. 
After washing off unbound virus and antibodies with chilled media, the cell culture was 
moved to 37˚C incubator. For post-attachment neutralization, Vero cells were incubated 
with viruses for 1 hr at 4˚C for virus absorption, followed by two washings to wash off 
unbound viruses, then antibodies were added to cell culture and incubated at 4˚C for 1 
hr, followed by washing and moving to 37˚C incubator. All the operations are done on ice 
before moving to 37˚C incubator. The rest of the experiment was the same as described 
in the FRNT assay.  
Furin Inhibition Experiment. Furin inhibitor I, also known as peptidyl 
chloromethylketone (Decanoyl-RVKR-CMK) is purchased from Calbiochem (Millipore, 
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Billerica, MA). Furin inhibitor I was dissolved in DMSO at 1mM concentration. For each 
infection assay or FRNT assay, the furin inhibitor was added at concentration of 25 µM.  
Western blot. Samples were mixed with loading dye without DTT, heated at 95°C for 5 
minutes, then loaded into a 12% acrylamide gel, and run at 70V until markers fully 
separated. Proteins in the gel then were transferred onto a nitrocellulose membrane 
(Amersham) in a Semi-dry Blotting Unit (Fisher Scientific, FB-SOB-2020) at 0.30 A for 50 
minutes. The membrane then was blocked with 5% skim milk for 1 hr, and stained with 
prM MAbs or MAb 4G2 in an orbital shaker at room temperature for 2 hrs, followed by 3 
washings with 0.2% Tween-TBS buffer with 5 minutes intervals. Goat-anti-mouse (or -
human) HRP conjugated secondary antibody (Sigma) was diluted 1:1,000 and incubated 
with membrane for 1 hr before three washings. Finally, the membrane was developed 
with ECL Prime Western Blotting Detection Reagent (GE Healthcare). The film (Hyblot 
CL, Denville Scientific) were exposed to the membrane in a dark room and then 
developed using a Konica SRX-101 film processer (Konica Minolta, Tokyo, Japan).  
Capture ELISA. High binding 96-well ELISA plates were coated with 400 ng of human 
MAb 1M19 per well in 0.1 M carbonate buffer. Plates were incubated at 4°C overnight, 
washed three times (All washes were performed three times with Tris-buffered saline 
containing 0.2% Tween-20), then blocked with blocking buffer (3% goat serum in Tris-
buffered saline containing 0.05% Tween-20) on a shaker at 37°C for 1 hr. Antigen was 
captured by adding virus in blocking buffer to wells and incubating on a shaker at 37°C 
for 1 hr. Unbound antigen was washed off, primary mouse MAbs were diluted to desired 
concentrations and added to wells, and plates were incubated on a shaker at 37°C for 1 
hr. Unbound primary antibody was washed off and 1:1,000 diluted alkaline phosphatase 
conjugated human sera-adsorbed, goat anti-mouse secondary antibody (Sigma) added; 
plate was incubated on a shaker at 37°C for 1 hr. Unbound secondary antibody was 
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washed off, pNPP substrate added, and absorbance readings were taken at 405 nm in 
an Epoch Microplate Spectrophotometer (Biotek Instruments Inc. Winooski, VT). In 
cases of testing human primary MAb, murine MAb 5C36 or 8A1 (EDIII binding type-
specific) was used as the coating antibody and alkaline phosphatase-conjugated diluted 
mouse sera-adsorbed, goat anti-human secondary antibody (Sigma) was used as 
secondary antibody.  
MAb Epitope Mapping. A DENV-4 Env expression construct (341750 strain) was 
subjected to high-throughput alanine scanning mutagenesis to generate a 
comprehensive mutation library. Each residue within prM/E was mutated to alanine, 
while alanine codons were mutated to serine. In total, 660 DENV-4 mutants were 
generated (>97% coverage), sequence confirmed, and arrayed into 384-well plates. 
Each Env mutant was transfected into HEK-293T cells and allowed to express for 22 hrs. 
Cells were fixed in 4% (vol/vol) paraformaldehyde (Electron Microscopy Sciences) and 
permeabilized with 0.1% (wt/vol) saponin (Sigma-Aldrich) in PBS plus calcium and 
magnesium (PBS++). Cells were stained with purified 2A10 antibody (0.8 ug/ml) diluted 
in 10% normal goat serum (NGS) (Sigma)/0.1% saponin, pH9. Antibody binding was 
detected using 3.75 µg/ml AlexaFluor488-conjugated secondary antibody (Jackson 
ImmunoResearch Laboratories) in 10% NGS/0.1% saponin. Cells were washed 3 times 
with PBS++/0.1% saponin followed by 2 washes in PBS.  Mean cellular fluorescence 
was detected using the Intellicyt high throughput flow cytometer (HTFC, Intellicyt). 
Antibody reactivity against each mutant Env clone was calculated relative to wild-type 
Env protein reactivity by subtracting the signal from mock-transfected controls and 
normalizing to the signal from wild-type Env-transfected controls. Antibodies that bind 
the fusion loop (1C3, 1I16, 1K16, 1L6, 1N5, 1N8, 3B4, 3D18, 4E8, and 5E6, unpublished 
data) or domain II (1A15, 1D6, 1D8, and 5C8, unpublished data) were used for reactivity 
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comparisons.  Critical amino acids that affected antibody binding were visualized on the 
DENV2 Env crystal structure (PDB ID #1OAN) (Modis, Ogata et al. 2003). 
 
6.3 Results  
The human monocytic cell line U937-DC-SIGN produced mostly mature DENV 
In humans, DENVs infect cells derived from the myeloid lineage such as 
monocytes and dendritic cells. However, most cell culture studies of DENVs have been 
conducted using viruses grown in insect cells or non-human, mammalian cells of 
epithelial origin. We began by comparing the maturation of state of DENV2 produced by 
a human monocytic cell line expressing a DENV attachment factor (U937-DC-SIGN) and 
non-human cell lines (mosquito C6/36 cells and monkey kidney epithelial Vero cells) 
commonly used to propagate DENV in laboratories. As a control, we obtained virus from 
C6/36 cells maintained in the presence of NH4Cl, which raises intracellular pH and 
blocks furin processing of prM protein to the cleaved state. The maturation state of the 
viruses was determined using an antigen capture ELISA to measure the ratio of prM to E 
protein in the virus preparation. As shown in Figure 6.1A, the NH4Cl-treated immature 
virus control had a prM/E ratio close to 1. Vero cell-derived viruses were similar to 
immature viruses in prM level. In comparison, C6/36 insect cell derived viruses had a 
prM/E ratio of 0.4, indicating that about half of the prM on these particles remained 
uncleaved. Viruses produced in U937-DC-SIGN cells were mostly mature, as indicated 
by a prM/E ratio of 0.15. This finding of variation in maturation state that depended on 
the type of infected cell was confirmed by studies using western blot (Figure 6.1B). 
Similar to the findings with DENV2, human monocytic cell line derived DENV3 particles 
also exhibited a predominantly mature phenotype (Figure6. 1C).  
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Maturation state of DENV modulates neutralization sensitivity to some MAbs  
Eight human and mouse MAbs of differing DENV serotype-specificity and 
neutralization potency were chosen to test whether variation in virion particle maturation 
influenced the ability of Abs to neutralize these viruses (Table 1). U937-DC-SIGN cell 
line derived mature viruses and C6/36 insect cell line derived partially mature viruses 
were chosen for comparison as they represent the main cell types that are relevant to 
the DENV transmission cycle involving human and mosquito hosts. The sensitivity of 
these different suspensions of virus to antibody-mediated neutralization was measured 
using FRNT (Durbin, Karron et al. 2001) (Figure 6.2 and Table 6.1). Cross-reactive 
MAbs with weak to moderate neutralizing potency (MAbs 4G2, 2A10 and DVC10.16) 
demonstrated decreased neutralization potency against mature virus, obtained from the 
U937-DC-SIGN cell line (Figure 6.2A and Table 6.1) compared to the partially mature 
virus, obtained from the C6/36 insect cell line. Five type-specific MAbs with moderate to 
strong neutralizing potency neutralized mature or partially mature viruses equally well 
(MAbs 9F16, 5C36 and 2D22) or neutralized mature viruses better than partially 
immature viruses (MAbs DVC3.7 and DVC25.5) (Figures 6.2B, 2C and Table 6.1). In 
summary, these results demonstrated that the maturation state of DENV virion particles 
modulates the sensitivity to neutralization mediated by MAbs.  
Epitopes recognized by maturation state sensitive MAbs   
As depicted in Table 6.1, with the exception of 2A10, all the MAbs used in the 
current study have been previously mapped to specific residues or epitopes on E protein. 
Previous studies had mapped the 2A10 epitope to E protein domains I or II (Smith, Zhou 
et al. 2012). We used alanine scanning mutagenesis to further map the binding site of 
2A10. Alanine mutations at residues C74 and C105 and an alanine to serine mutation at 
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position 245 greatly decreased binding of 2A10 to E protein (Figure 6.3). These results 
suggest that 2A10 binds an epitope at or next to the fusion loop on EDII (Figure 6.3B).  
Next, we compared the maturation-dependent neutralization pattern and epitope location 
of each MAb to test if neutralization patterns were linked to Ab binding to specific regions 
or epitopes on E protein.  MAbs that neutralized partially mature virions better than 
mature virions were serotype-cross reactive and bound to epitopes at the fusion loop 
(4G2 and 2A10) of EDII or A strand of EDIII (DVC10.16).  MAbs that neutralized partially 
and fully mature virions equally well or neutralized mature virions better than partially 
mature virions were serotype-specific and bound to the lateral ridge of EDIII (DVC3.7, 
DVC25.5, 5C36 and 9F16) or the hinge region between EDI and II (2D22) (Table 6.1).    
Binding of MAbs to mature or immature virions 
We next compared the ability of MAbs to bind to mature or immature virions to 
test if the ability to bind to viruses of different maturation state correlated with the 
observed variation in potency of neutralization.  An antigen capture ELISA was used to 
compare the ability of each MAb to bind to mature virions, derived from U937-DC-SIGN 
cells, or immature virions, obtained from NH4Cl-treated C6/36 insect cell line 
supernatants. The MAb’s binding preference is indicated as a mature to immature (M/I) 
ratio, which was calculated using the optical density (OD) in the ELISA for MAb binding 
to the mature virus suspension divided by the OD for MAb binding to the immature virus 
suspension. As shown in Figure 6.4, the prM-specific MAb 2H2 (negative control) 
exhibited an M/I ratio close to zero, consistent with the fact that prM MAbs do not bind to 
mature virus. Most interestingly, the three cross-reactive MAbs 4G2, 2A10, DVC10.16, 
which neutralized partially immature virions better than mature virions, had low M/I ratio 
(0.2 - 0.4) compared to the other five MAbs, which did not show preferential 
neutralization of partially immature virions. This finding suggests that the more potent 
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neutralization of partially mature virus by the three cross-reactive MAbs was due to 
better binding to immature compared to mmature virions. The two MAbs DVC3.7 and 
DVC25.5 that neutralized mature virus more potently than partially immature virions did 
not show an M/I ratio higher than that of the MAbs 9F16, 5C36 and 2D22 that 
neutralized both viruses equally well (Figure 6.4). This observation suggests that the 
enhanced neutralization of mature virus by DVC3.7 and DVC25.5 is due to mechanisms 
other than preferential binding to mature virions.  
Human immune sera from dengue patients displayed maturation dependent 
differences in neutralization potency 
We tested a panel of 10 well-characterized DENV immune human sera (Table 
6.2) for ability to neutralize DENV3 in the mature form (derived from human U937+DC-
SIGN cells) or partially mature form (derived from mosquito C6/36 cells). Similar to the 
findings with MAbs above, these polyclonal sera also exhibited different patterns of 
particle maturation-dependent neutralization (Figure 6.5). Six sera (designated 105, 129, 
133, 115, 116 and 121) neutralized partially mature virions better than mature virions 
(Figure 6.5A, Table 6.2). The remaining 4 sera neutralized both mature and partially 
mature viruses equally well (103 and 132) or neutralized mature virions better than 
partially mature virions (110 and 130) (Figures 6.5B and 6.5C, Table 6.2). Thus the three 
dominant patterns of neutralization observed with MAbs also were observed with 
polyclonal DENV immune sera.  
Endosome furin cleavage is involved in modulating antibody mediated 
neutralization  
It has already been shown that endosome furin cleavage is involved in conferring 
infectivity to immature DENV (Zybert, van der Ende-Metselaar et al. 2008; Rodenhuis-
Zybert, Moesker et al. 2011). So we speculated that furin may play a role in partially 
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mature DENV infection of Vero cells too. To test this hypothesis, furin inhibitor peptidyl 
chloromethylketone was employed to inhibit furin cleavage in endosome before or after 
virus infection. As shown in Figure 6.6, furin inhibitor added after virus infection failed to 
block the infectivity of any viruses. But with furin inhibitor added before virus infection, 
there is a 90% reduction of partially mature virus infectivity while the mature virus 
infectivity is only slightly inhibited (Figure 6.6A). This contrast indicated that partially 
mature virus is very sensitive to furin inhibition during the infection process while the 
mature virus is not. The same pattern was observed for the mature and partially mature 
virus of DENV3 and DENV1 (Figure 6.6B and 6.6C). The indispensable role of furin in 
partially mature virus infection of Vero cells suggested that partially mature virus will 
undergo further furin cleavage in endosome before infection can occur.  
Previous function study of DENV MAbs suggested that many strongly 
neutralizing MAbs neutralize DENV at post-entry steps in endosome (Nybakken, 
Oliphant et al. 2005; Lok, Kostyuchenko et al. 2008; Rajamanonmani, Nkenfou et al. 
2009; Deng, Dai et al. 2011; Teoh, Kukkaro et al. 2012; Costin, Zaitseva et al. 2013). 
The furin cleavage induces conformational rearrangement of immature patches of virion 
and this may lead to dissociation of MAbs and subsequently reduce their neutralization 
potency if these two MAbs neutralize virus in endosome (post-attachment neutralization). 
We speculate that this may be the mechanism of the reduced neutralization of partially 
mature DENV by MAb DVC3.7 and DVC25.5. To test this hypothesis, we employed 
function assay and demonstrated that DVC3.7 and DVC25.5 neutralize virus mostly at 
post-attachment steps, supporting out hypothesis that the furin cleavage in endosome 
may intervene with their neutralization (Figure 6.7). Finally, to demonstrate that furin 
cleavage is responsible for MAb’s enhanced neutralization of mature virus, I compared 
DVC3.7 neutralization in the presence or absence of furin inhibitor. The results 
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suggested that without furin cleavage, DVC3.7 neutralizes mature virus and partially 
mature virus equally well (Figure 6.8A). Using furin inhibitor in 4G2 neutralization 
experiments further demonstrated that this furin cleavage inhibition does not affect 
neutralization potency of cross-reactive MAbs like 4G2 and this is consistent with my 
argument that 4G2 differential neutralization is attributed to preferential binding (Figure 
6.8B). 
 
6.4 Discussion  
We characterized the maturation state of DENVs produced in non-human cell 
lines commonly used to grow the viruses in laboratories and a human monocytic cell-line 
expressing a DENV attachment receptor. We found that the human monocyte cell-
derived viruses were more mature than viruses derived from non-human cells. We also 
demonstrated that the ability of human or mouse Abs to neutralize DENV was influenced 
significantly by the maturation state of virions. The ability of Abs to bind to virions of 
different maturation state correlated with neutralization efficiency. We further found that 
furin cleavage of partially mature virus is critical for virus infectivity and this may 
contribute to increased neutralization resistance of the partially mature virus.  
The long-accepted view of the assembly of DENV and other flaviviruses is that 
immature, non-infectious virions produced in the ER are proteolytically processed in the 
Golgi apparatus and secreted from cells as mature, infectious particles. Recent studies 
have demonstrated, however, that many individual virions produced in cell culture 
contain envelopes that possess a mixture of E protein in the immature (trimeric) and 
mature (dimeric) forms (Cherrier, Kaufmann et al. 2009; Junjhon, Edwards et al. 2010). 
Recent studies also have demonstrated that these partially mature virions and even 
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almost completely immature virions can be infectious in cell culture under some 
conditions (Zybert, van der Ende-Metselaar et al. 2008; Rodenhuis-Zybert, van der 
Schaar et al. 2010). These observations have led investigators to speculate that 
immature virions play a previously unrecognized role in DENV pathogenesis, including 
the possibility of Abs directed against uncleaved prM protein playing a role in Ab-
enhanced infection and disease. However, the true biological relevance of immature or 
partially mature virions is unknown because we do not know the maturation state of 
virions that are produced within infected people.   
The observations reported here that a human monocytic cell line produced 
virions that are mostly mature suggests that the monocytic cells in infected people that 
are a principal target of infection also may produce predominantly mature virions. This 
conclusion is also supported by recent findings by Dejnirattisai et al. that virions 
produced by primary human dendritic cells are mainly mature compared to viruses 
grown in non-human cultured cell lines (Dejnirattisai, Jumnainsong et al. 2010). Thus, 
while mature particles are undoubtedly of significance in vivo, further studies are needed 
to assess the significance of immature particles in pathogenesis of naturally-acquired 
infection. As some of the in vivo cellular targets of DENV remain unknown, it is 
conceivable that some human cells produce partially mature particles. Moreover, the 
proportion of mature to immature virions in vivo may depend on factors such as the 
strain of infecting virus, primary versus secondary infection and inherent variation 
between different people. A major area for future work is to determine if the high level of 
production of partially and fully immature dengue virions in some cell culture lines is 
merely an in vitro artifact or if these less mature forms of virion particles play a significant 
role during natural human infection.   
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We currently do not understand why DENVs produced in different cell lines 
display differences in maturation state. Cell line dependent variation in furin or furin-like 
protease levels is one possible explanation. Alternatively, the quantity of virus produced 
might differ between cell lines, and cells that produce a non-physiologic burst size of 
virus might overwhelm the ability of the levels of furin-like proteases in infected cells to 
process DENVs. We favor the latter explanation because we have observed an inverse 
correlation between the total quantity of viral antigen secreted by cells and the efficiency 
of prM processing (data not shown). 
Our studies with a panel of 8 MAbs revealed that serotype cross-reactive weakly 
neutralizing MAbs (the murine MAb 4G2 and human MAb 2A10) and serotype cross-
reactive moderately neutralizing MAb (MAb DVC10.16) neutralized partially mature 
virions better than mature virions. MAbs 4G2 and 2A10 have been mapped to conserved 
epitopes at or close the fusion loop on domain II (Figure 4) (Trainor, Crill et al. 2007). 
These results are concordant with elegant studies done by Nelson et al. who 
demonstrated that MAbs binding to epitopes around the fusion loop neutralized partially 
mature West Nile virus (WNV) better than totally mature virus (Nelson, Jost et al. 2008; 
Vogt, Moesker et al. 2009). These investigators demonstrated that in WNV the fusion 
loop region is more exposed in immature virions compared to mature virions, which 
explains the increased sensitivity of partially immature virions to neutralization by fusion 
loop MAbs (Cherrier, Kaufmann et al. 2009). 
hMAb DVC10.16, which also neutralized partially immature virions better than 
mature virions, is a serotype cross-reactive MAb that binds to the A strand epitope of 
EDIII (de Alwis, Beltramello et al. 2011). In fact, studies with DENV cross-reactive 
murine MAb 1A1D-2 have demonstrated that the EDIII A strand epitope is hidden in the 
mature virus particle (Lok, Kostyuchenko et al. 2008). Studies by Lok et al. indicate that 
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this hidden epitope becomes exposed transiently and available for Ab binding as the 
virus particle flexes at elevated temperatures. Another study by Cockburn et al. indicated 
that the A strand-specific MAb 4E11 neutralizes virus by disrupting architecture of the 
mature virion and inducing premature fusion loop exposure (Cockburn, Navarro Sanchez 
et al. 2012). Based on our findings with MAb DVC10.16, we propose that the exposure 
of the EDIII A strand epitope also changes as a function of virus maturation state. 
The observation here that fusion loop-specific Abs neutralize partially immature 
DENVs better than mature viruses has important implications for characterizing 
polyclonal antibody profiles in human immune sera following natural infection or 
experimental DENV vaccination. Following exposure to natural DENV infections, the 
fusion loop is a major target of the total Ab response (Lai, Tsai et al. 2008; Costin, 
Zaitseva et al. 2013). The fusion loop targeting Abs can exhibit both strongly neutralizing 
and infection-enhancing phenotypes (Sukupolvi-Petty, Austin et al. 2010; Deng, Dai et al. 
2011; Rodenhuis-Zybert, Moesker et al. 2011; Lin, Tsai et al. 2012; Williams, Sukupolvi-
Petty et al. 2013). In sera dominated by fusion loop Abs, the overall neutralization titer is 
likely to vary widely depending on the maturation state of virions used to infect cells in 
the assay. We observed that 6 out of 10 human DENV immune sera neutralized partially 
immature virions better than mature viruses. When reference panels of DENV immune 
sera have been tested in different laboratories for neutralizing Abs, the actual titers vary 
widely between laboratories for the same serum sample. We propose that variation in 
the maturation state of viruses used in the neutralization assay is a major source of this 
variability. The current standard used to evaluate immunogenicity as a correlate of 
immunity for experimental DENV vaccine candidates is the serum neutralization assay. 
The increased susceptibility of partially immature virions to neutralization by fusion loop 
Abs will complicate the assessment of vaccine responses. 
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While fusion loop- and EDIII A strand-specific MAbs neutralized partially mature 
virions better than mature virions, the five strongly neutralizing, serotype-specific MAbs 
in our panel neutralized partially mature and mature virions equally well (MAbs 2D22, 
5C36 and 9F16) or neutralized mature virions better than partially mature virions (MAbs 
DVC25.5 and DVC3.7). Human MAb 2D22 is a strongly neutralizing Ab that binds to a 
quaternary epitope centered around the hinge between domains I and II (Li, Lok et al. 
2008). We also have tested EDI/II hinge Abs that bind to DENV1 or 3 and observed 
equal neutralization of partially mature and fully mature DENVs (data not shown). Recent 
studies have pinpointed the EDI/II as the major target of strongly neutralizing Abs in 
people after natural infection with DENV or WNV (de Alwis, Smith et al. 2012; Teoh, 
Kukkaro et al. 2012). We propose that EDI/II hinge antibodies, which are likely to be 
responsible for the solid long-term protection observed after natural exposure to DENV, 
do not discriminate between DENVs of different maturation state. 
All EDIII lateral ridge-specific MAbs in our panel neutralized both classes of 
mature and partially mature viruses equally well (MAbs 5C36 and 9F16) or neutralized 
mature particles better than partially mature virions (MAbs DVC3.7 and DVC25.5). We 
also observed preferential neutralization of mature DENVs by two of the DENV immune 
sera (samples DT110 and DT130).  
The lower M/I ratio of all the three cross-reactive MAbs suggests that these MAbs 
bind immature virions with higher affinity, or higher accessibility of cross-reactive MAb 
epitopes in immature virions, and this is consistent with Cryo-electron microscopy study 
suggested (Cherrier, Kaufmann et al. 2009). The association between cross-reactive 
MAbs and immature virion is intriguing. It implies a possible critical role of immature 
virion in eliciting cross-reactive antibody response, and also a critical role of immature 
virion in ADE mediated by cross-reactive MAbs. If both hypotheses were verified, it may 
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suggest immature and partially mature virions may play a bigger role than mature virions 
in vivo for dengue pathogenesis.  
Our results suggested that the preferential neutralization of mature virus by MAbs 
DVC3.7 and DVC25.5 is caused by endosome furin cleavage of the partially mature 
virus. The role of endosome furin in flavivirus infection is controversial as it was shown 
that WNV infection of Raji-DC-SIGN B cell lines is insensitive to furin inhibition 
(Mukherjee, Lin et al. 2011) and our results corroborated this by showing that partially 
mature dengue virus infection of monocytic cell line U937-DC-SIGN is also insensitive to 
furin inhibition (data unpublished). Nevertheless, our evidence suggested that, at least in 
the case of Vero cells, partially mature dengue virus might need to become fully mature 
post-entry in endosomes. It is possible that as cleavage processing of virus occurs to 
virus-antibody complex, the antibodies in proximity of cleavage site might be inevitably 
affected, leading to decreased neutralization of the partially mature virus. Most 
interestingly, in the presence of furin inhibitor, the differential neutralization of MAb 
DVC3.7 is abolished while the differential neutralization of 4G2 is still evident, suggesting 
this post-entry furin cleavage contributed to the differential neutralization of type-specific 
MAb DVC3.7 but not cross-reactive MAbs like 4G2. This also implies that inefficient 
cleavage of virus particles in virus production may have important evolutionary 
significance as it may serve as a means of immune evasion.   
Besides these two mechanisms discussed, other mechanisms may also 
contribute to the differential neutralization between the two viruses. One possibility is the 
structure kinetic difference (breathing) or stability difference between the mature virus 
and partially mature virus. The viral structure difference is very likely lead to variation in 
structure dynamic and stability. Another possibility is glycosylation. It has been shown 
that mosquito cell line is different from human cells in Env protein glycosylation (Hacker, 
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White et al. 2009). Glycosylation variation can alter antibody binding and affect 
neutralization sensitivity. Future works will include experiments to explore the role of 
glycosylation in MAb’s differential neutralization of mosquito derived and human 
monocytic cell derived virus.  
In summary, our studies demonstrate that the maturation state of DENVs 
produced in the laboratory depends to a large extent on the cell type used to produce 
the viruses. Moreover, the ability of some Abs to neutralize DENVs was influenced 
heavily by the maturation state of particles used in the neutralization assay, while other 
Abs were insensitive to maturation differences. The ability of fusion loop-specific Abs to 
neutralize partially immature virions preferentially is likely to be major source of variation 
in the use of the current standard neutralization test and likely confounds the 
reproducible analysis of vaccine serum samples. On the other hand, DENV serotype-
specific strongly neutralizing Abs, including those linked to long-term homotypic 
protection neutralized DENVs irrespective of maturation state. 
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Figure 6.1 
 
 
Figure. 6.1: Maturation state of DENVs produced by different cell lines.  A) Murine 
EDIII-binding MAbs were used to capture DENVs from various sources onto 96-well 
ELISA plates. The amount of prM and E protein on the captured virions was determined 
by ELISA using human prM MAbs and E MAbs and alkaline phosphatase conjugated 
anti-human IgG secondary antibody. The prM/E ratio was calculated using the optical 
density (OD) signal of human prM MAbs divided by the signal for human E MAbs. B) 
Western blot detection of prM and E protein levels of DENV2 virus samples from various 
cell lines. C) Western blot detection of prM and E protein levels of DENV3 virus samples 
from various cell lines. 
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Figure 6.2 
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Figure. 6.2: Maturation-dependent neutralization of DENVs by MAbs.  A) MAb 4G2 
is representative MAbs that neutralized partially mature virions (C6/36-derived) better 
than fully mature virions (U937-DC-SIGN-derived). B) MAb 5C36 is representative of 
MAbs showing equal neutralization of partially and fully mature virions. C) MAb DVC3.7 
is representative of MAbs that neutralized fully mature virions better than partially mature 
virions. 
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Figure 6.3 
 
Figure. 6.3: DENV Envelope Residues that Affect 2A10 Binding. A) Mammalian cells 
expressing mutant DENV envelope proteins were immunostained with MAb 2A10 and 
detected by flow cytometry. 2A10 binding assays were performed 2 times and ranges 
are shown. The mean reactivity of control MAbs that bind the fusion loop (10 Abs) or 
Domain II (4 Abs) are shown for comparison. B) Mutations that reduced 2A10 reactivity 
were mapped onto the DENV E protein structure (PDB ID # 1OAN) (33). DENV E protein 
domains I, II, and III are depicted in red, yellow, and blue, respectively. The fusion loop is 
shown in silver. 
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Figure 6.4 
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Figure. 6.4: Relative binding of MAbs to fully and immature DENVs. Equal amount 
of mature virus and immature virus were captured onto 96-well plates. The ability of each 
MAb to bind to mature and immature virions was detected by ELISA. Mature to immature 
(M/I) binding ratio was calculated as (OD of binding mature virus) / (OD of binding 
immature virus). 
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Figure 6.5 
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Figure. 6.5: Maturation-dependent neutralization of DENVs by human dengue 
immune sera. A) Serum 116 represents sera displaying better neutralization of partially 
mature compared to fully mature DENV3. B) Serum 103 represents sera displaying 
equal neutralization of partially and fully mature DENV3. C) Serum 110 represents sera 
displaying increased neutralization of mature compared to partially mature DENV3.  
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Figure 6.6  
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Figure 6.6: Furin cleavage inhibition abolishes majority of C6/36 virus infectivity 
but not that of U937-DC-SIGN derived virus. A) Furin inhibitor was added to U937-
DC-SIGN virus before infection and was added to C6/36 derived virus before or 2 hrs or 
4 hrs after infection; B) Furin inhibitor was added before infection of both viruses and 
DMSO, the solvent of furin inhibitor was added to cells alone as control.  
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Figure 6.7 
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B) 
DVC25.5 Function Assay
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Figure 6.7: Function Assay of MAb A) DVC3.7 and B) DVC 25.5 revealed that these 
MAbs mainly neutralize post-attachment step of infection. MAbs were tested at 
concentrations covering 10% to 100% neutralization.  
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Figure 6.8 
A) 
DVC3.7 Neutralization with Furin Inhibitor
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B) 
4G2 Neutralization with Furin Inhibitor
-1.0 -0.5 0.0 0.5 1.0 1.5
-25
0
25
50
75
100
C6/36
U937-DC-SIGN
Furin  Inhibitor-C6/36
Furin Inhibitor-U937-DC-SIGN
Mab Log concentration (µg/ml)
P
e
rc
e
n
ta
g
e
  
N
e
u
tr
a
li
z
a
ti
o
n
 
Figure 6.8: Furin Inhibition Experiment with MAb DVC3.7 and 4G2. A) Furin 
inhibition abolished the differential neutralization of MAb DVC3.7. B) 4G2 neutralization 
of mature and partially mature virus is unchanged in the presence of furin inhibitor. 
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CHAPTER 7  
DISCUSSION  
 
The results presented in this thesis focused on two general topics: The first topic 
was to understand the antibody responses following dengue infection; the second topic 
was about how genetic and maturation variations of DENV virion influence the ability of 
Abs to neutralize DENV. The significance of these findings and possible future directions 
had been discussed in each chapter respectively. In this chapter, all the results will be 
discussed under one unifying question: how dengue viruses evade the immune 
response. Based on the synthesis analysis of all the data presented, new hypothesis of 
dengue evasion of immune response will be proposed and discussed.  
7.1 The misled humoral immune response  
Humoral immunity is one of the critical host defenses against dengue virus 
infection and ironically it is also regarded as the major risk factor of the severe disease 
DHF/DSS. To solve the myth behind this paradox, a lot of studies have been dedicated 
to cloning and screening of MAbs from human PBMCs isolated during or post infection, 
including the results presented in Chapter 2 (Beltramello, Williams et al. 2010; 
Dejnirattisai, Jumnainsong et al. 2010; de Alwis, Beltramello et al. 2011; Smith, Zhou et 
al. 2012). A consensus of all these studies is the rarity of type-specific strongly 
neutralizing MAbs. The majority of the cloned dengue reactive human MAbs are cross-
reactive, weakly neutralizing and enhancing. To be more specific, EDIII harbors more 
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type-specific epitopes yet it plays a minor role in inducing antibody response in human 
despite its strong immunogenicity in mouse models (Wahala, Kraus et al. 2009; 
Cockburn, Navarro Sanchez et al. 2012); the majority of humoral immunity is directed 
against EDI/II but these two domains are more conserved than domain III between 
serotypes and are more likely to induce cross-reactive antibody response (Costin, 
Zaitseva et al. 2013). In general, human humoral immune response against dengue is 
far from being the “perfect” or “ideal” immune response. This dilemma implies that 
human immune response against dengue infection is “misled” to produce a 
“dysfunctional” humoral response that poses a risk of ADE for subsequent infections.  
This should not be a surprise as most successful viruses had adapted various 
strategies to evade the host’s immune response. The best known example is the 
evolution of HIV: The long infection period and high mutation rate of the HIV genome 
enable the virus to “outrun” the immune system and eventually crush it. However, for a 
virus like dengue, the viremia is short-lasting (4-5 days) and thus the virus does not have 
enough time to generate significant genetic and antigenic drift/shift in vivo.  Based on the 
argument presented below, I hypothesized that DENV utilizes several particular features 
of its life cycle to mislead the immune system, resulting in a “dysfunctional” humoral 
response.   
The first feature (1) is the maturation variation of the dengue virus. As shown in 
Chapter 6, cell type switch can lead to maturation variation of the progeny viruses. More 
specifically, immediately after virus injection through a mosquito bite, the human immune 
system is primed by the mosquito derived partially mature virus while later the viremia 
causing the disease is comprised of mostly monocytic cell-derived mature virus. The 
drastic difference of surface protein structures between mature and immature virus 
suggests that they have different antigenicity. Therefore, the immune response primed 
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by the partially mature virions may not be optimized to recognize and neutralize the 
mature virions. Though it is still unknown how much the mosquito-derived viruses shape 
the immune response compared to the monocytic cell-derived viruses do in the 4-6 days 
of viremia, it is reasonable to speculate that the maturation variation of the dengue virus 
may be an evolutionary strategy of virus to evade/mislead the immune response.  In 
terms of changing DENV surface antigenicity to escape neutralization, maturation 
variation may have advantages over genetic mutation: First, virus maturation changes 
can be done without losing or changing the genetic information of the genome, allowing 
more freedom of evolution; second, the change is triggered by alteration of the cell type 
the virus replicates in, which is faster than natural selection of genetic mutation.   
The second feature (2) is using different glycosylation. Hacker in our lab 
demonstrated that the glycosylation of viruses derived from mosquito cells and 
mammalian cells are not all the same (Hacker, White et al. 2009). Glycosylation variation 
may lead to antigenic differences between mosquito cell derived viruses and monocytic 
cell derived viruses thus the same argument above can be applied here, too.  
What we observed in our lab supports the above arguments. First, the cross-
reactive antibodies, which make up to 75% of the humoral immune response (de Alwis, 
unpublished data), have reduced neutralization against monocytic cell derived mature 
viruses. Secondly, 6 out of 10 polyclonal sera I tested have reduced neutralization 
against monocytic derived viruses (Chapter 6). Both observations support the argument 
that the immune response primed by C6/36 derived viruses is optimized to neutralize 
C6/36 derived viruses, not monocytic cell derived viruses. Both maturation and 
glycosylation may contribute to this evasion strategy. 
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The third feature (3) is the virion conformational change in the endosome. DENV 
will undergo low pH triggered conformational change after entry into the endosome. 
Antibody neutralization at this stage is called post-attachment neutralization. Therefore 
virions inside the endosome are most likely to have E in trimeric form instead of dimeric 
form. However, during the infection, the virions present themselves in pre-conformational 
change form for B cell to recognize thus the immune response is optimized to recognize 
the virus in pre-conformational change form, not post-conformational change form. As a 
result, the humoral immune response may not bind the post-transform virions as well as 
pre-transform virions. 
The fourth feature (4) is closely related to the third one: the peculiar environment 
inside the endosome, such as low pH and the presence of furin, is very different from the 
extra-cellular environment. It is known that pH is critical for protein binding affinity and 
the change of pH will affect antibody binding to virus. Similar to the argument I made in 
feature 3, the B cells were primed by dengue virions in close to neutral pH in the blood 
plasma, not the low pH in the endosomes, so it is expected that Abs that are optimized 
to recognize the viruses in physiological neutral pH may not be able to bind and 
neutralize the virus very well in the endosomes. In other words, the low pH environment 
helps DENV to evade the immune response that is optimized to recognize DENV at 
near-neutral pH. This may explain why certain MAbs (such as 12C1 or 13A5 in Chapter 
4) that bind virus strongly in a normal pH ELISA are not neutralizing at all in the 
neutralization test, since perhaps they just do not bind to the virus so well in the low pH 
conditions. Measuring antibody binding to viruses in the low pH environment shall be 
carried out to test this hypothesis. Besides the pH, the presence of proteases in the 
endosome may also interfere with antibody binding and affect neutralization, as 
indicated in Chapter 6.  
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What makes feature 3 and 4 ideal immune evasion strategies is that the flavivirus’ 
most important steps, such as envelope conformational change and membrane fusion, 
all occur inside the endosome. However, these post-attachment steps of the virus life 
cycle are hidden from the B cell repertoire and the B cells are trained to recognize 
viruses before or during attachment. It is expected that humoral response would 
recognize and neutralize the virus at pre-attachment better than at post-attachment. It 
has been shown that antibodies that block virus attachment to cells are a major 
component of the human neutralizing antibody response against the dengue virus (He, 
Innis et al. 1995). This supports my hypothesis that the immune system is optimized to 
neutralizing the virus outside the endosome, at its attachment step, which is not the most 
efficient way to neutralize the virus as the virus has other ways of attachment to the cell 
(such as Fc-gamma receptor).  More importantly, the most efficient stage to neutralize 
the virus is at the post-attachment steps, as the function data in Chapters 3 and 6 
suggested that most of the strongly neutralizing MAbs are post-attachment neutralizing. 
To illustrate this point, I made a table of the previous identified strongly neutralizing 
MAbs that have been studied for pre-attachment or post-attachment neutralization. As 
shown in Table 7.1, out of 28 studied MAbs, there are only 5 blocking attachment while 
the rest 23 MAbs, especially the strongly neutralizing MAbs, all neutralize at the post-
attachment steps. This is not conclusive evidence but it strongly implies that the post-
attachment steps are the vulnerable steps of virus infection and can be neutralized with 
high efficiency. In summary, my argument is: the most vulnerable stage of virus infection 
is at post-attachment stage, yet the virus at this stage is only inside the endosome, 
where the low pH environment and virus transformation can shield the virus from a 
humoral immune response that is optimized to recognize the virus outside the endosome. 
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In general, our interpretation of dengue humoral immune responses and antibody 
neutralization data pointed out one new hypothesis: The dengue virus utilizes cell type 
switch dependent maturation/glycosylation and endosome related transformation and 
low pH to evade the humoral immune response and this is why the majority of the cloned 
MAbs are weakly neutralizing and strongly enhancing. More data are needed to further 
support all the above hypotheses. If they are proved, it may shed light on dengue 
vaccine design. For example, the immunogen can be designed to mimic the post-
transformation virus to induce the most potent neutralizing antibodies. Furthermore by 
studying how affinity changes in low pH conditions, we may be able to design vaccines 
that induce antibodies that bind better in low PH environment.  
7.2 The gap between antibody binding and virus neutralization 
In Chapter 3, the association between neutralization mechanisms and 
stoichiometry models was discussed. In Chapter 4, monoclonal antibodies were tested 
for their neutralization potency in MAb mixtures, and we found independent 
neutralization instead of a synergistic effect. I propose that to obtain a synergistic effect, 
the two MAbs should have overlapping neutralization mechanism and have no 
competitive binding. In Chapter 5, 8A1 binding and neutralization differences were tested 
and compared and we observed neutralization variations not due to binding differences. 
In Chapter 6 and this chapter, the effects of low pH, furin cleavage and maturation on 
binding and neutralization were discussed.  Factors like antibody diversity, epitope 
accessibility, virus structure dynamic, pH, temperature, stoichiometry and cell type all 
play a role in modulating the antibody mediated neutralization. But these factors have 
been either understudied or neglected in previous research. Thus, all the points made in 
these chapters can boil down to one main goal: to elucidate the gap between antibody 
binding and virus neutralization. Each chapter solved a small piece of the big question 
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but by putting all the data and conclusion together, we may be able to get a better view 
of the overall landscape of virus binding-neutralization, and new directions of research 
can be planned accordingly.  
First, identifying and elucidating synergistic neutralization of MAb mixtures would 
greatly benefit future development of cocktail antibody therapy for dengue infection. It 
would also offer a good chance to understand how polyclonal serum works in 
neutralization. To do that, in Chapter 4, I proposed starting with a pair of MAbs with 
threshold stoichiometry and binding to non-overlapping epitopes. As my hypothesis 
predicts, MAbs with threshold stoichiometry should be able to block conformational 
change of the virus (Chapter 3). The MAb function assay data in Chapter 3 will be useful 
for designing such an experiment and it suggests that MAbs 8A1 and 1A1D-2 would be 
a good candidate pair. They both neutralize DENV3 and display threshold stoichiometry. 
8A1 binds to the EDIII lateral ridge and 1A1D-2 binds to the A-strand of EDIII, so the 
possibility of competitive binding is limited. Future experiments with the two MAbs should 
be done to identify a synergistic effect.    
Second, it would be quite revealing to compare the neutralization of virus during 
normal infection with that of the ADE infection. Elucidating their common neutralization 
mechanisms could be important for preventing ADE. It has been hypothesized that MAbs 
blocking attachment should not be able to neutralize ADE because ADE does not use a 
regular attachment molecule but rather use Fc-ɣ receptors and the Fc portion of the 
binding antibody. But our results in Chapter 4 disproved this hypothesis, as we found 
2Q1899 and 9F16 are very competent in inhibiting 2H2-mediated enhancement (Chapter 
4) and both MAbs neutralize by blocking attachment (Chapter 3). There are two 
explanations for this paradox. One is that 9F16 inhibits ADE by aggregating multiple 
virions into an immune complex to reduce infectious unit numbers and also by increasing 
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the complex size to cross-link the inhibitive Fc-ɣ receptors. This is consistent with the 
function assay results as aggregation of viruses occurs at pre-attachment steps. I 
propose to modify the current function assay to test the neutralization mechanism of 
ADE infection. The modification will include using the MAb-virus complex to replace the 
virus and using K562 or U937 cells to replace Vero cells. Comparing the results of this 
modified assay with the results of the original function assay will reveal the neutralization 
mechanism differences between normal infection and ADE infection.  
The third point is to systematically study how factors such temperature and pH 
affect antibody-mediated neutralization. Variation in temperature may alter the virus 
structure dynamic, stability, antibody binding affinity, and subsequently neutralization 
potency or the neutralization mechanism (Dowd, Jost et al. 2011). The function assay 
uses the temperature 4°C and it may not be an accurate estimation of the MAb 
neutralization mechanism at 37°C. Besides, in the life cycle of the dengue virus there are 
at least three temperature switches: 28°C or even lower inside the mosquito, 37°C inside 
the human and up to 40°C during the fever stage. Therefore, understanding how 
temperature affects the virus and its interaction with antibodies is indispensable. PH 
variation has the same effect on virus and antibody interaction. The significance of 
understanding how pH affects the virus and neutralization is presented in detail in 
section 7.1.  
In summary, the research presented in this dissertation revealed the persistence 
of cross-reactive antibodies with the potential for dengue virus disease enhancement 
decades after infection. The antibody’s stoichiometry and mechanisms of neutralization 
were explored and the MAbs’ combined neutralization and ADE were also measured 
and modeled using neutralization assay and ADE assay. The differential neutralization of 
DENV3 strains by MAb 8A1 was studied in detail and the mechanisms of this differential 
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neutralization were revealed. Finally, the differential neutralization patterns of the mature 
and partially mature dengue viruses were investigated and the mechanisms of 
differential neutralization were identified. The discoveries made and mechanisms 
revealed in this study will not only shed light on our understanding of how antibodies 
neutralize dengue viruses, but also provide insight into how dengue viruses evade the 
immune response. This study offers a rationale for new strategy of dengue vaccine 
design and provides guidelines for antibody therapy of dengue disease.  
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Table 7.1 neutralization mechanisms of Monoclonal antibodies 
MAbs Class
#
 Specificity Potency* Mechanism^ Source 
1A1D-2 mIgG1 cross-reactive strong post Chapter 3 
8A1 mIgG1 DENV3 strong post Chapter 3 
14A4 mIgG1 DENV3 strong post Chapter 3 
9D1 mIgG1 DENV3 strong post Chapter 3 
9F16 mIgG1 DENV2 moderate  pre Chapter 3 
2Q1899 mIgG1 DENV2 moderate pre Chapter 3 
5C36 mIgG1 DENV2 moderate pre Chapter 3 
2D22 hIgG1 DENV2 strong post de Alwis, unpublished data 
1F4 hIgG1 DENV1 strong post de Alwis, unpublished data 
5J7 hIgG1 DENV3 strong post de Alwis, unpublished data 
DVC3.7 hIgG1 DENV2 strong post Chapter 6 
DVC25.5 hIgG1 DENV2 strong post Chapter 6 
DVC10.16 hIgG1 Sub-complex strong post Zhou, Unpublished data 
14c10 hIgG1 DENV1 strong pre (Teoh, Kukkaro et al. 2012) 
9F12 mIgG1 cross moderate pre (Rajamanonmani, Nkenfou et al. 2009) 
2A10G6 mIgG1 cross moderate post (Deng, Dai et al. 2011) 
4.8A hIgG1 cross moderate post (Costin, Zaitseva et al. 2013) 
D11C, hIgG1 cross moderate post (Costin, Zaitseva et al. 2013) 
1.6D. hIgG1 cross moderate post (Costin, Zaitseva et al. 2013) 
1A5 Fab cross moderate fusion (Goncalvez, Purcell et al. 2004) 
5H2 cIgG1 DENV4 strong post (Lai, Goncalvez et al. 2007) 
DV2-44, 
DV2-58, 
DV2-76, 
DV2-77, 
DV2-87, 
DV2-104. 
mIgG1 NA strong to moderate post (Sukupolvi-Petty, Austin et al. 2010) 
 
Notes: #:  mIgG means mouse origin IgG, hIgG means human origin IgG, cIgG means 
chimpanzee origin IgG.  
          * :  Strong neutralization is defined as neutralizing at picomolar concentrations. 
Moderate neutralization is defined as neutralizing at nanomolar concentrations 
^ :  pre means pre-attachment; post means post-attachment  
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